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ABSTRACT 
Over the past few decades many researchers have investigated the utility of in vitro 
- in vivo correlations for the assessment of dosage forms . These investigations are, 
however, dependent on reproducible dissolution data and well conducted biostudies 
in order to establish meaningful and robust correlations . Despite the fact that the 
establishment of such correlations is perhaps idealistic, considerable interest has 
still been shown in this area of research. 
Various Controlled/Modified Release Dosage Forms (CMRD's) of theophylline, a 
weakly basic drug, and indomethacin, a weakly acidic drug, were assessed in order 
to establish in vitro - in vivo correlations. Dissolution rate studies were carried out 
using either the USP basket or paddle apparatus. The dissolution rate studies were 
conducted in a range of dissolution media of varying pH. Bioavailability studies 
were conducted on the dosage forms used by the Biopharmaceutics Research 
Institute at Rhodes University. The results of these biostudies were kindly made 
available for use in this research project. 
Type A correlations were established using a mathematical simulation process 
whereby expected in vivo responses are simulated and compared to actual profiles 
obtained for the dosage forms. In order to perform the simulations the dissolution 
rate profiles were stripped and using linear regression and the methods of residuals 
the dissolution rate order and the relevant dissolution rates were obtained. The 
results of the s imulations indicated that the in vivo serum concentration-time curves 
could be accurately predicted for the theophylline dosage forms but to a lesser 
extent, for the indomethacin formulations. 
The dissolution rate studies indicated that the paddle method is a suitable method 
for dissolution rate studies of theophylline CMRD's, although it appeared that the 
optimum pH of the dissolution medium was formulation dependent. Dissolution rate 
xxi 
studies conducted on indomethacin formulations indicated that the USP specified 
basket method for extended-release indomethacin formulations was not able to 
distinguish between two formulations which exhibited different in vivo profiles. The 
conversion to the paddle method was, however, able to highlight the differences 
between these formulations . 
The use of three dimensional topographs to depict dissolution rate profiles was 
demonstrated for formulations of both theophylline and indomethacin. The 
topographs .enabled the successful differentiation between bioinequivalent 
formulations. The dissolution rate profiles were also fitted to the Wei bull equation 
and the parameters obtained from this were compared to the Weibull parameters 
obtained from the in vivo absorption plots obtained using the Wagner-Nelson 
method. The results indicated that the Weibull function was suitable to describe 
both the in vivo and in vitro data . 
The following recommendations for the preformulation dissolution studies of weakly 
acidic and weakly basic drugs are proposed. The dissolution rate studies of weakly 
acid drugs, such as indomethacin, should be carried out over a range of pH utilising 
the paddle apparatus. Three dimensional topographs based on the dissolution data 
should be constructed and used as a comparative tool for different formulations . 
Based on these comparisons the appropriate formulation can then be selected for a 
pilot scale in vivo bioavailability study. 
The dissolution rate studies of weakly basic drugs, such as theophylline, should be 
carried out over a range of pH utilising the paddle apparatus . The dissolution data 
should then be used to simulate the expected in vivo profile and on this basis the 
appropriate formulation selected for a p ilot scale bioavailability study. The above 
approach to the preformulat ion studies of new CMRO's would allow for the more 
careful selection of new dosage forms and could thus eliminate costly and 
unnecessary bioavailability studies performed on inferior formulations. 
CHAPTER 1 
Introduction to in vitro - in vivo correlations 
1.1 Overview 
The development of complex oral controlled/modified release dosage forms, 
(CMRD's), has brought with it many advantages including increased patient 
acceptance and compliance .. These developments have, however, also brought 
about their unique biopharmaceutical problems . Historical claims that all the drug 
present in a solid oral dosage form is available for absorption clearly no longer 
applies as the understanding of all the complex processes involved in drug 
absorption become more clearly understood . 
These developments have also brought about the need for in vitro test procedures 
during the early stages of research and development which could limit the number 
of costly and time consuming in vivo tests. One method of achieving this is with 
the use of in vitro - in vivo correlations. Langenbucher has suggested that it is not 
possible to immediately correlate an in vitro parameter with an in vivo plasma 
concentration-time curve as the two entities have nothing in common (1) . Some link 
must be established between the in vitro parameters and the in vivo response 
obtained after administration of a solid oral dosage form. The most common 
approach today is the use of in vitro dissolution rate testing. Parameters obtained 
from the dissolution tests are then, by mathematical processes, equated with the 
parameters obtained in vivo. The premise is that dissolution of a dosage form must 
occur in vivo before any drug can be available for absorption . 
In order to establish a correlation between the two elements, some third factor is 
required to link them. Generally two approaches can be employed . Firstly, the in 
vivo dissolution input function can be derived by a method of deconvolution from the 
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in vivo response and directly compared with the in vitro dissolution. Secondly, the 
opposite process can also be employed whereby using a process of convolution of 
the in vitro dissolution, an expected in vivo response can be predicted (1). 
In vitro - in vivo correlations therefore serve as a link between in vitro data and in 
vivo data. In theory, correlating dissolution to clinical responses would appear to 
be a worthwhile undertaking for the assessment of new dosage forms, especially 
during the developmental stages. It is, however, ironic that most correlations have 
been established after bioavailability problems have been identified. la. vitro - in 
vivo correlations have therefore been used as methods of explaining product failures 
rather than predicting product performance in vivo. Hence, there exists a need for 
correlations to be established during the research and development stage of product 
design, as opposed to their use as a retrospective tool. 
Many different attempts have been made to establish in vitro - in vivo correlations, 
both for immediate release solid oral dosage forms as well as sustained release 
preparations. Despite reservations as to whether meaningful in vitro - in vivo 
correlations can be obtained, the literature is replete with reports of attempts at 
correlating these two aspects. Needless to say, these attempts have produced both 
positive and negative results. The literature is abundant with reports showing the 
variability in the clinical response between administered drug products that contain 
chemically equivalent amounts of a drug (2). Early retrospective in vitro - in vivo 
correlations led to research projects which centred on intentionally varying a 
particular parameter of either the drug; i.e. by changing the polymorph, or the 
dosage form in order to ascertain whether such variations would correlate with 
changes in bioavailabilty. These changes were expected to be reflected by either 
changes in the absorption rate, total drug absorbed or some other relevant in vivo 
parameter. 
HOttenrauch and Speiser (3) have, however, indicated that due to the many sources 
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of variability and their possible additive effect, the establishment of an in vitro - in 
vivo correlation should be seen as an unrealistic problem . From the 
biopharmaceutical point of view the necessity arises to consider and evaluate both 
the in vitro and in vivo processes . In drug research , both must be considered as 
indispensable, but more importantly the one cannot be substituted for the other . 
The in vitro methods are important in the development of pharmaceutical procedures 
and optimisation of the dosage forms , while in vivo tests are invaluable in obtaining 
quantitat ive estimates of the behaviour of a dosage form in a living organism . 
1.2 Historical Development of In vitro - In vivo correlations 
In the early years of tablet assessment the physical appearance of the dosage form 
represented the only control procedure of the manufacturing process . However, the 
recognition that tablets could pass intact through the gastrointestinal tract brought 
about the development of the disintegration test for the assessment of so l id dosage 
forms. These tests assumed that if the tablet disintegrated, its active component 
or drug content would automatically be ava i lable. There was , however, also an 
awareness that the rate of dissolution of drug particles played a fundamental role 
in the determination of drug availability. Coinciding with these developments 
researchers began to develop in vivo assessment procedures which included the 
studies of plasma and ur inary concentrations of a drug as a measure of the 
physiological availability . Dissolution tests can only be regarded as valuable tools 
if they provide results which have been correlated with quant itative measures of 
physiolog ical avai lability (4 , 5) . 
Initially, the disintegration test was considered to be the sole criterion of drug 
availab il ity . T his presupposed that the dis integration of a do sage form must be 
follo w ed by d issolution under essent ially uniform cond it ions . For many dosage 
forms this has been sho w n, to some exte nt , to be the case (4) . However, pioneering 
studies conducted by Le vy (6) found that there w as no direct relationship between 
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disintegration of salicylate tablets and the amount of salicy late excreted in the 
urine . Furthermore , the disintegration test was not able to dist inguish between 
rapidly and slowly dissolving small granules or primary particles . The test therefore 
gave no handle on any changes in the dissolution characteristics due to changes in 
the physical characteristics of the drug compound (5). Campagna et 81 (7) 
suggested that while the disintegration test may be a useful test as an industrial 
control procedure, it has no value as an index of the bioavailability of compressed 
tablets . The replacement of the disintegration test with a dissolution test was 
suggested . 
It is now a well established fact that the therapeutic efficacy of any dosage form is 
dependent on factors related to both the in vitro dissolution characteristics of the 
drug and its in vivo bioavailability. For the drug to be available i t must be released 
from the dosage form (8) . In the late 1960's the dissolution rate test became 
acceptable as a test procedure for tablet evaluation. Many dissolution test 
procedures are in use today which vary from extremely gentle procedures to 
relatively act ive turbulent mixing. Wood (4) noted that each procedure must have 
its in vivo correlat ion established before it may be validly used as a criterion of 
release propert ies . The dissolution rate of a specific dosage form is , in essence, a 
parameter which is arbitrary and very dependent on the methodology utilised in 
obtain ing it. Any changes in the type of apparatus used, the dissolution medium, 
agitation speed etc, can dramatically modify the dissolution pattern . It is therefore 
important that the in vitro dissolution test be shown to have some bearing on the in 
vivo situation in order for a meaningful correlat ion to be established (8). 
The establishment of in vitro - in vivo correlations can be attempted in various ways , 
incl ud ing (a) pharmacological corre lations based on cl inical observations, (b) 
semiquantitative correlat ions based on the drug ' s blood concentrations or ur inary 
excretion data and (c) quantitative correlations arising from absorption k inetics and 
calculation of in vivo dissolution rate and absorption rate constants . In theory, the 
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correlation of in vitro dissolution rates with clinical responses would be ideal, 
however, a clinical response is a very poor tool for accurate measurement of 
bioavailability (2, 8). This is particularly true where the clinical response is an all 
or nothing response, which is often the situation. In cases where in vivo differences 
are observed, the in vitro parameter can be altered to optimise the correlation. This 
is achieved by varying the test conditions of the in vitro test such as the method 
itself, the media used, rate of agitation etc (8). Shah (9) noted that an in vitro - in 
vivo correlation can generally be achieved with the use of any reproducible method. 
However, proper selection of the medium and the degree,of agitation are necessa.ry 
so as to permit di t ~rimination amongst products. Measurement of blood levels at 
the site of action would also be a useful approach but the current state of 
technology does not allow this (8). 
Numerous variables have been used to establish correlations between in vitro and 
in vivo data. Variables derived from in vivo data which have been correlated with 
in vitro variables have been summarised by Wagner (10) and include the following: 
i) Plasma or serum concentration-time plots or the corresponding 
numerical values, 
ii) Peak plasma or serum concentrations, Cm,,' 
iii) AUC during some time interval, AUCo_" 
iv) AUCo_T - i.e. area under the blood curve to the last blood 
sample at time T, 
v) AUCo_oo - i.e. area under the entire blood concentration time 
curve, 
vi) Rate constant for absorption, k .. or the half-absorption time 
derived by applying a pharmacokinetic model to urinary 
excretion data or blood data, 
vii) Amount of drug excreted per a given time interval, 
viii) Plots of cumulative amount of drug excreted versus time, 
ix) Percent absorbed time plots derived by pharmacokinetic 
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analysis of blood or urinary excretion data, 
x) Pharmacological responses such as lowering of blood sugar 
levels, blood pressure, pain relief etc. 
Many variables derived from in vitro data, using various methods, have been 
correlated with in vivo variables . These include: 
i) Disintegration time (4, 11, 12), 
ii) Time for a certain percentage of the drug to dissolve in vitro 
eg o t20,,' t60" etc (13, 14, 15, 16, 17), 
iii) Concentration or amount in solution at a given time (9, 11, 12, 
18, 19), 
iv) Percent dissolved time plots (9, 20, 21, 22), 
v) Rate of dissolution versus time plots (6), 
vi) First order plot of percent to be dissolved on logarithmic scale 
versus time (13), 
vii) Plots of percent dissolved on probability scale versus time on 
logarithmic scale, 
viii) Rate constants or dissolution half times derived by kinetic 
analysis, 
ix) Intrinsic dissolution. 
Wagner (10) noted that the best variable to correlate in vivo data is the time taken 
for 50% of the drug to dissolve in vitro, i.e . t 60 ". The reason given for this choice 
is that: (1) its value indicates the central tendency of the dissolution data and (2) 
its use does not commit the use of any formal kinetic interpretation of the data . If 
absorption is dissolution rate limited then the best in vivo parameter is the time for 
50 % of the drug to be absorbed . 
Differences in bioavailability observed in vivo between two different formulations, 
products or lots should be reflected by similar differences in the in vitro dissolution 
7 
test. Correlations can be judged as poor when: 
il significant differences in the dissolution are not reflected in the 
plasma or urine. bioavailability data, 
ii) differences in the in vivo data are not shown by the in vitro 
data, 
iii) the rate orders are inverse between the two data sets and 
iv) dissolution is faster or slower than is consistent with the in 
vivo data (23). 
The failure to establish meaningful correlations can possibly be due to the choice of 
incorrect in vitro testing conditions, such as excessive agitation rates, thereby 
masking differences between products (23). Within reason, the closer the in vitro 
test conditions are to those prevailing in the physiological environment, the greater 
is the chance the results obtained will be reflective of those occurring in vivo. The 
testing of dosage forms with inappropriate conditions such as excessive agitation, 
unphysiological pH, high concentrations of organic solvents etc, is unlikely to have 
any real assessment value (24). 
1.3 Early Case Studies 
It was probably the work of Levy and co-workers (6) that led to and maintained the 
interest in the subject of dissolution and bioavailability and the subsequent proposal 
of the first in vitro - in vivo correlation. Through carefully designed studies on 
various commercial brands of aspirin tablets the authors found that the absorption 
rate of the salicylate was dependent on the dissolution rate of the drug. A 
quantitative relationship was obtained between the amount of aspirin excreted and 
the amount of aspirin dissolved in vitro. The authors noted that such relationships 
would be of extreme importance for the dissolution test to qualify as a predictive 
tool for bioavailability . 
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Levy et at 120) suggested that the development of more generalised in vitro 
dissolution rate testing could proceed via two pathways, namely: Ii) the 
development of a single test which would correlate the in vivo absorption of a 
number of different drugs adm inistered in a single type of dosage form or Iii) the 
development of a single in vitro test which would correlate with the absorption of 
a single drug administered in several different dosage forms. A correlation of the 
type as described in Iii) above was established for three different formulations of 
aspirin. The authors concluded that the successful quantitative correlation of drug 
absorption w ith the results of a single in vitro dissolution test was an encourag ing 
indicat ion that the development of more generalised dissolution rate tests was 
feasible 120) . 
Numerous other researchers have endeavoured to estab l ish meaningful correlations. 
Many have done so successfully using a multitude of different disso lution 
procedures 19, 13, 14, 15 , 16, 18 , 19, 21, 22, 25) . On the other hand, various 
researchers have found that no correlation was possible for some specific dosage 
forms tested 111,12,26,27,28). 
Weintraub and Gibaldi 121), also working with various dosage forms of aspirin 
found that they could correlate the percent dissolved in vitro to time T with the 
percent absorbed to time T . Good correlations were found using various in vitro test 
condit ions employing the rotating flask method of dissolution 121). Aoyagi and co-
workers 113) established correlations for griseofulvin tablets using dissolution 
cond itions w hich provided for both sink and non -sink environments. They correlated 
the amount dissolved at t 6% and t 3 0 % with the amount of drug absorbed at 1 hour 
using normal -reciprocal and log-log regression s. 
In a study conducted by Shah et at125) using chlorothiazide tablets employing the 
paddle method of dissolution a correlation for bioequi valent products was 
established . The authors concluded that the corr elat ion established, would 
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reasonably assure that a product meeting the dissolution limits would be 
bioequivalent with the existing products. Studies conducted on phenytoin dosage 
forms, also by Shah et a/19) found positive correlations between dissolution data 
obtained at 30 and 60 minutes and the em" and t m" values. The best correlation 
was obtained using the basket apparatus, followed by the spin filter method and 
then the paddle method. 
McNamara and co-workers 114) established in vitro - in vivo correlations for 
furosemide tablets. It was found that the amount of furosemide excreted in the 
urine could be associated with the percent drug dissolved in vitro at 30 min. It was 
further established that dissolution carried out in media of pH 5 . 6, as opposed to 
previous studies carried out in media of pH 4.6, allowed for the assessment of batch 
uniformity and bioavailability of furosemide tablets. Attempts were also made to 
establish correlations between the MDT; •• ; •• and the MDT; •• ;". in these studies, but 
these proved to be statistically insignificant. 
In a bioavailability and dissolution study on digoxin tablets Fraser et al (18) found 
that good correlations existed between the area under the serum concentration-time 
curve from 0 to 6 hours and the amount of digoxin dissolved in one hour. Good 
correlations were also established using the reciprocal of t60" and the AUe. These 
studies were able to distinguish between products of differing bioavailabilities and 
it was concluded that the in vitro test could be employed to control this variable. 
Wagner et a/I19), in a study on the in vivo and in vitro availability of commercial 
warfarin tablets, found that the results obtained in vivo correlated very well with the 
results of the in vitro rate of dissolution. No correlations were, however, found 
between the in vivo data and the disintegration tests conducted on the same tablets. 
The authors concluded that the establishment of the correlation did not necessarily 
imply that other commercial warfarin tablets, irrespective of the manufacturer, 
would provide satisfactory results in vivo. 
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Using the USP paddle and basket apparatus and a commercial dissolution simulator 
(Sartorius Dissolution Simulator, Sartorius Filters Inc., Calif . ), an apparatus designed 
to simulate in vivo dissolution, Yau and Meyer (15) carried out dissolution studies 
on a number of different dosage forms of methamine, nitrofurantoin and 
chlorothiazide. Using the data obtained from the dissolution simulator more 
meaningful correlations were obtained for the tablets, except the chlorothiazide, 
when compared to those obtained using the data from the USP dissolution methods. 
In vivo measurements, such as the cumulative percent of drug excreted at specific 
times and the maximum urinary excretion rates, were correlated viiith the in vitro 
data including the cumulative percent of drug dissolved and t,." and t.o,,' The 
authors concluded that the general applicability of the dissolution simulator was 
limited to a few drugs because only two dosage forms could be tested 
simultaneously and its small volume restricted it to testing highly water soluble 
drugs. 
A good correlation between the t m .. value and the percent of drug dissolved at 60 
minutes was found by Meyer et al (17) in a study on phenobarbital tablets . No 
correlations were, however, found between the blood concentration-time curve and 
the in vitro dissolution rates. 
The failure to establish positive or meaningful and potentially predictive in vitro - in 
vivo correlations is often due to the dissolution method which is employed (26, 27). 
DiSanto et al (26). in a study on prednisone tablets, found that the dissolution 
procedure which they employed was not sufficiently predictive of the commonly 
utilised in vivo bioavailability parameters of Cm .. and AUC . 
Smolen (29) has indicated that it should be possible to establish a single in vitro 
test which could adequately reflect the bioavailability of at least a number of drugs, 
but that the in vitro conditions would have to optimised. Prior to the development 
of any in vitro - in vivo correlation careful selection of sensitive variables and 
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parameters to characterise both the in vitro and in vivo bioavailability would have 
to be made. Using the established correlations the assessment of similar 
formulations could be made, providing that the untested products do not differ 
drastically in their formulation from the products from which the correlation was 
established (30). 
1.4 Limitations of In vitro - In vivo correlations 
In certarn situations poor correlations are obtained for reasons related to the drug 
itself. Such factors may include the fact that the in vivo dissolution rate is not the 
rate limiting step for the availability such as is observed for very polar drugs. For 
certain drugs, differences in the dissolution rate do not necessarily reflect 
differences in the total amount of drug absorbed (8). Smolen (29) has further 
reported that an awareness of the limitations of in vitro dissolution tests must be 
exercised. This is especially true if the tests are conducted under a set of arbitrarily 
chosen conditions. Skelly (31) noted that a single method cannot be extrapolated 
across different types of formulations. This was found to be specifically the case 
for slow release dosage forms. Kaplan (32) reported that the in vitro release or 
dissolution rates do not necessarily equate to in vivo absorption rates. Furthermore, 
the dissolution rate of a drug is often an arbitrary parameter and appropriate studies 
must be performed with individual drugs in order to establish meaningful 
relationships between in vitro and in vivo data . 
In order for there to be any value in the development of in vitro - in vivo correlations 
there must be a direct relationship between the two aspects of the attempted 
correlation . It must be demonstrated experimentally that the in vitro dissolution 
reflects the in vivo performance. If this is not the case then the data can be of no 
real value in predicting or assessing the clinical effectiveness of a dosage form (8) . 
This was summarised by Kaplan (32) when he said, "the bioavailability implications 
of dissolution should never be accepted on faith , rather it has to be proved through 
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carefully designed in vitro - in vivo correlation studies· . 
Smolen (33) warned that the improper choice of process variables, such as 
excessively high rate of agitation, can mask significant bioavailability differences 
between formulations . On the other hand, however, the dissolution test can be 
overly sensitive in detecting differences that are of little or no clinical significance. 
This could lead to discarding drug products that may be satisfactory in terms of their 
in vivo performance . 
Before any correlation can be established some mathematical manipulation of either 
the in vitro or in vivo data, or both, must be carried out. This i s necessarily 
accompanied by a number of assumptions which include the following; 
i) the system must behave linearly over the entire concentration 
range studied or if this is not the case then the kinetics must be 
well estab l ished, 
ii) the dissolution rate is the rate limiting step in the absorption 
process, 
iii) the drug is only absorbed from solution, 
i v) the drug does not show a narrow· Absorption Window· and 
v) the in vitro dissolution rate which is calculated using specific 
in vitro conditions are relevant to the drug's in vivo dissolution 
mechanism (8) . 
It however remains unlikely that anyone in vitro dissolution test can actually 
reproduce the in vivo dissolution of the drug in the gastrointestinal tract. Many of 
the physiological factors such as gastric secretions, affect of food, stomach 
emptying time, first pass metabolism etc all greatly affect the bioavailability of a 
drug, but are all difficult to reproduce in vitro (8, 34, 35). 
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1.5 Advancements in In vitro - In vivo correlations 
The development of more complex dosage forms, such as CMRD's, has brought 
about the realisation that the standard methods of correlating in vitro and in vivo 
performance are not adequate. The fact that slow release dosage forms are 
designed to release their drug content over extended periods of time, implies that 
they will necessarily encounter a milieu of varying pH as they move through the 
gastrointestinal tract. These pH changes will therefore playa significant role in the 
. dissolution of the drug from its dosage form and therefore pH becomes an im-portant 
variable that must be considered and evaluated in the design process. The situation 
is therefore much more complex for slow release products than for conventional 
dosage forms 18, 31, 36, 37). 
This problem was exemplified by two quinidine gluconate formulations. The two 
formulations were found to be bio-inequivalent despite their similar dissolution 
profiles at pH 1 .0 wh ich indicated the products to be almost identical regarding their 
in vitro release characteristics . By repeating the dissolution studies under slightly 
altered conditions of pH the poorly available product was able to be discriminated 
from the fully bioavailable formulation 1371. At this time the FDA concluded "that 
because controlled-release products which had virtually the same rate of dissolution 
over time in the same media were not equivalent in vivo, conventional dissolution 
testing might not be a reliable predictor for controlled -release products" 1361. A 
comprehensive analysis of the problem indicated that if the dissolution had been 
determined as a function of pH, the possible lack of bioequivalence of the 
formulations may have been recognised 1311. This together with the complexity of 
the many factors which are involved in in vitro dissolution rate testing led to the 
development of a multidimensional topographical procedure as a tool for decision 
making by Skelly and his associates 1361. 
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The multidimensional graphs using a topographical plotting technique were found 
to be quite effective in showing the effects of pH and buffer composition on the 
dissolution of test products as well as the in vitro condition that best correlates with 
in vivo data (37) . The authors concluded that whilst relying on a dissolution test 
carried out at a single pH is better than not conducting any test at all, in vitro 
topographical characterisation would provide much greater assurance of lot to lot 
uniformity and possibly bioavailability of controlled release formulations. As 
indicated before, this approach can however not entirely replace the assurance 
provided by a single dose or a steady state bioavailability study (36). 
Some researchers have pointed out that the use of single-point correlations, such 
as those already described, may lead to misinterpretation of the results since the 
methods are often based on arbitrarily chosen data points (33). It is preferable to 
attempt to correlate the entire in vivo response time profile with the entire 
dissolution rate profile. Such correlations can result in developing dissolution test 
procedures that can reliably predict the time course of the in vivo response (8, 33). 
Two approaches have been attempted to predict the average blood concentration 
profiles that would be observed for a drug product in vivo from in vitro dissolution 
data. The first of these is purely mathematical where conversion methods are used 
to optimise the amount of information which can be obtained from conventional 
dissolution data . The second approach is one in which special in vitro dissolution-
simulator models are designed specifically to predict bioavailability through 
feedback mechanisms (8). 
An example of a mathematical approach to the problem of in vitro in vivo 
correlations is the application of statistical moment theory to evaluate the in vivo 
dissolution and absorption time. This method was introduced by Riegelman and 
Collier (38). The use of statistical moments in pharmacokinetics follows from the 
fact that drug transit through the body has been recognised as a stochastic process 
(38,39) . If a single molecule is introduced to the body at time zero it is clearly quite 
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unpredictable as to how long the molecule resides in the body. However, if we 
consider a large group of molecules, their behaviour is more regular. The mean 
residence time (MRT) is a characteristic of this collective behaviour and is the mean 
of the residence times of the individual molecules (39, 40) . The main advantage of 
this method is that it describes the overall characteristics of the concentration 
versus time curve and is independent of a description of the pharmacokinetic model 
for drug elimination (41). Riegelman and Collier (38) suggested that the difference 
in the MRT after the administration of a test dosage form and the MRT after the 
administration of an aqueous solution is eventually equivalent to the mean in vivo 
dissolution time MDT. The generally accepted pharmacokinetic definition of mean 
residence time is based on plasma concentration data. Cutler (39) however 
proposed that urinary excretion data can be used in place of plasma concentration 
data, especially when a significant proportion of the drug is excreted in the urine 
unchanged. 
A second mathematical approach to the establishment of in vitro in vivo 
correlations is the use of numerical convolution/deconvolution . Convolution and 
deconvolution algorithms are best described by Linear Systems Analysis. According 
to this the input may be the kinetics of dissolution, absorption or the combined 
dissolution - absorption process. The response of the system may be the amounts 
or concentration of the drug, or one of its metabolites, or any other suitable 
pharmacological effect. Langenbucher (42) concluded that the technique requires 
a minimum of prior assumptions, the only prerequisite is. that the body system 
behaves linearly and time-invariantly. 
A further approach to the development of correlations between in vitro and in vivo 
data is the use of so-called dissolution simulators . These were introduced in an 
attempt to enhance the capability of in vitro dissolution as a predictor of the in vivo 
behaviour of dosage forms. Many of these systems, however, required highly 
complex and costly apparatus which were not necessarily advantageous over the 
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traditional systems (8). One such system which enjoyed some popularity is the 
Sartorius Dissolution Simulator which was designed to be used together with the 
Sartorius Absorption Simulator . The absorption simulator was designed to simulate 
the passive drug transport processes across a lipoidal membrane which occur in vivo 
between the gastrointestinal tract and the plasma . The function of the dissolution 
simulator is to simulate drug dissolution and its subsequent absorption into the 
plasma (33). This system has been used by Smolen (33) and Vau et al (15) with 
mixed success . Smolen advanced the system by incorporating a feedback control 
which was triggered by the in vivo data generated from a reference tablet . This 
method allows for the automatic determination of the time-varying process variables 
necessary to predict in vivo profiles. In addition it simultaneously generates the 
predicted blood concentration-time curves for one or more drug products undergoing 
in vitro dissolution testing (33). These systems, however, have the disadvantage 
that they are too expensive, complex and require highly qualified personnel to 
operate and interpret the data . It should also be noted that in order to prove any 
systems reliability it is necessary to show that the test can identify between 
acceptable and unacceptable batches of formulations (8) . 
It is now generally accepted among pharmaceutical scientists that the present state 
of science and technology does not always allow for the establishment of 
meaningful in vitro - in vivo correlations for slow release dosage forms (43). It is 
further accepted that a single in vitro - in vivo correlation for different products of 
the same drug cannot be accomplished at this time . It appears that a separate 
correlation will have to be developed for each manufacturer's product (44). In vitro 
tests are desirable for the purposes of Ii) providing the necessary process and 
stability determinations of the release characteristics, and (ii) facilitating in the 
approval process when minor formulat ion changes or site of manufacture changes 
are made(43) . The in vitro dissolution procedure used for the quality control should 
be validated by app ropriate in vivo bioa vailability studies (44). 
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In 1988 the US Pharmacopoeial Subcommittee defined in vitro - in vivo correlations 
as "the establishment of a relat ionship between a biological property, or a parameter 
derived from a biological property produced by a dosage form, and a 
physicochemical characteristic of the same dosage form" (45). The subcommittee 
also class ified the correlation methods into four levels, namely A , S, C and D, in 
descending order of priority (44, 45, 46). 
In level A correlations, the in vitro dissolution curve of a product is compared with 
the in vivo dissolution curve, i.e. the curve which is produced by deconvolution of 
the plasma concentration data by model-dependent or model independent methods . 
The in vitro and in vivo profiles should be superimposable. Currently, this is the 
preferred type of correlation for slow release formulations. There should be a 1: 1 
relationship between the in vitro and in vivo profiles (45, 46) . 
Level S correlations compare the mean in vitro dissolution time with either the mean 
residence time of the product in vivo or the mean in vivo dissolution time. This type 
of correlation utilises the principles of statistical moment analysis. These 
correlations are not considered to be 1: 1 correlations as they do not reflect the 
actual in vivo plasma level curves 145, 461 . 
In level C corre lations one dissolution parameter, such as t,O% ' t,O% etc, is related to 
one pharmacokinetic parameter such as AUC, Cm" or T m,,' They represent a single 
point correlation and do not reflect the complete blood concentration curve and are 
useful for the manufacturing of the product in that they can porvide information on 
the lot to lot uniformity . They should not be relied upon to justify changes such as 
formulation mod ifications or manufacturing site changes (461 . 
Level D correlations are qua litati ve relationships of in vitro and in vivo pa rameters . 
These include relating disintegration to in vivo performance . The USP cons iders 
these type of correlations of little value 145, 461 . In the test ing of any slow release 
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dosage form attempts should be made to demonstrate level A correlations . If this is 
not poss ible then attempts at Level B or C correlations should be made (44). 
The cur r ent thinking is that dissolution should be carried out over a full range of 
physiological pH values . It is also recommended that dissolution tests be carried out 
over a range of different ag itation rates and that the media be confined to aqueous 
systems only . Finally, the dissolut ion profile should be characterised over the entire 
release profile with a min imum of at least three t ime points (44) . These concepts 
were first proposed by Levy in 1967 (47) . 
It has been reported that standard pharmacokinetic methods can be used to s imulate 
plasma drug concentrations when a drug is given according to a specific input (48). 
An example of this method was first introduced by Leeson and coworkers (49). The 
proposed method employs a formulation's dissolution data and the drug's 
pharmacokinet ic parameters . From th is, anticipated plasma concentrations for 
var ious formulations are predicted . The potentially most desirable formulation is 
then selected for a pilot bioavailability study (49). This process has been termed as 
"biorelevant dissolution" . The use of the in vitro/ in vivo procedures offer a valuable 
approach to developing new controlled /modified release dosage forms whilst 
m inimis ing the need for clinical test ing, sav ing time and unnecessary expense . The 
application of these methods allow for the development of new products with less 
trial and error (48) . 
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CHAPTER 2 
Experimental Procedures 
2.1 Introduction 
2.1 . 1 Dissolution Studies 
In biop'harmaceutics, rate of dissolution usually refers to the rate at which a solid 
drug dissolves from an intact dosage form or from fragments of the dosage form . 
Dissolution of a drug usually occurs not only from the particles into which a dosage 
form eventually breaks up, but also to some small extent from the intact dosage 
form before disintegration and deaggregation occur (10). The process of drug 
dissolution involves the transfer of individual drug molecules from the solid state 
into an aqueous environment. Since dissolution may be the rate-limiting step in drug 
absorption it is important to investigate the dissolution properties of all new dosage 
forms . 
The gastrointestinal tract acts as a natural sink since it has been shown that the 
drug is absorbed instantaneously following dissolution. According)y, in vitro 
dissolution rate studies should be carried out under in vitro sink conditions. Under 
sink conditions the solute concentration is much lower than the solubility limit of the 
solute. Conversely, under non-sink conditions the concentration of the solute 
increases in the medium until the s.olubility limit of the solute is reached . Therefore, 
dissolution rate limited absorption implies that there is very little or no build up of 
dissolved drug at the absorption site . Hence in dissolution rate studies it is thought 
that sink conditions lead to a better chance of achieving good in vitro - in vivo 
correlations . Sink conditions are usually achieved by us ing a large volume of 
dissolution medium or by replacing the solution constantly with fresh med ium at a 
specified rate (8, 51, 52) . 
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The most common theory of dissolution is the film theory or the diffusion layer 
model which was proposed by Nernst (531. Essentially the process involves two 
steps: (i) solution of the solid at the interface of the solid and the dissolution 
medium and (ii) diffusion from the stagnant layer into the bulk of the medium . The 
drug is thus found at a uniform concentration throughout the bulk of the dissolution 
medium . The first step is very rapid and results in the formation of a stagnant layer 
around the dosage form. The second process is much slower and is therefore 
considered as the dissolution rate limiting step (8, 31). 
The traditional mathematical expression which is used to describe the dissolution 
process is the Noyes-Whitney equation which was first proposed in 1897 and 
modified by Underwood and Cadwallader (55) : 
Eqn 2_1 
where dw/dt = dissolution rate 
k = dissolution rate constant 
S = surface area 
C." concentration of the saturated solution 
C •• , the concentration at any time 
In order for the dissolution rate constant to be defined, the surface area must be 
kept constant and the dissolution medium must be maintained at sink conditions. 
This will provide the intrinsic dissolution rate which is described as the mass of drug 
dissolved in a system with a constant surface area. The intrinsic dissolution rate is 
of use in studying the solubility characteristics of a substance but has limited value 
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in biopharmaceutical applications because the surface of a dosage form changes 
with time. Of more importance is the apparent dissolution rate which may be 
described as the total mass of drug dissolved per unit time. Under sink conditions 
equation 2.1 can be rewritten as: 
dW=kS 
dt Eqn 2.2 
A dosage form must not only serve as a vehicle for drug delivery but must also 
provide a stable environment during storage. During research and development, 
dissolution rate studies should be carried out to ascertain the effects of excipients 
and other process variables on the release of the drug from the dosage form. The 
test conditions need, however, to be optimised in order to yield accurate, reliable 
and reproducible results which can be correlated with in vivo phenomena (56). 
Over the past decades numerous methods have been described for dissolution rate 
studies of solid oral dosage forms (8,32,50,51,57,58,59,60,61,62,63,64). 
An ideal method should meet six basic criteria, namely: reproducibility, sensitivity, 
correlation with in vivo results, flexibility, simplicity and the potential for 
automation. The methods should also be economically practical (32). In the last 
two decades there has been a proliferation of literature concerning the problems and 
deficiencies of dissolution testing. The more flexible a standard method is, the more 
easily it can be adapted to accommodate new findings. A good method should also 
yield data which can be quantitatively related to the theoretical dissolution rate 
equations. Lastly, the method should also be sensitive enough to distinguish 
between products which differ only slightly (51). 
The methods available for dissolution rate testing can be grouped according to 
various characteristics, such as; the geometry of the vessel, the method of 
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agitation, the degree of agitation, the way by which solvent enters and leaves the 
system and the achievement of sink or non-sink conditions. Methods available for 
dissolution rate studies include those in which the dissolution vessel is agitated, 
systems in which the dosage form moves through the medium, apparatus in which 
the dissolution medium flows through the dissolution vessel and methods which 
have some form of mechanical agitation of the dissolution medium. 
2.1 . 1.1 Vessel agitation 
These methods include the Wruble method (65, 66), the rotating flask apparatus 
(67,68) and the Souder and Ellenbogen method (58, 69) (See figure 2.1 a, b, c). 
The method of agitation of the latter is similar to that described in the British 
Pharmacopoeia 1948 and 1953. The rotating flask method became the official 
method of the National Formulary in 1967 (58) for CMRD's and was based on the 
method of Souder and Ellenbogen (58, 69). The apparatus consists of a flask in 
which the dosage form is sealed with the dissolution medium in cylindrical bottles 
which are rotated through 360° end-over-end in a water bath at 37°C . Variations 
of this method have been used by Nessel et al (70) and Chaudhry et al (71). 
Adaptations include the use of different volumes of media, agitation speeds and 
vessel size and shape. This method has however fallen into disuse as the CMRD's 
are now being tested by the official compendial methods (8). A major drawback of 
this method is the difficulty of withdrawing samples without interfering with the 
process. It also does not lend itself to automation which is of particular use in the 
dissolution assessment of CMRD preparations for which sampling times may 
continue for up to twenty four hours. 
2.1.1.2 Dosage form movement 
A second group of apparatus are those in which the dosage form moves through the 
dissolution medium. Modified versions of the USP/NF disintegration apparatus (72) 
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have been widely used . Major modifications of the disintegration appa ratus cited 
in the literature include the elimination of the plastic disc and the replacement of the 
1 O-mesh screen with either a 30- or 40-mesh screen (73 , 74, 75, 76 , 77, 78 , 79) . 
Advantages of this method include the fact that it can be automated and that 
information about tablet dis integrat ion times are also available . 
Drawbacks of these methods include the fact that there is only a single high level 
of agitation which is difficult to assess . With the use of varying sizes of dissolution 
beaker fhe agitation intensity also varies . As a result of the excessive agitation, 
general correlation with in vivo results have not been successful (8) . 
2.1 . 1.3 Flow-through methods 
A third group of dissolution apparatus are those in which the dissolution medium 
flows through the system . An example of such an apparatus is the flow-through cell 
or the column-type flow-through apparatus (fig 2 . 1 d) (32). This method has been 
proposed in response to several disadvantages in the previously discussed methods-
such as the variability in the rate of shear over the particles which leads to large 
variations in the individual rates of dissolution . In this method the dosage form is 
held in a cylindrical cell, made of glass or another suitable material and is immersed 
into a waterbath at 37°C. At the bottom of the cell there is either a porous glass 
p late i .e . scintered glass, or a bed of glass beads wh ich should be capable of 
dispersing the solvent to provide laminar f low . A filter is also incorporated into the 
top of the cell. A modificat ion of this apparatus is the cascade barrier bed which 
was used by Rippie et a/ (80) . The system can be run either as a closed system (62, 
8 1) or as an open system (51 , 82 , 83,84 , 85) . An advantage of the open system 
is the ab ility to maintain sin k conditions . Th is is especia lly important for drug 
substances which form saturated solutions in volumes of 10- 2 0 % of the 900ml 
normally used in the off icial compendia I methods. The open flow-through method 
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allows for the maintenance of near perfect sink conditions since fresh dissolution 
media is continually presented to the dosage form . Conversely, in the closed system 
fresh media is only presented to the dosage form once , which implies that the drug 
concentration of the medium gradually increases as the drug dissolves. 
Further advantages of the flow through method include such features as built-in 
filtration, the convenience of changing the pH during testing, and fewer external 
variables resulting in more reproducible results. Another advantage is that the 
dosage form may be placed in a fixed position which makes it easier to maintain a 
constant and repeatable fluid-flow pattern around the dosage form than is the case 
with the paddle or rotating basket methods (8). Furthermore, problems such as 
wobbling, shaft eccentricity, verticity, vibration, stirrer position etc, which occur 
in the official USP methods, do not exist (32) . 
The open flow through systems also have their inherent disadvantages, the most 
important of which is the tendency of the filter to clog due to the unidirectional 
flow . Dissolution characteristics may change if particles adhere to the filter causing 
turbulence at the solid/liquid interface. The parameters of flow rate and the 
influence of ripple effects must also be investigated further and understood (8, 32, 
50). 
2.1 . 1.4 Beaker methods 
The fourth group of dissolution apparatus can be classified as those having a large 
dissolution vessel with a mechanical agitator of some description. This group 
encompasses a large number of methods including the Levy and Hayes beaker 
method (86, 87,88,89,90,91), the Pernarowski basket stirrer apparatus (92) and 
the USP rotating paddle method (72) . Other methods include the stationary basket 
method used by Withey (60), the magnetic basket dissolution apparatus used by 
Needham (91) and the rotating filter - stationary basket (63, 93) (fig . 2.1 e - j). 
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Goodhart et a/ (64) developed and evaluated an apparatus for both testing 
disintegration and dissolution rates of tablets and capsules in 1973. These methods 
of dissolution have gained widespread use for many tablet and capsule formulations. 
They are relatively simple to use and are easily adapted to automated use and allow 
for a number of determinations to be run simultaneously (93,94,95,96). 
(i) The USP Rotating Basket Apparatus 
In 1970 the USP dissolution apparatus, described as the rotating basket apparatus 
first appeared (figure 2.2). This is based on the Pernarowski basket stirrer 
apparatus described in 1968 (92) and which consisted of a simple stirrer flask with 
a round bottom and three necks. It also had a tablet/capsule container built into it. 
The basket method has, because of its official status, been widely applied for both 
conventional dosage forms, such as tablets and capsules, as well as for CMRO's 
(89,97). The official apparatus (See figure 2.2) consists of a covered cylindrical 
vessel with a hemispherical bottom made of glass or any other suitable transparent 
material. The vessel has a capacity of 1000ml and must be flanged at the top. A 
fitted cover with openings for a thermometer, the drive shaft and the sample 
withdrawal apparatus may be used to limit evaporation. The vessel is partially 
immersed in a suitable waterbath so that the temperature of the medium in the 
vessel is kept constant at 37° ± 0.5°C. No part of the assembly, including the 
environment in which the apparatus is placed should cause any significant agitation 
or vibration. The stainless steel basket assembly consists of two parts, viz. the 
basket which is constructed of 40-mesh stainless steel and a shaft to which the 
basket is attached. The shaft is placed so that its axis of rotation does not deviate 
by more than 2mm from the vertical axis. It must also rotate smoothly and without 
significant wobble. A speed regulating device must also be included so that the 
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rotational speed of the shaft can be selected and controlled to within ± 4%. The 
distance between the inside bottom of the dissolution vessel and the basket must 
be maintained at 25 ± 2mm 18, 72). 
Various modifications to the basket apparatus have been described. Mesh sizes of 
10-,20- and 30-mesh have been evaluated. Each type of mesh presented their own 
problems such as clogging or releasing of particles. Baskets with 80-mesh screens 
have been used for the testing of microencapsulated particles. This particular mesh 
size was selected since it retained the particles whilst still allowing the dissolution 
medium to penetrate the basket without clogging 18) . 
A variety of dissolution media are used and are outlined in the individual drug 
monographs in the USP 172). If the dissolution medium is a buffered solution, the 
pH should be adjusted to within ± 0 .05 pH units of the specified pH (32). 
Dissolution media used in the testing of CMRD's include USP simulated gastric fluid 
for one or two hours followed by USP simulated intestinal fluid (24). 
Even though today many in vitro dissolution studies are performed using the basket 
apparatus, the method has nevertheless attracted much criticism over the years. 
This method has also shown to be adversely affected by a number of variables which 
led to the development of an alternative method, namely the rotating paddle 
apparatus. 
(ii) The USP Rotating Paddle Apparatus 
The second official compendial method noted in the USP XXII/NF XVI (1990) 172) 
is the rotating paddle dissolution apparatus Ifig. 2.3). This method of dissolution 
rate testing is becoming increasingly popular 198, 99). The construction of the 
apparatus is very similar to that of the rotating basket with a 1 OOOml vessel made 
of glass or other suitable transparent material and a variable speed drive . 
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The difference is that a paddle, formed from a blade and shaft, is used as the stirring 
element in place of the basket. The blade passes through the diameter of the shaft 
so that the bottom of the blade is flush with the bottom of the shaft. During the 
course of the test, the blade must remain 25 ± 2mm from the inside bottom of the 
vessel. The blade and shaft consist of a single metallic entity and may be coated 
with a suitable non-reactive fluorocarbon polymer. The dosage unit is allowed to 
sink to the bottom of the vessel before rotation of the blade is started. 
For dosage forms which float on the dissolution med ium a small loose piece of non-
reactive material, such as a few turns of wire or a glass helix, may be used to sink 
the dosage form (8, 72, 100). This has however been criticised as being 
impractical. The helix may also become clogged with sticky material form the 
capsule. This may influence the release of particles from the dosage form and hence 
influence dissolution . The wire may also react with the dosage form or the 
dissolution media especially if acidic media are used. There are also no strict 
definitions for the size of the helix which may lead to many interpretations of its 
exact description . Some researchers have modified the paddle method to include 
a basket, similar to the USP basket, to hold the dosage form (101) . 
Discrepancies in dissolution rates determined with the use of the paddle apparatus 
have been traced to minor variations in the vertical alignment of the paddle shafts . 
To minimise errors the base of the apparatus must be horizontal, the shafts of the 
paddles must be vertical, each shaft must be positioned along the vertical axis of the 
dissolution vessel and the paddles must be positioned at a standard depth in the 
vessel (102). It has also been found that the curvature of the base of the 
dissolution vessel may influence the results. Vessels with a curvature which is less 
than that of a sphere cause a higher bias. These differences can be ascribed to 
differences in flow patterns brought about by the vessel shape (103). 
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(iiil Limitations of the official methods 
The methods described have a number of shortcomings which may affect the 
results. At relatively low agitation intensities, together with the shape of the 
dissolution vessel, mound formation of the granules or particles at the bottom of the 
beaker may occur. This phenomenon may lead to a decreased surface area being 
presented to the medium (681. Researchers have also reported that the location of 
the mound may influence the dissolution results, i.e . whether the mound of 
particles forms in the centre of the beaker or at the periphery, as would be the case 
with beaker type vessels (104, 1051. 
Lerk and Laga (861 have shown that the positioning of the dosage form can have an 
effect on the dissolution rate. The highest rates were found when the dosage form 
was placed in the centre of the vessel. Dissolution rates were found to decrease as 
the dosage form was moved to the periphery of the vessel. Furthermore, it was 
found that higher values were determined for tablets that were placed against the 
wall of the basket than when they were placed centrally . 
Two types of agitators have been used in the beaker method, viz . the marine 
propeller and straight-bladed turbine impeller. 80th of these produce mainly radial 
and rotational flow patterns . The marine propeller produced longer mixing times 
than the straight-bladed impeller. Mixing times also appeared to be dependent on 
the direction of rotation of the propeller and the angle of the propeller blades from 
the horizontal - a decrease in the angle producing an increased mixing time (86, 
1061 . In order to centre the dosage form, the authors recommended that the beaker 
method be modified to use round bottomed beakers and straight bladed impellers 
(861 . 
Flow patterns in the dissolution vessel must be consistent in order to obtain 
reproducible results . Dissolution rate data are also affected by the geometry of the 
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stirring device, shape of the dissolution vessel, alignment of the stirring device and 
the presence of sampling probes and a thermometer in the dissolution medium. Flow 
patterns have been found to affect the dissolution rates through slight differences 
in the shape of the bottom of the dissolution vessels (107). It was shown that the 
differences in shape altered the hydrodynamics within the vessel and subsequently 
affected the dissolution patterns. It was also noted that particles tended to 
aggregate at the periphery of the vessel where they tend to remain undisturbed. 
Withey and Bowker (105), in an investigation into the flow patterns in various 
dissolution methods, found undesirable mixing and flow characteristics in all the 
methods that they investigated. It has also been found that the mixing times and 
hydrodynamics of the dissolution medium are dependent on or affected by the 
density and viscosity of fast dissolving drugs and excipients (106). The effect of 
the return of large volumes of dissolution medium to the vessel and the effects of 
the agitator shaft length have been reported by Carstensen et al (108). They found 
that the longer shaft length resulted in increased dissolution rates. 
Sampling positions in the dissolution vessel also influence the results of the 
dissolution test. Variations in the sampling point should be avoided as this causes 
poor reproducibility, especially at low rotational speeds of the basket (105,106). 
This phenomenon seems to occur as a result of inadequate mixing in the bulk of the 
dissolution medium (109). The USP XXII/NF XVI (72) recommends that samples be 
removed at a point midway between the top of the basket or paddle and the surface 
of the medium, not closer than 1 em form the sides of the flask. The BP 1980 (110) 
varies slightly - it recommends a sampling point halfway between the basket wall 
and the wall of the vessel, level with the midpoint of the side of the basket. This 
has since changed in the BP 1988 (111) to the same specifications as those in the 
USP XXII. 
Vibration can also be a problem in a dissolution system and may have many causes. 
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This problem was particularly evident in early systems where the drive motor and 
water pump were not separated from the waterbath and the dissolution vessels. 
This has the effect of changing the flow patterns of the dissolution medium and 
introduces unwanted energy into the dynamic system (8, 112). In a study on the 
effects of vibration on the dissolution process, Beyer and Smith (113) stated that 
excessive vibration of the apparatus can lead to significant differences in the 
dissolution times for different formulations. Newer designs of dissolution apparatus 
do not have this problem since the drive motor and water recirculation pump are 
separated from the waterbath. 
Corrosion of the dissolution vessel is also a problem which occurs with the USP 
rotating basket apparatus. This was shown by Mattock et al (1 14) who exposed the 
basket to USP simulated gastric dissolution fluid for 42 hours - this led to the basket 
being unsuitable for further investigation. This problem can be minimised by using 
more dilute HCI solutions or replacing them with buffered solutions. Alternat:vely 
the basket can be coated with a very thin layer of gold to make it more acid 
resistant, but this is costly (8). Corrosion of the basket may also lead to excessive 
abrasion of the dosage form resulting in increased dissolution rates (114). A further 
problem of the 40-mesh screen of the basket apparatus is the clogging of the basket 
by particulate matter (115). This leads to an impairment of visual observation of the 
capsule or tablet in the basket. 
Dissolved gases may also affect the dissolution process. If this is the case, then the 
dissolution medium must be degassed prior to commencement of the procedure. The 
effect of dissolved gases include a change in the pH of the dissolution media, 
although this is less likely to be the case in buffered media. Dissolved gases may 
also influence the flow patterns within the medium as the bubbles rise to the 
surface. Air bubbles may also collect on the basket surface thereby altering the 
mesh porosity. In addition, air bubbles may attach to the dosage form before 
disintegration thereby altering the disintegration and deaggregation processes via 
34 
an alteration of the effective surface area exposed to the dissolution medium (8). 
A further problem with air in the system is the entrapment of air within the basket 
itself. Two types of these bubbles seem to occur with the basket method, viz., 
entrapment of air in the basket device causing floating of the dosage form at the top 
of the basket, and the entrapment of an air bubble at the base of the basket. There, 
however, appears to be no significant effect due to these (8). A possible method 
of avoiding the first situation was proposed by Sarapu and Clark (116) who 
suggested that the surface of the basket drive plug be made conical in shape. 
The variability that occurs in the results from different laboratories and to an extent 
within laboratories have raised questions about the reproducibility of dissolution 
testing (117) . One way to improve this situation was seen in the use of specially 
prepared test samples which can act as calibrators for dissolution testing apparatus. 
Three tablets were selected for a collaborative study - these included a 
nondisintegrating 300mg salicylic acid tablet, a disintegrating 50mg prednisone 
tablet and a 1 OOmg nitrofurantoin tablet . For official compendial use the latter has 
fallen away. Operating standards, apparatus and limits were also decided upon. 
The study concluded that appropriate standards had been identified as dissolution 
calibrators and that acceptance limits for these had been established. 
In a study conducted by Prasad et 81 (118) to evaluate different performance 
standards it was concluded that no single standard can predict the suitability of the 
basket or the paddle dissolution apparatus. This was found after tests were 
conducted using the USP prednisone calibrator which proved to be sensitive to 
perturbations by the basket method and not the paddle method. The converse was 
found for a prednisone standard from the National Centre for Drug Analysis (NCDA). 
Storage conditions may affect the dissolution rate of the calibrator, the acceptance 
range may be too broad and validation procedures may be run too infrequently. In 
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order to continually monitor the dissolution apparatus, calibrators should be run at 
the same time as samples. The use of in vitro dissolution calibrators was 
demonstrated by Mazeul et 81 (119) . The standard was a preselected lot of the same 
formulation as that which was being tested . Th is standard was run simultaneously 
with the product being tested and adequately compensates for small changes in test 
conditions, such as slight pH and temperature changes, which may influence 
dissolution rates. This, therefore, allows a continuous control of the dissolution 
apparatus . 
It has also been shown that large sampling probes may cause significant 
disturbances in flow patterns in the dissolution medium. This was particularly 
evident in automated systems where the sampling probe remains in situ for extended 
periods (120). The use of small capillary type probes are recommended as this 
reduces interference of the hydrodynamic conditions. 
2 . 1 . 1 . 5 The Bio-DisR Apparatus 
The Bio-DisR dissolution apparatus was specifically designed to assess the 
d issolution characteristics of extended release tablets and multiparticulate systems . 
Impetus for its design were derived from the fact that: 
(a) the need for a robust, simple and relatively inexpensive method for 
dissolution of controlled · release formulations ; 
(b) the need to carry out dissolution testing employing sequential changes 
of pH values without the need for manual transfer of the media as in 
the compendial methods; 
(c) the need to include autom at ion of the procedure and allow the use of 
various programme se quences, including those to 24 hours (121). 
The apparatus (fig 2 .4) consists of six rows of six glass containers of 225 ml 
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Figure 2.4 Bio-Dis dissolution apparatus. 
capacity called the outer dissolution tubes. The inner dissolution tubes consist of 
a glass tube of approximately 10 cm in length closed off at each end with a plastic 
mesh filter holder. The top of the tube is screwed into the shafts of the shaft driver. 
The shaft driver moves the inner tubes into the outer dissolution tubes through a 
gentle up and down motion. The degree of agitation can be precisely controlled via 
a variable speed adjuster . The top and bottom ends of the inner tubes are fitted 
with either 74, 250, 420 or 840 micron mesh screen in order to prevent the particles 
from falling into the outer dissolution tubes. All the outer tubes are suspended in 
a suitable waterbath maintained at 37 DC. 
Weintraub and Gibaldi 168) have reported that dosage forms, including CMRD's, may 
produce a cone or mound of particles or pellets at the base of the vessel. 
Furthermore, a semi-stationary film of drug concentration may form in the cone 
when the paddle or basket apparatus are used, thereby retarding the drug release. 
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Increasing the agitation rate may lead to a faster dissolution rate but may 
simultaneously lead to an increased abrasion of the pellet membranes . These 
problems are adequately overcome by the Bio -Dis apparatus (121). 
The Bio-Dis dissolution apparatus is designed so that pellets , sol id particles and 
tablets move through the dissolution manner analogous to their movement in the 
rotating bottle apparatus. The pellets are kept moving and only come into contact 
with the liquid and the soft mesh i. e. they undergo similar conditions to those that 
they would undergo in vivo . The rate of release of drug form the pellets is thus not 
hindered by a semi-stationary film of drug concentration around the pellets . It is 
therefore expected that the Bio-Dis apparatus will give excellent correlation of drug 
release with the in vivo situation with a w ide number of sustained release 
preparations (121). 
This apparatus has recently been employed by Esbelin et al (122), in a study to 
investigate the dissolution properties of various extended release formulations of 
theophylline . 
2.1 .2 Analytical methods 
Many techniques are available for the analysis of dissolution samples . Two such 
methods which have gained widespread use are UV spectrophotometric and High 
Performance liquid Chromatographic IHPLC) methods. These methods each have 
their own advantages and disadvantages . 
The major advantage of UV spectrophotometr ic over chromatographic methods is 
that the samples for analysis do not ha ve to be manipulated pr ior t o introduction into 
the spectrophotometer . A second factor whi ch makes thi s method particularly 
suited to routine analysis is that it is a very rap id technique, requiring only a few 
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seconds to analyse a single sample using the highly specialised equipment that is 
ava i lable today. A disadvantage of these methods is that they lack specificity i. e . 
if two compounds in a sample absorb UV radiation at the same wavelength the 
absorption value obtained will be due to both compounds. For these types of 
situations it is necessary to separate each component by HPLC methods. 
The major advantage of HPLC methods is its specificity. The specificity is obtained 
from the fact that compounds are injected onto a collJmn from which they are eluted 
at different times. Thus if a sample contains more than one compound they may be 
separated on the column and detected as two separate entities by a suitable 
detection system. Drawbacks of HPLC methods include the fact that some 
manipulation of the sample is often necessary prior to analysis and that the analysis 
time per sample usually takes several minutes. Recently, however, a fully 
automated HPLC apparatus for dissolution rate studies has been developed (123). 
2 . 1.3 Bioavailability 
Bioavailability is an absolute term that indicates the measurement of both the true 
rate and total amount or extent of a drug that reaches the systemic circulation 
following the administration of a dosage form. Absolute bioavailability can only be 
determined following the administration of an intravenous dose, whereas 
comparative bioavailability studies allow the assessment of relative bioavailability. 
Bioavailability is usually assessed relative to a standard and is often also referred 
to as "biological availability" or "systemic availability" (124) . The activity of a drug 
at a site in the body is usually related, in a quantitative relationship, to the 
concentration of the drug in the blood and to a lesser extent to its concentration in 
other fluids. There is usually also a relationship between the availability of the drug 
and the rate at which the body excretes or metabolises the drug (56). The 
absorption rate constant, k" is the net effect of the rate of dissolution of the drug 
in the biological fluids at the site of absorption and the net transfer of the compound 
from the site of absorption to the circulation (10). In order to provide a general 
evaluat ion of the overall rate and extent of the absorption of a drug, several 
parameters are used. 
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The serum concentration time curve is the focal point of bioavailability assessment 
and is obtained when serial bloods sample are taken after the administration of a 
dosage form (124). 
Pharmacokinetics is mainly associated with the quantitative characterisation and 
treatment of the time course of the drug through the different compartments of the 
body. Pharmacokinetics can be defined as the application of kinetics to Pharmakon 
which is the Greek word for drugs and poisons. The problem of establishing 
adequate metbods to interpret in vivo data frequently leads to the use of 
compartment methods. The pharmacokinetic compartment models are an 
approximation of the biological system. The models are mathematical equations 
which are used to describe and interpret the data which are obtained by in vivo 
experimentation . Correctly selected models allow for the simulation and prediction 
of pharmacokinetic data. Most drug behaviour in a biological system can be 
described by either a one or two compartment model (8, 10, 125). 
A number of model independent parameters can be derived or calculated. These 
include such parameters as tmul emu and AUC. The maximum concentration, ernul 
and the time at which the maximum occurs, t m .. , are a crude indicat ion of the 
absorption rate and can be directly estimated from the serum concentration versus 
time curve or such data. A disadvantage of these parameters is that they do not 
only refer to the absorption process but also to the disposition of the drug. 
Although t m .. is influenced by the absorption rate, any absorption processes which 
occur after t m .. have no influence on that parameter (125). 
Area under the plasma/serum concentration curve (AUC) is defined as the area under 
the serum concentration versus time curve from zero time to the last sample time 
point or to infinity (AUCo _ 00)' The area under the curve provides an estimate of the 
extent of the absorption. 
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In statistical moment theory, as already mentioned, the absorption process is 
regarded as a stochastic process. Statistical moments are characteristic of the 
shape of the statistical distribution curve, such as the time course of a serum 
concentration time curve following a single dose and are therefore only dependent 
on the observed time course data and hence also independent of the 
pharmacokinetic compartmental model. The use of this approach allows the 
separation of the absorption and disposition processes. From the serum 
concentration versus time curve, the area under the moment curve (AUMC) can be 
calculated. The ratio of the AUMC. to the AUC. yields the in vivo mean residence 
time (MRT). The MRT method of pharmacokinetic analysis has the advantage over 
other methods in that it is a non-compartmental method (38). 
The zero moment represents the AUC • . The AUMC. is defined as the area under the 
curve of the product of time, t, and the serum concentration, C p ' from zero time to 
infinity. The MRT can thus be calculated as follows: 
MRT = 
• f t Cp dt 
o 
• 
= 
AUMC. 
AUC • 
Eqn 2.3 
The MRT is defined as the mean time for intact drug molecules to move through the 
body and it provides information about all the kinetic processes including the in vivo 
release from the dosage form, drug absorption and the disposition processes (38). 
The MRT for non-instantaneous input (n.i. v) involves a mean absorption time (MAT) 
and is defined as: 
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MRT ; MATn . i . v + MRTi . v Eqn 2.4 
The MAT refers to the mean time involved in the in vivo release and absorption 
processes as they occur in the input compartment. In order to evaluate the MAT, 
the MRT;,. should be subtracted from the MRT,.i.. . The MAT can however be 
approximated in cases where the concentration time curve yields a terminal log-
linear slope from which the terminal rate constant, A" can be derived . The 
rec iprocal of A, is deducted from the MRT to give MAT""" ", the uncorrected mean 
absorption time. 
MATuncoIr = MRTn, i.v 
1 
Az Eqn 2 . 5 
When using multi-compartment kinetics this would result in an error, however, if a 
solution and solid dosage form were evaluated in the same person , the error term 
would be constant . For an ex travascu lar dose equation 2 .5 takes on the following 
form, where MAT,,". refers to the exact value of MAT: 
MATuncorI 
1 
A1 
1 
A2l Eqn 2 . 6 
When no intravenous data are available MAT offers significant advantages over the 
use of t m " as a means of comparing ab so rpt ion rate s since the latter depends on the 
d isposit ion and absorption of the drug w hereas MAT is independent of the 
d ispos it ion 138, 126) . 
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A further parameter which can be estimated from bioavailability data is the 
absorption rate . This constant can be determined in a number of ways. One method 
is by the use of the Wagner-Nelson method (B, 125, 127) which assumes a one 
compartment open model and linear ·kinetics. The method has, however, also been 
successfully applied to a two compartment model in certain instances by Wagner 
(12B) . 
Assuming that the druQ elimination is by a first order process, then: 
Amount absorbed Amount in body + amount eliminated 
v Cp + CL AUCo_c 
The fraction absorbed, F .. to time t is given by: 
Cp + k AUCo_c 
k AUC
o
_ 
Eqn 2.7 
Eqn 2.8 
The value of the absorption rate constant, k, can be estimated from the slope of the 
terminal concentration-time data if the absorption is sufficiently slow. 
The Wagner-Nelson method has the following advantages: (i) it does not require 
intravenous data, Iii) no prior estimate of the volume of distribution is required and 
(iii) no limitations are placed on the order of the absorption process . Whilst the 
method is convenient, a number of shortcomings exist in determining the absorption 
profile without intravenous data. 
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2 . 1.4 Correlative methods 
Dissolution data can be presented in a number of different ways. The simplest 
format is to plot dissolution profiles graphically representing the percent or amount 
dissolved versus time on cartesian axes . More recently, dissolution data have been 
presented in the form of multi-dimensional plots. These are three dimensional 
representations of the percent or amount of drug dissolved versus time against some 
other parameter of the dissolution test conditions, such as pH. 
In order to obtain more meaningful information from in vitro dissolution data some 
mathematical manipulation must be performed. In vitro drug release involves a 
number of complex kinetic processes and it is therefore illogical to assume that in 
vitro dissolution will fit a specific zero or first order equation. The problem is 
greatly facilitated by the application of a general mathematical function in which the 
entire dissolution curve is described in terms of meaningful parameters. The Wei bUll 
function is an example of such a mathematical distribution . 
2 . 1 .4.1 The Weibull Function 
The Weibull function, which is very versatile, was first proposed by Rosin in 1933 
and reinvestigated by Weibull in 1951 (129) . The distribution is now often referred 
to as the Rosin-Rammler-Sperling-Weibull, RRSW, distribution . The function has 
been applied to a number of distributions such as y ield strength of steel fibres, size 
of insects and the failure rate of electronic components (129, 130) . The function 
has been applied to linea rise dissolution data by Langenbucher (131, 132) and has 
also been applied by many other researchers to describe dissolut ion data and 
dissolution curves (133, 134, 135) . 
The Weibull function parameters were interpreted by Chr istensen et al (134) for drug 
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release from CMRD's. Riegelman and Upton (136) described the application of the 
function to in vitro dissolution rate data and to the in vivo absorption rate data 
obtained after the administration of the same dosage form to a group of volunteers. 
When the Weibull function was compared to a complex function proposed by 
Pederson, both equations were found to fit the data equally well (133). 
The Weibull function is represented in the following equation: 
_(C-To)p 
F = F~ [1 - e Cd J Eqn 2.9 
In the above equation F is the dependent variable and is representative of the 
fraction of the administered dose which is dissolved at time t. The fundamental 
form of the equation is not defined for data points within the time period 0 to to and 
an ordinate value of F = 0 is usually assigned in this range. 
F~ gives an indication of the amount of active ingredient which is released from the 
dosage form at infinite time under the given experimental conditions. It 
characterises the actual drug content of the dosage form. Analytical or method 
errors such as incorrect calibration, dilution, volume, flow rate and interactions or 
degradation in solution will affect the F ~ value. 
The lag time, to, describes any processes which occur before the onset of 
dissolution, e.g. removal of a tablet layer, disintegration of a tablet or the rupturing 
of a capsule. In most cases this will be equal to zero. The time parameter, t" 
represents a scaling factor of the time axis with two individual curves differing in 
t, appearing only as stretched or shortened along the x-axis. When t-to=t" then 
F = 1-e" = 1-0.368 = O. 632 i.e. t, is representative of the time required for 63.2 % 
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of the drug dose to be dissolved. 
The shape parameter, p, defines the shape of the curve and is a non-dimensional 
number ranging from zero to values greater than one. When p = 0 the system 
describes zero order dissolution with p = 1 describing a system in which simple first 
order exponential characteristics are displayed. Decreasing values of p correspond 
with a steeper initial part of the curve followed by a flattened tail in the final part. 
For values of p greater than 1 .and p ..... oo the curve takes on a sigmoidal shape, 
increasing in sigmoidicity as the value of p increases (131,136). 
Langenbucher has applied the Weibull distribution function to linea rise dissolution 
data. Equation 2.9 takes on the following form: 
log [-In (l-m) 1 = blog (t-TJ -loga Eqn 2.10 
A linear relationship is obtained for a log-log plot of -In(1-m) versus t (131). The 
Weibull distribution has also been applied to describe in vivo absorption kinetics by 
Piotrovskii (137). Using theophylline data he concluded that the Weibull function 
adequately described absorption data and may be considered as one of the possible 
approximations of the complex process of absorption. 
2.1 .4.2 Computational Predictive Methods 
Data from dissolution studies have also been employed in the prediction of in vivo 
responses. These methods are often referred to as computational conversion 
predictive methods. Leeson and co -workers (49) applied such an approach to 
develop controlled release products in lieu of the trial and error approach of 
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conducting multiple bioavailability studies . The use of in vitro dissolution data as 
a basis for the design and development of any product with specific in vivo 
performance necessarily implies an in vitro-in vivo correlation. As discussed in 
chapter 1 the use of un ivariate correlation methods are of little utility for CMRD's. 
It would appear that relating the in vitro dissolution behaviour of a CMRD to the 
whole plasma concentration time curve could be of great value during dosage form 
development. 
Although this technique is based upon theoretical considerations, it represents a tool 
for the development of controlled release dosage forms . The ability to predict a 
dosage form's in vivo performance based on in vitro measurements in combination 
with a drug's pharmacokinetic parameters clearly offers distinct advantages. 
The success of the above approach for the prediction of plasma level curves is based 
on four assumptions: 
i) The products in vitro dissolution must mimic the in vivo 
dissolution; 
ii) The main pharmacokinetic parameter of the drug in the 
controlled release dosage form which should not differ from 
those found in the conventional dosage form is clearance; 
i ii) There is no absorption window for the drug under study; and 
i v) Plasma concentrations are directly related to the drugs 
efficacy . Although a correlation between in vitro dissolution 
rate and bioavailability might still be achieved even if plasma 
drug concentrations do not relate to pharmacological effect, 
the value of such a correlation would be of no practical value. 
The procedure used to predict the in vivo profiles is summarised in the following four 
steps: 
i) Determination of the products in vitro dissolution rate and the 
subsequent development of an appropriate dissolution 
equation ; 
47 
ii) The development of a pharmacokinetic model equation for the 
drug. Ideally this information should be obtained from data 
derived from the administration of a solution of the drug or if 
this is not possible, from a rapidly dissolving dosage form; 
iii) Redefinition of the pharmacokinetic model by substituting the 
in vitro dissolution equation for the dosage form into the 
differential form of the pharmacokinetic model equation; and 
" iv) The generation of the expected plasma concentration-time 
curve using the parameters obtained in (i) and (ii) and the 
equat ion derived in (iii). 
An important aspect of this method is the careful determination of the in vitro 
dissolution rate, since the method is almost totally dependent on this information. 
In general a three component model is used. The general equation which assumes 
that the CMRD has an immediate release fraction, a fast first order releasing fraction 
and a slow first order releasing fraction is as follows: 
Ad = FJD + F,D [A) + F.D [B) 
where : 
A = 1-exp( - K,t) 
B = 1 - exp (- Ks t) 
Eqn 2_11 
where Ad is the amount dissolved, D is the dose, F, the immediate release fraction, 
F, is the fraction in the faster exponential portion, F. is the fraction in the slower 
release portion, K, is the dissolution rate constant for the fast fraction, K. is the 
dissolution rate constant for the slower fraction and t is the time (49) . Models for 
a three component release, a model for a zero order release followed by first order 
release and a model which employs two compartment kinetics have been developed 
and are shown below . 
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and are shown below. 
Model A : Equations for a first order release with three fractions . 
where: 
A = 
B = exp (-K. t) 
c = 
exp ( -K.1 t) 
where: 
D = 
exp (-Ks t) 
E= 
exp (-K. t) 
F= 
exp ( - K. 1 t) 
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The plasma concentration time curve is generated from the following equation: 
Model B: Equations for zero order release prior to first order release. 
[exp (-K. t) -exp (-Ke t)] 
Model C: Equations for first order release following zero order release. 
c= exp ( -Kd t) 
+ 
Ko } 
-- [l-exp(-K t)] exp(-K t) K a a e 
• 
Model D: 
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Equations for first order release, assuming a three component dosage 
form, using a two compartment model. 
where: 
A ; 
B ; 
c; 
(K. -K21 ) exp (-Kat) 
(13 -Ka) (Ka -a) 
(a-K21 ) (exp(-at) 
(a - (3) (K. - a) 
(13 -K21 ) exp (-13 t) 
(a-p) (p - Ka) 
where: 
D; (Kf -K21 ) exp (-Kft) 
(13 -Kf ) (Kf-a) 
E; 
F; 
G; 
(K21 -K) exp (-Kat) 
(13 -Ka) (Ka -a) 
(a -K21 ) (Ka-Kf) exp (-at) 
(a -(3) (Kf-a) (Ka-a) 
(p-K21 ) (Kf-K.) exp (-13t) 
(a -(3) (13 -Kf ) (13 -K.) 
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K.KsF,jJ 
Vd(K.-Ks) 
[H+I+J+K1 
where: 
H= 
I = 
J= 
K= 
(Ks -K21 ) exp (-Kst) 
(~-Ks) (Ks-a) 
(K21 -K.) exp (-Kat) 
(~-K.) (Ka -a) 
(a-K21 ) (Ka-Ks)exp(-at) 
(a -~) (Ks - a) (Ka-a) 
(~-K21) (Ks-Ka) exp (-~t) 
(a -~) (~-Ks) (~-Ka) 
The plasma concentration time curve is generated from the following equation : 
Definition of variables: 
C;m concentration due to immediate release fraction 
C, concentration due to fast release fraction 
C, concentration due to slow release fraction 
K, absorption rate constant 
Ke elimination rate constant 
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t time 
V d apparent volume of distribution 
D dose 
F'm immediate release fraction of dose 
F, fast release fraction 
F, slow release fraction 
K, rate constant of fast fraction 
K, rate constant of slow fraction 
Ko zero order release rate constant 
Kd f i rst order release rate constant 
to time of zero order release 
a el imination rate constant for alpha phase 
B elimination rate constant for beta phase 
K21 distribution rate constant 
The foregoing equations were used Ivide infra : chapters 3 and 4) to simulate drug 
concentration versus time profiles using the appropriate pharmacokinetic constants 
obtained from the in vitro and in vivo studies reported. 
This techn ique can be modified so that it is no longer necessary to design a number 
of different formulations. The desi red plasma concentration-time curve is generated 
using the drugs pharmacokinetic parameters and then the in vitro characteristics of 
the dosage form are computed in order to obtain the dosage form wh ich will provide 
that particular response. 
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2.2 Methods 
2.2.1 Chemicals, Drugs and Reagents 
i) Ortho-Phosphoric acid, 85%, Holpro Analytics, RSA 
ii) Sodium dihydrogen phosphate, SAARChem, RSA 
iii) Sodium hydroxide, BDH Chemicals, Analar, RSA 
iv) Hydrochloric acid, 34%, Holpro Analytics, RSA 
v) HPLC grade Methanol, Burdick and Jackson, USA 
vi) HPLC grade Acetonitrile, Burdick and Jackson, USA 
vii) Theophylline powder, batch L085295, Lennon Limited, RSA 
viii) Indomethacin powder, batch L066133, Lennon Limited, RSA 
ix) TheodurR 300mg tablets, batch A800413, Adcock Ingram, RSA 
x) Theophylline Test Product 1, batch 6081, Lennon Limited, RSA 
xi) Retafyllin R 300mg tablets, batch Ol-IS, Orion Pharmaceutica, Finland 
xii) Indocid RR 75mg capsules, batch N4048, Logos Pharmaceuticals, RSA 
xiii) Indomethacin Test Product 2, batch 5791, Lennon Limited, RSA 
xiv) Caffeine powder, batch L046158, Lennon Limited, RSA 
xv) Naproxen powder, batch 23092, Lennon Limited, RSA 
xvi) Decon, Atomic Research, RSA 
2.2.2 Equipment 
i) Pharmatest PTW-S Dissolution Apparatus, Pharmatest, Germany 
ii) Beckman DU 68 Spectrophotometer, Beckman Instruments, USA 
iii) Model M51 0 constant flow pump, Waters Associates, USA 
iv) Model 71 OB WISP Automatic Sample Injector, Waters Associates, USA 
v) Model 481 Lambda Max LC Spectrophotometer, Waters Associates, USA 
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vi ) C,g 150mm x 4 . 6mm i .d . Hypersil 5pm column, Phenomenex, USA 
vi i) Model 561 Strip Chart Recorder , Perkin Elmer, USA 
2.2 .3 Additional Equipment 
i) Model 601 Digital lonanalyser, Orion Research, USA 
i i) Model 2004MP Analytical Balance, Sartorious, USA 
i ii) Adjustable volume pipettes , Pipetteman, SA 
i v) Rheodyne 7125 Injector, Rheodyne Inc ., USA 
v) Model 1040A Diode Array Ultraviolet Detector, Hewlett Packard, USA 
vi) Model 85A Data Processor, Hewlett Packard, USA 
vii) Microlab-P Programmable Automatic Pipette, Hamilton-Bonaduz-
Ag,Switzerland 
viii) Vortex-Genie, Scientific Industries, USA 
ix) 1 Oml plastic syringes, Promex , SA 
x) Micro sample filters , 45pm , Millipore, SA 
2 .2 .4 Dissolution Studies 
2 .2.4.1 Buffer Preparation 
Phosphate buffer was utilised in all dissolution rate studies . A quant ity of 18 . 5ml 
of ortho phosphoric acid was measured into a 5 .OL volumetric flask and made up to 
volume with distilled water. The resultant 0 .05M acid solution was adjusted to the 
required pH using sodium hydroxide . The pH of all buffers was adjusted to with in 
0 ,05 pH un its . The buffers w ere allowed to equ ilibrate to 37°C before the 
dissolution studies were initiated . 
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2.2 .4 .2 pH meter calibration 
The pH meter was calibrated da i ly using pH 4 .01 and 7 .00 calibrators . The 
calibration of the pH meter was checked against a pH 6 .00 reference buffer to 
determine the precision of the meter on a day to day basis . 
After calibration of the instrument the pH of the pH 6.0 buffer was measured and 
the value recorded on a daily basis over a four week period . The pH was determined 
to be pH 6.03 ± 0 .02 (mean ± S.O). The mean pH determined was well within the 
tolerance limit set by the USP of ± 0 .05 pH un its. 
2.2.4 .3 The Basket Apparatus 
The dissolution apparatus used consisted of two main components, the waterbath ' 
and the mechanicals which included the drive mechanisms and water pump. The 
w aterbath holds six pyrex glass vessels of one litre capacity . Each vessel was 
covered with a perspex cover with three openings, a central one for the shaft and 
two others for sample withdrawl and flu id replacement. The temperature of the 
waterbath was maintained at 37 ± 0 .5 °C . The basket assembly consisted of a 
sta inless steel shaft and a 40-mesh screen basket . A single tablet or capsule was 
placed in the basket and immersed into 900ml of equilibrated dissolution medium. 
Rotation of the baskets was initiated immediately and the time noted as time t = O. 
The baskets were rotated at 75 or 100 r .p.m . Three dosage forms were tested in 
each study. Samples, of either 3ml or 5ml, were withdrawn from the dissolution 
medium at specified time intervals us ing a 10ml disposab le syringe fitted w ith a 
15cm luer lock needle , to w hich a sample f i lter w as attached . Samples w ere ta ken 
f rom a point midway betw een the basket and the vessel wall at half the he ight of the 
basket (see figure 2 .5) . Sample volumes w ere immediately replaced with an equal 
volume of equilibrated fresh dissolution medium . 
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Luer lock needle 
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Figure 2.5 The Basket Apparatus showing sample removal specifications . 
2 .2.4.4 The Paddle Apparatus 
The apparatus used was as described in section 2.2 .4.3 with the following 
modification . The basket assembly was replaced with paddles consisting of a 
stainless steel shaft ending in a paddle coated with teflon . Rotation of the paddle 
was initiated immediately after introduction of the dosage form to the dissolution 
medium. Capsules were weighted with a single twist of stainless steel wire around 
the centre of the dosage form . The paddle rate was set at 50 or 75 rpm. Samples 
were withdrawn at a position in accordance with the USP XXII specifications. Three 
dosage forms were tested in each study. 
2 . 2.4 .5 Ac id exposure dissolution method 
This method involved the exposure of the relevant dosage form for one hour to a 
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0 . 1 N hydrochloric acid medium . A 0.1 N HCI medium was prepared by measuring 
64 . 2ml HCI solution and diluting this to 6 .0 L with distilled water . The resultant pH 
was 1.2. After the 1 hr exposure, a sample was withdrawn from the d issolution 
vessel and the medium was discarded by gently pouring it off, taking care not to 
disturb the dosage form . The acid medium was then replaced with the required 
phosphate buffer medium and the test was continued. Three dosage forms were 
tested in each study . 
. -
2 . 2 . 5 Sample analysis 
2 .2.5.1 UV Analysis 
Analysis of all samples was performed using a UV spectrophotometer fitted with a 
1 cm micro flow-through cell and a sample aspirator. The instrument was calibrated 
for each dissolution study. Calibration curves were programmed into the instrument 
in order to obtain the results as amount dissolved per mill i litre. 
Ii) Calibration standards 
Stock solutions of indomethacin (103 !1g/ml) and theophylline (404 !1g/ml) were 
prepared by weighing the appropriate mass of the respective raw material and 
dissolving it in 1 Oml methanol and diluting to 1 OOml with phosphate buffer. Stock 
solutions were stored at 4°C. Appropriate dilutions were prepared in 10 or 20ml 
volumetric flasks with A grade glass pipettes to obtain calibrators in the range of 
5 .40 - 97 . 75!1g / ml and 20 . 20 - 404 .00!1g / ml for indomethacin and theophylline 
respectively. All calibrators were prepared in the appropriate buffer . Calibration 
lines were obtained by analysing the calibrator solutions. Data obtained from this 
were then utilised to program the spectrophotometer. 
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(ii) Sample preparation 
No manipulation of the indomethacin samples was necessary prior to UV analysis. 
A 1 in 10 dilution of the theophylline samples was achieved by diluting 400pl of 
sample to 5ml with the appropriate buffer. Each sample was vortex mixed prior to 
analysis. 
2.2.5.2 HPLC Analysis 
Analyses of certain batches of dissolution samples were carried out using HPLC. 
(i) Chromatographic system 
The modular chromatographic system used in all the HPLC analyses consisted of a 
solvent delivery system, autosampler, strip chart recorder and a UV LC 
spectrophotometer. Separation was achieved on a C 18 column . 
(ii) Mobile phase preparation 
The optimum mobile phase for indomethacin consisted of 55 % v/v acetonitrile and 
45% v/v O.05M phosphate buffer of pH6 .0. The pH of the resultant solution was 
readjusted to pH3.5 using sodium hydroxide. In order to select the mobile phase 
conditions for indomethacin separation, the following aspects were considered in 
terms of their influence on the retention time of indomethacin: 
a) effect of pH of the mobile phase 
b) effect of percentage organic phase content 
c) effect of buffer molarity 
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d) effect of organic solvent type 
The effect of pH , percent organic phase , buffer molarity and type of organic solvent 
are summarised in figures 2 . 6a - d . From these it is evident that the optimum 
conditions are as follows : 
- 55% v/v Acetonitr i le 
- 45% vlv O.05M phosphate buffer 
- pH adjusted to 3 . 5 . 
Methanol was found to be an unsuitable organic solvent because very large volumes 
were necessary to obtain elution of the indomethacin peak . Methanol also caused 
poor peak resolution. 
Figure 2 . 6 (a) Effect of pH (b) Effect of Buffer molarity 
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Figure 2 . 6(c) Effect of Acetonitrile 
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For the theophylline studies the chromatographic method used was based on that 
described in the USP XXII (72) . The mobile phase was prepared by mixing 35% v/v 
methanol and 65% v/v 0.05M phosphate buffer of pH 6 .0. The resultant solution 
was then readjusted to pH6.0 with sodium hydroxide . 
The mobile phases were filtered and degassed through a 45pm filter (Millipore). 
(iii) Calibration standards 
a) Indomethacin 
A stock solution of indomethacin (100 pg/ml) was prepared by dissolving 
1 Omg indomethacin in 1 Oml methanol and diluting to 1 OOml using 0 .05M pH 
6 . 2 phosphate buffer. Appropriate dilutions were made in order to obtain a 
set of calibrators over the range 1.00 - BO .OOpg/ml. Three additional 
standards were prepared to serve as in vitro standards. Naproxen was 
selected as the internal standard and was prepared by dissolving an 
appropriate mass of naproxen in phosphate buffer in order to obtain a 
2 .04pg/ml working solution. 
b) Theophylline 
A stock solution of theophylline (399 ug/ml) was prepared in 0.05 M 
phosphate buffer. Appropriate dilutions were prepared to yield calibrators in 
the range 19.95 - 399 .00 pg/ml. Calibrators were prepared in buffer of the 
same pH as the dissolution medium used in the particular dissolution study. 
Caffeine was selected as the internal standard. A stock solution was 
prepared by dissolving 41.Bmg caffeine in 200ml phosphate buffer. A 
dilution was prepared to yield a working solution of 6 . 27 pg/ml . 
The calibration lines for both indomethacin and theophyll ine were found to be linear 
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over the concentration ranges studied. This was found to be the case for both the 
UV analysis and the HPLC analysis. Correlation coefficients were determined to be 
0.99 or better for all determinations. Within run precision was assessed by running 
three spiked samples. The coefficients of variation were found to be 4.07%,3.64% 
and 3 . 3% for the upper, middle and lower end of the concentration range used. 
Figures 2.7 and 2.8 are examples of calibration lines for indomethacin and 
theophylline respectively . 
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Figure 2.7 Calibration Line for indomethacin 
x Coefficient = 0.090 
Constant = 0.087 
r-squared = 0.998 . 
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Figure 2 . 8 Calibration Line for theophylline 
x Coefficient = 0.028 
Constant = -0.142 
r:squared = 0.992 
(iv) Chromatographic conditions 
(a) Indomethacin 
Column reverse phase C" 
HPLC system see section 2.2 .5.2(i) 
Detection wavelength 254nm 
Sensitivity 0.01 Aufs 
Flow rate 1 ml / min 
Pressure 800 psi 
Temperature ambient 
Recorder input 10mV 
Mobile phase see section 2.2.5.2(ii) 
(b) Theophylline 
Column 
HPLC system 
Detection wavelength 
Sensitivity 
Flow rate 
Pressure 
Temperature 
Recorder input 
Mobile phase 
(v) HPLC UV 3-D chromatograms 
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reverse phase C,. 
see section 2.2.5.2(i) 
280nm 
0.1 Aufs 
1 ml/min 
1400 psi 
ambient 
10mV 
see section 2.2.5 . 2(ii) 
For both theophylline and indomethacin products 3-D chromatograms were obtained 
for the 24h dissolution samples. These were carried out using a diode-array 
detector connected in line to the chromatographic system described above. 
2.2.6 Bioavailability Studies 
All in vivo data used in this research project was obtained from bioavailability 
studies conducted by the Biopharmaceutics Research Institute at Rhodes University, 
Grahamstown. To compare the rate and extent of indomethacin and theophylline 
absorption from different dosage forms, single-blind, randomised crossover studies 
were conducted . The trial periods were separated by a 7 day washout period . The 
subjects were screened according to the normal procedures for a clinical trial. A 
complete medical history was taken and haematological examination, clinical 
chemistry and urine analysis was conducted. All studies were approved by the 
Rhodes University Ethical Standards Committee and informed consent was obtained 
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from each volunteer. 
(i) Study BRI 14/89 
Data for the indomethacin studies were obtained from BRI study number 14/89 (138) 
For the trial, eight (8) healthy, non-smoking male subjects were used . Each was 
given one capsule of Indocid R and one capsule of Test Product 2 during the two 
phases of the trial, which were conducted according to a balanced design. The trial 
was conducted according to the following protocol : 
Ohrs 
0.5 
1.0 
1.5 
2.0 
2 .5 
3.0 
3.5 
4 .0 
5 .0 
6.0 
Comment: 
The subjects reported to the clinic after a ten hour 
overnight fast . An indwelling needle was inserted into 
an arm vein and a zero time sample was collected. The 
respective dosage form was administered with 200ml 
water after a standard light breakfast. 
remained sedentary in bed for the first 8hrs. 
Blood sample 
Blood sample 
Blood sample 
Blood sample, 200ml water administered 
Blood sample 
Blood sample, standard light snack provided 
Blood sample 
Blood sample , 200ml water administered 
Blood sample 
Subjects 
Blood sample, standard low fat meal given to volunteer 
8.0 
10 .0 
12 .0 
24.0 
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8100d sample, standard light snack given to volunteer 
Blood sample, standard low fat meal given to volunteer 
Blood sample 
Blood sample 
After 6 hours the subjects were allowed to take water ad libitum . Serum samples 
were centrifuged and separated into two portions and frozen at -20°C until the time 
of analysis . The serum concentrations of indomethacin were determined by HPLC 
with ultraviolet detection following a solid phase extraction procedure . Results are 
shown in Appendix B. 
(ii) Study BRI 1/89 and 15/90 
For study BRI 1/89 (139) six (6) and for BRI 15/90 (140) ten (10) healthy male 
subjects were used . The protocol for the theophylline studies differed slightly and 
a summary is given below . The subjects were each given a single Theodur 300mg 
tablet , a Retafyllin tablet or a single tablet of Test Product 1 during the different 
periods of the trials. 
O.Ohrs 
0.5 
1 .0 
2 .0 
3 .0 
4 .0 
Comment: 
As per above, but no breakfast was given. 
Blood sample 
Blood sample 
Blood sample, 200m I water administered 
Blood sample 
Blood sample and standard l ight breakfast given to 
volunteer 
5.0 
6.0 
7.0 
8 .0 
10 .0 
12.0 
24 .0 
36 .0 
48.0 
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Blood sample 
Blood sample, standard low fat meal given 
Blood sample 
Blood sample, standard light. snack given to volunteer 
Blood sample 
Blood sample 
Blood sample 
Blood sample 
Blood sample 
Serum samples were centrifuged, separated and stored at -20°C until analysis . 
Serum concentrations of theophylline were determined by means of a fluorescence 
immunoassay technique (Abbott-TDX). Results are shown in Appendix A . 
2 .3 Data Manipulation 
2.3 .1 In vitro data 
2.3.1 . 1 3-D plots 
Three dimensional plots or topographs were constructed of the dissolution profiles 
of indomethacin and theophylline dissolution studies . The plots were constructed 
with the aid of a computer software package designed at the School of 
Pharmaceutical Sciences. Plots were obtained by entering the sets of data in the 
following form: time points on the x-axis, range of pH on the y-axis and percent 
dissolved on the z-axis . 
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2.3.1.2 % Dissolved versus Time plots 
Before any p lots of the data could be constructed the data obtained from the UV 
analysis first had to be transformed into % dissolved of the labelled amount from the 
concentration data generated by the spectrophotometer . This was achieved by 
employing a custom designed PlanPerfect (WordPerfect Corporation, USA) computer 
worksheet. The % dissolved data obtained were then plotted using a graph plotting 
package, plotting time on the x-axis and % dissolved on the y-axis. 
2 .3 . 1 .3 Dissolution rates 
Percent remaining to be dissolved data were necessary in order to plot the log (In) 
% remaining to be dissolved versus time plots . These plots were used to calculate 
the dissolution rates and to determine the order of the dissolution processes. The 
dissolution rates of the pseudo first order processes were determined by linear 
regression analysis of the log-normal plots using a computer software package (SPS, 
Rhodes Pharmacy). The zero order dissolution rate constants were determined by 
l inear regression of amount dissolved versus time plots . This provided an estimate 
of the dissolution rate constant and an estimate of the correlation coefficient. 
2.3 .1 .4 We ibull distribution analysis 
Weibull distribution analysis of the dissolution data was performed using the 
computer software package MINSQ (Micromath, USA) . The user function was 
entered into MINSQ and the iterative program was suppl ied with initial estimates of 
the parameters F~, t d , t o' and p. 
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2.3 .2 In vivo data 
2 .3.2.1 Plots of serum concentration versus time 
Plots were generated with a computer graphics package using the data obtained 
, 
from the bioavailability trials as in Appendix A and B. 
2.3 .2.2 Parameter estimations 
In order to obtain the relevant parameters from the serum concentration data, the 
data sets were entered into a BIOPAK data analysis package (Statistical Consultants 
Inc .). The following parameters were calculated using BIOPAK's Pharmacokinetic 
module: 
i) Area under the curve (AUC); 
ii) Area under the moment curve (AUMC); 
iii) The time for the maximum concentration to occur (t m ,, ); and 
iv) The maximum serum concentration (C m,,) 
These parameters were determined for the individual plots and the mean parameters 
calculated from these . Parameters were also estimated for the mean data set . 
2 .3.2 .3 Wagner-Nelson analysis 
Percent drug absorbed, and hence the percent drug remaining to be absorbed, was 
obtained using the Wagner-Nelson method for the individual data and the mean data . 
The calculations were achieved w ith the assistance of a computer software package 
(SPS , Rhodes Pharmacy). The data were entered as sets of concentration values 
w ith their corresponding time po ints . The point at which log-linearity was assumed 
to commence was also entered in order to obta in an estimate of k • . 
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2.3.2.4 Weibull distribution analysis 
The data obtained from the Wagner-Nelson analysis were also fitted to the We ibull 
function . This was performed in the same manner as described in section 2.3.1 .4 . 
2 .3.3 In vitro - In vivo Correlations 
2.3.3.1 Type A correlations 
To achieve a level A correlation between in vitro and in vivo data, the in vitro 
dissolution curve of a dosage form was compared with the in vivo response curve . 
An example of a level A correlation is the Leeson predictive model (148). 
2.3.3.1 (i ) Leeson predictive model 
The Leeson method depends on both the in vitro and in vivo parameters of the drug 
in its dosage form . The calculations to obtain data for the profile were generated 
with the aid of MathCAD (Math Soft , USA), a computational software package. The 
relevant formulae were entered into the database as depicted in section 2 .1.4.2 . 
Model worksheets were designed to simulate first order processes (Model A) and 
zero order processes followed by first order (Model B & C) . For the simulation of the 
indomethacin profiles model D was employed . In cases where the simulated profile 
was obtained with the aid of more than one model, the cumulative profile was 
obtained by a summation of the data generated by each model. 
In order to generate the required data the fo l lo w ing general population parameters, 
obtained from the literature, were entered into the relevant model : k " k. , Dose, Vd , 
kd and a time range. Plots were constructed with the aid of a graphics package. 
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2.3.3.1 (ii) Wagner-Nelson plots versus % dissolved plots 
Overlay plots of percent absorbed in vivo and percent dissolved in vitro were 
constructed to determine whether any correlation existed between these two 
aspects. 
2.3.3.2 Type B correlations 
These correlations are not considered as 1: 1 correlations since they do not reflect 
the actual in vivo plasma level curves. 
2.3.3.2 (i) MRT versus T, 
Mean residence times (MRT) in vivo were calculated from the parameters generated 
by BIOPARAMS (SPS, Rhodes Pharmacy) and compared to the t, values obtained for 
the in vitro dissolution data by the Weibull analysis. 
2.3.3.2 (ii) T, in vitro versus t, in vivo 
The Weibull parameter, t" was compared for the in vitro dissolution and in vivo 
Wagner-Nelson data. T, values for the dissolution studies carried out at the differing 
pH's were compared directly to the in vivo parameters. 
2.3.3 .3 Type C correlations 
To establish a level C correlation a specific in vivo parameter is compared to an in 
vitro parameter . The in vivo parameters em", t m .. , and AUC were compared with the 
t60~ and t.o~ in vitro, as well as the Weibull parameter Foo. 
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CHAPTER 3 
THEOPHYLLINE STUDIES 
3.1 Introduction 
3.1.1 Oral Controlled/Modified Release Dosage Forms (CMRD's) 
Over the past four decades, pharmaceutical manufacturers have introduced an 
increasing number of products which are reported to provide extended therapeutic 
responses. Controlled-release dosage forms cover a wide range of • prolonged 
activity" preparations that provide continual release of their active ingredients at a 
predetermined rate and for a predetermined period. The majority of these products 
have been designed for oral administration, however, recently there have been 
significant developments in the design of delivery systems for intramuscular and 
subcutaneous drug administration and for use as ocular inserts, intra-uterine devices 
and transdermal patches. 
Enteric coating was the first attempt at delaying the release of an active ingredient 
from a dosage form as well as to prevent gastric irritation during transit along the 
gastro-intestinal tract. It was only in 1952 that the first practical sustained-release 
type of dosage form was marketed. This has since led to a great deal of research 
activity in this area of pharmaceutics (8). 
The prime goals of these types of formulations are to provide an extended duration 
of action, to minimise toxicological effects, to improve therapeutic efficacy and to 
ensure patient compliance or simply to improve the convenience of the dosing 
regimen . 
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3.1.1.1 Definitions 
Over the years a number of different terms have been used to describe these 
formulations; it is therefore necessary to classify these 1124, 141, 72). 
Ii) Delayed-release: These systems utilise repetitive, intermittent dosing 
of a drug from one or more immediate release units which are 
incorporated into a single dosage form. Examples of these dosage 
forms include repeat action tablets and capsules and enteric-coated 
tablets where timed-release is achieved by a barrier coating. These 
dosage forms do, however, not produce or maintain uniform blood 
concentrations within the therapeutic range but are nevertheless more 
effective than conventional dosage forms. The USP defines these 
dosage forms as "dosage forms which release a drug at a time other 
than promptly after administration". 
liil Sustained-release: These include any drug delivery system that 
achieves slow release of drug over an extended period of time. If 
these systems are capable of maintaining constant blood 
concentrations they are considered as controlled-release systems. If 
this is not achieved but the dosage form still extends the duration of 
action over that achieved by a conventional delivery system, they are 
considered as prolonged-release systems. The USP defines these 
dosage forms as those "that allow at least a twofold reduction in 
dosing frequency as compared to that drug presented as a 
conventional dosage form". 
liii) Site-specific and receptor release: These systems refer to the 
targeting of a drug to a specific biological location. In the case of 
site-specific release, the target is a particular organ or tissue; for 
receptor release, the site is a receptor of the drug in a specific organ 
or tissue. 
3.1.1.2 Advantages and disadvantages of CMRD's 
Patient compliance has for many years been recognised as a necessary and 
important component for the success of self administered drug therapy. The general 
advantage of these dosage forms therefore lies in the fact that the frequency of 
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dosing is reduced . Economic advantages are seen in the hospital situation since 
nursing time for drug distribution and administration is minimised. Adequate 
overnight therapy is prov ided without the need for the patient to be awakened 
during the night . The nature of the kinetics of these dosage forms implies that less 
drug should be utilised than for conventional dosage forms to achieve successful 
therapy. 
Therapeutic advantages include control of the level of sleep throughout the sleep 
period, control of nocturnal seizures associated with epilepsy, control of enuresis, 
control of migraine headache on awakening and the control of appetite over 
extended periods of time (124) . Variations in drug concentrations with high peak 
concentrations and sub-therapeutic concentrations commonly associated with 
conventional therapy is reduced with controlled-release products. With the 
reduction of toxic effects due to high blood concentrations, a better control of the 
disease state can often be achieved at lower concentrations. The severity and 
frequency of side effects may also be reduced . In addition, the method by which the 
extended release is achieved can improve the bioavailability of some drugs (124, 
142) . 
Disadvantages include the lack of precision of the dose between patients depending 
on the stomach emptying time, thus affecting the absorption rate. Poor dosage form 
design may result in incomplete dosage release or dose dumping which may lead to 
toxic drug concentrations . Too frequent administration of these dosage forms may 
also lead to toxic concentrations . Accidental or intentional poisonings also pose 
special problems since the slow release of the drug and its extended absorption 
often results in a slowed clearance, making it more difficult to terminate the effects 
of the drug if severe toxic side effects develop (10, 124, 142) . 
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3.1.1 .3 Desirable properties of drugs for use in CMRD's 
The drug should be effective when administered orally and resistant to 
decomposition in the gastrointestinal tract. The drug should also have a short 
duration of action, have an elimination rate constant of less than 12 hours and be 
effectively absorbed throughout the gastrointestinal tract . The drug dose should also 
be small since these formulations usually contain three or four times the amount of 
drug used in conventional dosage forms. The final product size should also be of a 
suitable size for ingestion (142). 
Rowland and Beckett (143) suggested that drugs with a slow onset of action should 
be formulated with only part of the dose in the slow release form. With drugs which 
have an inherent long duration of action due to their particularly long half-lives, 
there is very little need to formulate these in slow release products . Drugs which 
are poorly absorbed and those which have a narrow "therapeutic window" should 
not be used in CMRD's . Other properties of the drug which must be assessed 
include the aqueous solubility, pK., partition coefficient, protein binding and 
molecular size (124, 142). 
3.1.1.4 Design of CMRD's 
Before a CMRD can be developed, the drugs which are to be incorporated into the 
dosage form must first be evaluated in terms of their pharmacological properties, 
chemistry, therapeutic indications and toxicity. From the pharmaceutical approach 
the only variables which can be modified are the strength, disintegration and 
dissolution properties of the dosage form (144). 
A practical problem in the design of a CMRD is the amount of drug which must be 
incorporated into the dosage form . Factors which influence the dose size include 
the biological half li fe of the drug, intrinsic act ivity , intended duration of 
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prolongation of the therapy and the parallel loss of drug occurring prior to systemic 
availability . Further considerations include a knowledge of the initial dose and the 
frequency of administration (142) . An important parameter in the des ign of these 
systems is a knowledge of the input rate constant, k " which is a combination of the 
in vivo dissolution and absorption . If , however, the elimination half life is very long 
then the elim ination rate constant, k., will determine the overall kinetics, and any 
changes in k, will have little effect . The purpose of CMRD's is to improve therapy 
by maintaining a constant and uniform plasma concentration at steady state. Th is 
can be ach ieved by m in imising the ratio of the maximum and min imum 
concentrations (Cmu/Cm;") at steady state and can be made possible if the release of 
the ctrug from the product results in zero order or sufficiently slow first order 
absorption of the j rug from the gastrointestinal tract. This will result in the 
absorption of the drug into the body being much slower that the rate of elimination 
(flip-flop kinetics) (145) . 
If k., k" and the conventional dose size, DO' required to produce a satisfactory blood 
concentration are known, the maintenance dose, D, can be determined (142) . The 
method is based on the argument that in order to maintain a blood concentration at 
steady state the rate in must equal the rate out , so that the total dose is g iven by : 
or 
where : 
Eqn 3.1 
D = eBB v + k. f h 
D, = the dose from a conventional dosage form wh ich gives a 
desired clinical response , 
f a fraction relat ing the peak drug concentration after D, to the 
optimum therapeutic concentrat ion of the drug in the body, 
h = the number of hours required for a sustained level of the drug, 
t . = the biologica l half li f e of the drug . 
C .. = concentration at steady state 
V volu me of d istr ibut ion 
k. el iminat ion rate constant 
76 
Rowland and Beckett (143) have indicated that this equation can lead to a higher 
drug quantity than is required if no account is taken of the effect of the maintenance 
dose of the drug that is released from zero time to t m " . The consequence of this is 
that the initial dose will be too large. 
3.1 . 1. 5 Evaluation of CMRO's 
Lazarus and Cooper (141) reported that the assessment of CMRO's should ideally 
be performed by prop9;rly designed in vivo trials in which actual measurements of 
blood concentration are compared to the concentrations resulting from the 
administration of a solution of the drug or a rapidly disintegrating tablet. The 
pharmacokinetics of the drug in these dosage forms should also be well established. 
The most common method for the determination of bioavailability is the 
establishment of plasma concentration-time curves as discussed in section 2.3.2.1. 
From this, the Cm", t m", and AVC can be determined. Consequently the onset and 
duration of action can be estimated provided that the therapeutically effective 
minimum and maximum concentrations have been previously determined (141,142, 
144) and is illustrated in Figure 3.1 . 
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Urinary excretion of a drug or of a drug and its metabolites have also been used to 
measure the bioavailability of a dosage form. This method has several advantages 
which include such factors as the fact that samples are more readily obtainable and 
that the method is non-invasive . Concentrations of drug in urine are usually higher 
than in the blood and thus less sensitive analytical methods can be used (144). This 
method is, however, only of use when the drug, is excreted predominantly in the 
unchanged form. It must also be shown that the urinary drug concentrations are 
proportional to the blood concentrations. Important parameters which can be 
derived from excretion data include the cumulative amount excreted and the rate at 
- -
which the excr p. tion occurs . 
3.1.1.6 Controlled/Modified Release Formulations (124,146,147,148) 
There are several types of CMRD's based on one or more different mechanisms 
(Table 3 . 1) . 
Table 3.1 Controlled release mechanisms 
1) Reduced solubility of the drug 
2) Ion exchange resin complexes 
3) Slow eroding matrix tablets 
4) Strongly swelling hydrophillic gel tablets or capsules 
5) Porous inert matrix tablets 
6) Polymer controlled delivery systems, including: 
(a) Disintegrating or dispersable coating 
(b) Diffusion-controlling membrane 
(c) Microencapsulation 
7) Osmotic pumps 
78 
Systems employing some of the above mechanisms include : 
(i) Coated Pellets or Granules 
The manufacture of these types of dosage forms involves the manufacture 
of beads, pellets or granules. Groups of these are then coated with a coating 
of varying thickness to retard the release of the drug . The drug is coated 
onto the nuclei prior to the coating procedure . Some of the nuclei are left 
uncoated to provide the drug in an immediate release portion which is 
intended to establish the initial therapeutic concentration . Materials used for 
the coating of the pellets include beeswax, carnauba wax and bayberry wax 
with glyceryl monostearate or similar fatty acid esters . The fact that the 
drug dose is divided into many smaller portions greatly increases the 
probability that the whole dose will be available for absorption . The 
uncoated and coated pellets are then blended and placed into hard gelatin 
capsules or compressed into tablets. 
(ii) Tablets with slow release cores 
These formulations consist of a drug core which is evenly mixed with a 
substance of low solubility i.e. a hydrophobic material, which permits the 
drug to dissolve slowly or to be leached from the material. The core is 
coated with a film which also contains the drug, excip ients and binders. 
(iii) Tablet mixed-release granules 
These systems contain granules prepared in the standard manner as well as 
granules which are coated with a material which will retard the drug release. 
Materials used to achieve th is include beeswax, glyceryl monostearate, 
glyceryl mono palmitate, stearic acid and cetyl alcohol. The two types of 
granu les are lubricated and compressed into tablets . 
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(iv) Multiple layer tablets 
The development of modern compressing machines has facilitated the 
production of tablets with multiple layers of granu les , One layer provides the 
initial dose, the second a dose at an intermediate release rate and a third 
layer provides an additional portion at a slow rate of release , 
(v) lon-exchange resins 
The development of these systems stems from the fact that the ionic 
concentration of the gastrointestinal fluids varies only within narrow limits. 
The rate of interchange of ions and hence the release of a drug can thus be 
fairly well controlled . An ionic drug is allowed to diffuse through an ion-
exchange resin where it replaces the inorganic ions on the resin , A slow 
displacement reaction occurs when the drug-resin complex comes into 
contact with intestinal fluids, A decreased rate of solution is thus obtained 
and hence a prolonged action is possible, 
(vi) Osmotic systems 
These dosage forms are designed as mini-osmotic pumps, The system was 
first described by Theeuwes (149) in 1975 . The drug substance is contained 
in a solid core which is surrounded by a semipermeable membrane that has 
a single micro-opening . In operation, the system imbibes water at a rate 
driven by the osmotic pressure difference which occurs across the 
membrane, The rate is also controlled by the membrane, The system 
delivers drug at a constant zero order rate as long as it contains excess 
osmotic driving agent. 
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3 . 1.2 Introduction to Theophylline 
3 . 1.2.1 Properties of theophylline 
Theophylline, designated as 1, 3-dimethylxanthine, is closely related chemically to 
caffeine and theobromine. It is also occasionally referred to as theocin. The 
structure of theophylline is shown in Figure 3.2. 
Figure 3.2 Structure of theophylline. 
Theophylline occurs as a white, odourless, crystalline powder with a bitter taste and 
has been reported to exist in both anhydrous and monohydrate forms. The 
compound is sparingly soluble in water (S.3mg/ml). It is a weakly basic compound 
with a pKa of S.6 due to the free pr9ton on the nitrogen in position 7 which is 
dissociable. A full analytical profile is well documented (150) . 
Theophylline is a bronchodilator that is effective in the treatment of acute and 
chronic asthma . The precise mechanism of action is not fully understood but it is 
known that theophylline inhibits phosphodiesterase. This results in a delayed 
degrada tion of 3 '5' -cyclic ad en os i ne monop hosph a te . Th eophylline th erefo re exerts 
its effect by a different mechanism to that of other bronchodilators . As with the 
other xanthine compounds, theophylline can potentially induce a transient diuresis, 
stimulate the central nervous system, produce cerebral vasoconstriction, increase 
gastric secretion and inhibit uterine contractions (151). 
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The bronchodilator effect of theophylline increases in proportion to the logarithm of 
the serum concentration in the range of 5 - 20 ,ug/ml. The ability of the compound 
to prevent exercise-induced bronchospasm also relates directly to the serum 
concentration, with the greatest effect occurring at concentrations of 15,ug/ml. 
This effect is maintained with continuous dosing and maintenance of the serum 
concentration in the range of 10 - 20,ug/ml. 
Minor caffeine-like side effects, including slight nausea, insomnia , nervousness and 
headache are common after the rapid attainment of concentrations in excess of 
1 O,ug/ml but less than 20,ug/ml. Most users, however, develop a tolerance for these 
effects. More severe and persistent adverse effects may, however, occur at 
concentrations above 20,ug/ml and include nausea, vomiting, severe headache, 
diarrhoea, irritability and in cases of severe toxicity, hyperglycaemia, hypotension, 
cardiac arrhythmias, seizures, brain damage and even death may occur (See Figure 
3.3) (151, 152, 153). 
Figure 3.3 
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Theophylline is readily absorbed after oral administration and is highly bioavailable 
(F>0 . 9). Rectal suppositories have however been shown to produce a delayed and 
erratic absorption of theophylline. Following administration, peak concentrations 
are reached within 0.5 to 2.0h. The plasma concentration-time course after 
intravenous administration fits a two compartment open model (154). The a or early 
distribution phase is, however, very rapid and is usually complete within 30 to 45 
minutes . Consequently many researchers have applied a 1 compartment open model 
to perform pharmacokinetic analysis of theophylline data. The volume of 
distribution averages approximately 0.5 I/kg with a range of 0.3 - 0 , 7 I/kg . The V d 
is apparently not affected by age, sex, history of cigarette smoking, asthma or acute 
pulmonary oedema. The elimination of theophylline is highly variable with an 
average elimination half life of 8hrs and an elimination rate constant of 0.087hr·'. 
The variability of the elimination appears to be due primarily to differences in the 
rate of hepatic metabolism, which changes with age, physiological abnormalities, 
smoking habits, aberrations in diet and concurrent drug therapy (151,152,153, 
155). 
The fact that theophylline has a half-life of 4 - 9 hours and a narrow therapeutic 
range makes it an ideal candidate for controlled release. Standard dosing schedules 
of every six hours may result in low trough levels in the early hours of the morning 
resulting in breakthrough symptoms. The use of properly designed CMRD's may 
eliminate this early "morning dip" and as a result many CMRD preparations of 
theophylline have been developed over the past decades (156) . 
3.1.2.2 Overview of some dissolution studies conducted on theophylline 
To-date there is no official dissolution method described in either the USP XXII (72) 
or the BP 1988 (111) for the dissolution rate testing of theophylline extended 
release tablet preparations . Due to this fact various methods have been employed 
to characterise the dissolution properties of theophylline CMRD's. Jonkman et al 
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(156), in a study to develop a simple method, used a modification of the 
disintegration apparatus of the European Pharmacopooia employing an initial 2 hour 
acid exposure followed by a phosphate buffer of pH6.8 . The results indicated that 
the dissolution of Theodur, wh ich is a tablet of coated theophylline pellets 
embedded in a matrix, under these conditions correlated favourably with the in vivo 
data. Furthermore, it was shown that the dissolution of theophylline from Theodur 
was not dependent on the pH of the system, but that the release from Neulin was 
pH-dependent. 
In an investigation into the effect of pH on the dissolution of Theo-24 which is a 
capsule containing theophylline coated pellets designed for once a day dosing, Vashi 
and Meyer (157) found that the release of theophylline from the dosage form was 
highly pH-dependent . These investigators found that the drug release was more 
rapid in simulated intestinal fluid than in simulated gastric fluid. These results 
correlated well with the in vivo results from a study conducted using the product in 
dogs under normal conditions and under conditions of achlorhydria. 
In a further dissolution study of Theodur, Jonkman et al (158) exposed the dosage 
form to an acidic medium followed by a phosphate buffer using the compendial 
paddle apparatus at 75 rpm . The researchers found that a slight dip occurred in the 
dissolution profile at about 30% release. This they ascribed to the fact that the 
tablet consists of two compartments, which contain one third and two thirds of the 
dose respectively . It was also found that the dissolution rate profile correlated well 
w ith the in vivo results in that the dissolution profile indicated a delayed release of 
theophylline corresponding to the delayed absorption. 
Buckton et al (159) conducted dissolution studies on various formulations of 
theophylline including Theodur. Dissolution studies were carried out under varying 
condit ions of pH. It was found that drug re lease from the Theodur tablet, in 
contradiction with previous studies , was pH-dependent with the product showing 
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a more rapid release in intestinal fluid than in simulated gastric fluid. These authors 
also simulated the expected in vivo response using dissolution data obtained at the 
various pH's . An in vivo study, however, was not carried out using these dosage 
forms to confirm their predictions . 
Certain formulations of theophylline have been shown to be influenced by the 
presence or absence of food. Maturu et al (160) developed a modified dissolution 
method to simulate in vivo fed conditions. The method involves the prior exposure 
of the dosage form to peanut oil. The results indicated that the release rates were 
increased, decreased or unchanged, depending on the particular formulation, by the 
peanut oil pretreatment and that the changes correlated with the in vivo absorption 
rates found in an in vivo study. These authors also determined that the dissolution 
rate from Theodur tablets was pH -independent and would therefore, according to the 
criteria set out by Skelly et al (311. not likely show a food-drug interaction. 
However, this was not found to be the case with Theodur Sprinkle (a capsule 
containing theophylline granules intended for paediatric usel which, from dissolution 
studies, indicated that no food-drug interaction would be expected although this 
was exhibited in vivo (31). Further studies conducted by Aiache et al (161) 
concluded that the peanut oil pretreatment dissolution method provided good 
correlations with the in vivo data for various other formulations of theophylline 
CMRD's. 
The above findings are not in agreement with the results found in studies conducted 
by EI-Arini et al (162). Dissolution studies were conducted on Theodur tablets and 
Theodur Sprinkle capsules to determine the effect of pH , peanut oil in the 
dissolution medium and the presence of bile salts. The results indicated that the 
release rate of theophylline from the Theodur tablets was affected by different 
conditions of pH . The dissolution profiles indicated that the release rate was 
significantly higher in alkaline media than in acidic media . The addition of the 
peanut oil and bile salts did not have an effect on the overall dissolution profile . 
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Theodur Sprinkle showed a lag time upon which dissolution continued at a rate 
independent of the pH of the dissolution media . The addition of 10% peanut oil to 
the media ,however, produced a decreased dissolution in media of varying pH. This 
suggests that in the presence of high fat meals there should be a delayed absorption 
and a decreased bioavailability of theophylline from Theodur Sprinkle. 
In a study to investigate the effect of food on the absorption of theophylline from 
CMRD's, Macheras et a/ (163) conducted dissolution rate studies on 4 controlled 
(elease theophylline dosage forms in milk . It was. found that the dissolution of 
theophylline f ro m Theodur was little affected by the milk media and that overall, the 
dissolution profiles were the same when compared to dissolution studies carried out 
in normal dissolution media . 
Despite the availability of many different types of CMRD's of theophylline many 
researchers (164, 165, 166, 167, 168, 169) are still investigating the design of 
improved types of release mechanisms to retard the release of theophylline from 
dosage forms. Together with these developments researchers have also attempted 
to correlate theophylline in vitro data with in vivo data . To this effect, a 
comprehensive study was conducted by Dietrich et a/ (164) . (n their investigations, 
they found that several successful correlations could be obtained provided that 
analogous data were correlated, i.e. in order to obtain a good correlation an in vivo 
parameter with a corresponding in vitro parameter must be used. They also found 
that for every comparison that agreed, another was usually found that did not. 
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3 . 2 Ex perimental 
3 . 2.1 Test Product 1 versus Theodur 
3.2.1 . 1 Statement of the prob lem 
Following a bioavailability study (Study BRI 15/90) (140) conducted on Test Product 
1 (a theophylline controlled release formulation) versus Theodur, it was found that 
the rate of absorption of theophylline from the Test Product was significantly more 
rapid than the rate calculated for Theodur . These results were in contrast to data 
obtained from dissolution studies carried out on the test product during the R&D 
phase. The dissolution studies revealed that the release of theophylline from the 
Test Product would be very s imilar to that of the reference formulation . 
3.2.1 . 2 Objectives 
In order to f ind possible explanations for these discrepancies , it was decided to 
conduct a series of dissolution rate studies on the two formulations in order to 
establish wether the in vivo findings could have been predicted more accurately . 
3 .2 .2 Methods 
3 . 2 .2.1 Bioavailability Study 
The studies were conducted as described in section 2 . 2.6(ii). Results of the serum 
concentrations are depicted in Table A3 .4 for Theodur and in Table A3.5 (see 
Appendix A) for the Test Product . 
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3.2 .2 .2 Dissolution Studies 
Three replicate dissolution rate determinations on each dosage form were carried 
out . 
(i) Dissolution media 
Dissolution media were prepared as set out in section 2.2.4.1. Media of pH 
3.0, 4.0, 5.0, 6.0, 6 .8 and 7 .5 were utilised in the various dissolution 
studies. 
(ii) Sampling times 
Samples were taken according to the following time schedule: 0.0 (blank), 
1.0, 2.0, 3.0, 4 .0, 5.0, 6.0, 7.0, 8.0, 10.0, 12 .0 and 24.0 hours after 
initiation of the dissolution test. 
(iii) Sample analysis 
All samples were assayed for drug content according to the method set out 
in section 2.2.5. Analysis of certain studies was also carried out by HPLC as 
set out in section 2.2 .5.2. 
3.2.2.3 Data manipulation 
Data obtained from the bioavailability studies and dissolution studies were analysed 
according to the procedures set out in section 2.2.3. 
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3 . 2.3 Results and Discussion 
3 . 2.3.1 Bioavailability Studies 
The serum concentrations of theophylline are presented in Tables A3.4 and A3.5 
(Appendix A) for Theodur and the Test Product. The statistical results from these 
studies are shown in table A3 . 19 (Appendix A) . The mean serum concentration 
versus time curve is depicted in Figure 3 .4 . 
Concentntion (mgll) 
7 
• 
• 
• 
• 
o~------~--------~------~------~ 
o '0 .. 
lime (hn) 
.0 .0 
Figure 3.4 Mean serum concen~ration versus time curve of 10 subjects. 
The results indicate that the absorption of theophylline from the Test Product was 
significantly more rapid than that from Theodur. The mean t m .. was found to be 
4 . 8h ± 2.3 and 7 . 5h ± 2 .2 (mean ± S .D . ) for the Test Product and Theodur 
respectively . The C m .. values were determined as 6 .29 ± 1 . 53 mg/l and 5.27 ± 
0 .84 mg l l for the Test Product and Theodur respect i vely. The two formulations 
were, however, found to be equivalent in terms of their extent of absorpt ion . This 
is clear when the AUC,." for the two products are compared (see Table 3 . 21 . 
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Table 3.2 Mean Bioavailability Parameters . 
Test Product 1 
Parameter 
Mean ± S.D. 
AUC,." (mg.h/l) 96 .60 ± 20 .28 
AUC la, (mg .h/l) 109.25 ± 25 . 12 
Cm .. (mg/l) 6.29 ± 2.30 
Tm .. (hr) 4.80 ± 2.30 
3.2 .3 .2 Analysis of samples and chromatography 
Theodur 
Mean ± S.D. 
93.40 ± 20 .69 
109 .90 ± 30 . 15 
5.27 ± 0.84 
7.50 ± 2.20 
Analysis of dissolution samples by UV spectrophotometric analysis was rapid , 
accurate and precise. The results of these determinations are given in Tables A3.1 
and A3.2 of Appendix A. Sampling with the syringe fitted with the luer lock needle 
and sample filter enabled rapid, accurate removal of the medium from precisely the 
same point within the vessel. Since samples of 3ml were removed, this volume was 
immediately replaced w ith an equivalent volume of equi l ibrated fresh medium in 
order to maintain sink conditions . 
Since the results of the UV analysis indicated that dissolution was occurring beyond 
100% of label claim , it was decided to analyse the dissolution samples using HPLC. 
Analysis of samples using this method was found to be rapid and precise. Standard 
de v iations of les s than 4.0 % were determined and each analysis was completed in 
under 6 minutes . A guard column was placed in line before the HPLC column to 
remove any particulate material which may have been injected into the system . 
Figure 3.5 is representative of the chromatography achieved for theophylline . 
2 
• 
209.0 mg!l 
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199.5 mg!l 
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2 min 
Figure 3.5a, band c 
209.0 mg!l 
2 
90 
1 
319.2 mg!l 
Inject Inject 
(b) 
(c) 
. Chromatogram of theophylline (1) and caffeine 
(2) in a calibrator (a) a representative dissolution 
sample (b) and a blank (c). 
Results of the concentration of drug determined by both methods were found to 
compare very favourably. Differences between the UV and HPLC data differed by 
no more that 3% for any single samp le. Inspection of some of the 24h dissolution 
samples indicated more than 100% release. In order to determine whether this was 
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due to any contaminating / interfering species, possibly the excipients of the dosage 
forms, a series of three dimensional chromatograms were constructed. These are 
depicted in Figures 3 .6 and 3.7. Inspection of these indicate that the three 
dimensional chromatograms are identical for a sample of pure theophylline powder 
and a 24hr dissolution sample. The occurrence of release percentages in excess of 
100% was therefore not due to any contaminating species in the samples . 
Furthermore, quality control data obtained from the suppliers indicated that the 
content of the dosage forms were within the limits of specifications of the label 
claim. 
1 
.5 J.O 1. 5 2.0 2..5 3. 0 :5 
TI,.. u..Jn,J 
Figure 3 .6 Thr ee dimens ional chromatogram of theophyll ine (1) po w der. 
Abeor-banc8 [.AU] 
132. 
Figure 3.7 
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Three dimensional chromatogram of a 24 hour dissolution sample 
containing caffeine (2) as internal standard. 
3.2.3.3 Dissolution Rate Studies 
Visual inspection of the dissolution process revealed that the Theodur tablets 
showed a swelling of the tablet matrix after about one hour into the test. The 
swelling was more pronounced in media above pH 5.0. After 2 to 6 hours the 
tablets showed varying degrees of disintegration depending on the pH of the 
medium, with this event occurring earlier at the higher pH's. At the 24 hour sample, 
the tablet matrix had broken up completely and only beads were still visible in the 
dissolution medium. The Test Product also exhibited early signs of swelling, with 
fines breaking free from the matrix. During the course of the tests, the Test Product 
showed considerable surface erosion but did not disintegrate . 
The dissolution of theophylline from Test Product 1 and Theodur are depicted in 
Figure 3.8a . f. 
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Figure 3.8 (a) Mean dissolution rate profile of Test Product 1 and Theodur. 
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Figure 3.8 (b) Mean dissolution rate profile of Test Product 1 and Theodur . 
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Figure 3.8 (cl Mean dissolution rate profile of Test Product 1 and Theodur . 
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Figure 3.8 (d) Mean dissolution rate profile of Test Product 1 and Theodur. 
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Figure 3.8 (e) Mean dissolution rate profile of Test Product 1 and Theodur. 
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Figure 3 .8 (f) Mean dissolution rate profile of Test Product 1 and Theodur. 
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Inspection of these plots indicate that the rate of release of theophylline from the 
Test Product is more rapid than that from Theodur at all pH's except pH7 . 5. It is 
also evident that the release of theophylline from the Test Product is not affected 
by the pH of the dissolution medium . This is, however, not the case for Theodur 
which appears to show some dependency on the pH of the medium and is in 
agreement with the results found by Buckton et a/ (170) . 0' Arcy (171) reported 
that the dose dumping of theophylline from Theo-24, following food intake, is 
consistent with the increased dissolution which occurs following exposure of the 
dosage form to alkaline bile salts and/or pancreatic juices . Hendeles and co-workers 
(172) have reported that Theo-24 showed a dose dumping effect when administered 
with a meal. 
From these plots and plots of log % remaining to be released, the orders of 
dissolution rate were determined. The rates of the relevant processes were 
determined by linear regression analysis. The results of these determinations are 
depicted in Tables 3.3 and 3.4. The goodness-of-fit data are depicted in Table 
A3 .20 (Appendix A). 
Table 3 .3 Results of dissolution rate order determinations . 
Test Product I Tbeodur 
pH 
Rate Order Rate Order 
3.0 Zero order for 6 hours followed by 20% instant release fraction with a 
first order or two first order single first order fraction 
fractions equivalent to 80% of tbe dose 
4.0 Zero order for 5 hours followed by 15 % instant fraction with a single 
a first order fraction first order fraction 
5 .0 Zero order for 6 hours followed by 18 % instant release fraction with a 
a first order fraction single first order fraction 
6.0 Zero order for 5 hours followed by 15 % instant release fraction with a 
a first order fraction single first order fraction 
6 .8 Zero order release only 20 % instant release with zero order 
release for 8 hours followed by a 
first order fraction 
7.5 Zero order for 6 hours followed by 10 % instant release fraction with 
a first order fra c ti o n zero order release for 8 hours 
followed by first order fraction 
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Table 3.4 depicts the various calculated values for the relevant rate constants 
determined at each pH. 
Table 3.4 Summary of dissolution rates for the Test Product 1 and Theodur. 
Product 
Dissolution pH 
Test Product 1 Tbeodur 
3.0 K. = 35.43mg/b 
. 
K. = 0.56b·' 
or K. = 0.07b·' 
Kr = 0.38h·' 
K. = 0.24b·' 
4.0 K. = 42.96mg/h K. = 0.09h·' 
K. = 0.32h·' 
5.0 K. = 39.69mg/h K, = 0.12h·' 
K. = 0.35h·' 
6.0 K. = 56.10mg/h K, = 0.22h·' 
K. = 0.45h·' 
6.8 K. = 41.79mg/h K. = 31.58mg/h 
K. = 0.38h·' 
7.5 K. = 33.15mg/h K. = 29.46mg/h 
K. = 0.36h·' K. = 0.39h·' 
where: zero order release rate constant 
K. first order release rate constant after zero order release 
K. rate constant of slow fraction 
Kr = rate constant of fast fraction 
As is apparent from the above two tables, the dissolution rate order is pH 
dependent. This is of significance as a CMRD is exposed to various pH's as it 
traverses the gastrointestinal tract. Since the solubility of theophylline is 
independent of pH, the rate limiting step of theophylline release from the matrix will 
be the interaction of the tablet matrix with the environment in which it is found. 
This seems to be the case for the Theodur matrix more so than for the Test Product 
matrix. It was found that the dissolution rate profile for Test Product 1 suggested 
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the existence of two possible release mechanisms, namely a zero order fraction 
followed by a first order fraction or two first order fractions. 
3.2.3.4 3-D Dissolution profiles 
As previously mentioned, the concept of presenting dissolution data in the form of 
three dimensional plots was first introduced by Skelly and coworkers (36, 37). By 
definition, CMRD's are designed to release their drug content over an extended 
period of time and will therefore be exposed to a varying milieu of pH's as they move 
through the GI tract. The pH range that such a dosage form will encounter varies 
from pH 1.0 in the fasting stomach, through pH 4 - 5 in the duodenum to about pH 
7 - 8 in the intestinal tract. The basic assumption for all in vitro - in vivo 
correlations is that the rate limiting step in drug absorption is the availability of the 
drug at the absorption site. Dissolution studies carried out at a single pH will 
therefore be representative of the in vivo dissolution only at a particular point in the 
GI tract. Drugs may show regional differences in absorption which is dependent on 
pH and the environment, particularly those compounds which show marked changes 
in solubility in the pH range experienced in the gut (136). Dissolution rate studies 
carried out over a range of pH should therefore provide more information about the 
dissolution characteristics of a dosage form under varying conditions. Three 
dimensional dissolution rate profiles of the Test Product and Theodur are depicted 
in Figures 3.9 and 3.10. 
Inspection of Figure 3.9 indicates that the dissolution contour of the Test Product 
is fairly uniform throughout the pH range tested. The dissolution rate is slightly 
higher at the higher pH's. Particular note must be made of the individual profiles at 
the lower pH's. In this region it appears that the release of theophylline is not 
influenced by the pH of the medium. It is therefore expected that in vivo, the 
release of theophylline from the Test Product will not be adversely affected by the 
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Figure 3.9 3-D dissolution profile of Test Product 1. 
low pH's of the stomach and duodenum. Inspection of Figure 3.10, however 
indicates that the release of theophylline from Theodur is retarded at pH's below 
6.0. It can therefore, be expected that the in vivo release of theophylline may be 
delayed in the regions of the GI tract where the pH is below 6 .0 . 
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Figure 3.10 3-D dissolution profile of Theodur. 
These observations are significant when the in vivo serum concentration profiles are 
considered, from which it is apparent that the absorption of theophylline from the 
Test Product is more rapid than from Theodur . This can possibly be explained by the 
above, i.e. more theophylline is available for absorption from the Test Product at the 
absorption sites and therefore a more rapid em .. is attained . 
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above, i.e. more theophylline is available for absorption from the Test Product at the 
absorption sites and therefore a more rapid emu: is attained. 
The results obtained using the 3D data presentation technique are, however, in 
contrast to those found by Skelly (31 I . In a dissolution study of Theodur it was 
found that the dissolution of theophylline from Theodur was not affected by the pH 
of the dissolution medium. It should, however, be noted that the authors do not 
report the test conditions employed in their studies. Also, using this technique of 
three dimensional visualisation of the dissolution profiles, Skelly was able to identify 
a product which had exhibited dose dumping when administered under fed 
conditions. 
3.2.3.5 Simulation of Serum Profiles (Type A Correlation I 
This type of correlation can be regarded as a Type A correlation since the entire 
serum profile is generated using in vitro and in vivo data. Simulations for the Test 
Product and Theodur were obtained using the parameters as set out in Tables 3.3 
and 3.4 . 
(il Test Product 1 
Predicted serum concentration data are given in Table A3.8 (Appendix AI. The 
predicted profiles are depicted in Figure 3.11 a-g. The plot of Test Product 1 
describes the actual in vivo profile obtained following the administration of a single 
300mg tablet of the formulation. Table 3.5 is a summary of the pharmacokinetic 
parameters used for the simulations and are based on the population parameters for 
theophylline (1531. Literature values were used since an intravenous study was not 
performed to obtain the volume of distribition (V.I nor was a study performed 
following the administration of an immediate release product (eg. a solutionl to 
obtain the necessary k • . The equations as set out in Models A, Band C (section 
2.1.4 . 21 were used to perform the simulations. 
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Table 3.5 Pharmacokinetic parameters of theophylline employed in simulations. 
I 
Figure 3.11 (a) 
Figure 3.11 (b) 
Parameter 
k. 
k. 
V, 
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Simulated profile at pH 3.0 using zero order followed by first 
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Simulated profile at pH 3 .0 using two first order release 
fractions . 
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Figure 3 . 11 (e) Simulated profile at pH 4.0 . 
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Figure 3.11 (d) Simulated profile at pH 5 .0 . 
Concentration (mgll) 
7 
• 
• 
• -G- SiD:lW.UOQ 
...... Tnt prod\lot 1 
3 
• 
a 
• 
• 
,. •• 3. • • 
Time (hrs) 
Figure 3 . 11 (e) Simulated profile at pH 6.0. 
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Figure 3.11 (g) 
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Simulated profile at pH 6.8. 
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Simulated profile at pH 7.5 . 
For pH 3.0, two possible profiles are depicted which are based on the possibility 
that the dissolution profile could be interpreted in two ways, i.e. zero order followed 
by first order or two first order release fractions. Inspection of the profiles reveal 
that the predictions from dissolution data obtained at pH 4.0, 6.0 and 6.8 
approximate the actual in vivo profiles obtained for the Test Product. The 
simulation obtained at pH 6.0 seems to be particularly similar to the actual 
experimental profile. with both showing similar t m .. values of 5 and 4 hours for the 
observed and predicted profiles respectively. It appears, therefore that a simulation 
based on dissolution data obtained at pH 6 .0 adequately predicts the expected 
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serum concentration-time course. 
(ii) Theodur 
Similar simulations were performed to determine the expected serum concentration-
time profiles following the administration of a single 300mg Theodur tablet . The 
results of the simulations are reported in Table A3. 7 (Appendix A) and depicted in 
Figures 3.12 a-f . 
The simulations obtained from dissolution data at the lower pH's i.e. pH 3.0, 4.0 
and 5 .0, did not provide accurate predictions. In each of these cases the predicted 
profiles showed noticeably lower values for Cm .. compared to the values obtained 
for the experimental data. However, the predicted values for t m .. compared very 
favourably with the actual value. Simulations obtained for pH 6 .0, 6.8 and 7.5 
closely followed the actual profiles obtained. The profile of particular interest, is 
that obtained at pH 6.0 . It is clear that the simulated profile is almost entirely 
superimposable onto the actual profile. The Cm .. values are 4.96 and 4.77 mgtl for 
the actual and simulated profile respectively with the t m .. value for both being 8 
hours . 
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Figure 3.12 (e) Simulated profile at pH 6.8 . 
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Figure 3.12 (f) Simulated profile at pH 7.5 . 
3 .2 .3.6 Weibull Distribution Analysis 
Ii) Analysis of dissolution data 
The observed dissolution rate data and the predicted values calculated according to 
the Weibull equation are depicted in Figures 3.13 and 3.14 for the Test Product and 
Theodur respectively . The Weibull function proved to be a robust and versatile 
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function as it enabled the description of all the dissolution profiles studied. In all 
cases the correlation coefficients were greater that 0.99 . 
The detailed parameter values from the Weibull function analysis of the two 
products over the range of pH are summarised in Table 3 .6 and 3 .7. 
Table 3.6 Weibull function analysis of dissolution data for Test Product 1 . 
. Dissolution pH 
Parameter 
3.0 4.0 5 .0 6 .0 6.8 7.5 
to (b) 0.07 0.00 0 .00 0.00 0.00 0.00 
t, (b) 6.30 4.81 4.85 4.96 5.40 6.09 
f3 1.25 1.30 1.38 1.63 1.75 1.44 
F~ (%) 111.50 104.36 103.69 111.35 113.50 104.78 
Table 3.7 Wei bull function analysis of dissolution data for Theodur. 
Dissolution pH 
Parameter 
3 .0 4.0 5 .0 6.0 6.8 7 .5 
to (b) 0 .00 0 .56 0 .88 0.34 0.00 0 .00 
t, (b) 15.49 13.64 9.62 6.78 8.31 7 .31 
f3 0 .80 0.80 0 .80 1.44 1.19 1.46 
F~ (%) 109.37 111.10 107.62 102.56 118.10 109.30 
The lag time, to' only occurred for the Theodur formulation at pH 4.0, 5 .0 and 6.0. 
No lag time was, however, evident at pH 3 .0. All other dissolution profiles did not 
exhibit a lag time. The mean dissolution time, t" was slower for the Theodur 
formulation at all pH's studied when compared to the values obtained for the Test 
Product. These findings are in agreement with the in vivo findings of the Test 
Product exhibiting a faster absorption rate . 
. 
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Figure 3.13 Dissolution rate profiles and Weibull fits for Test Product 1. 
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Figure 3 . 14 Dissolution rate profiles and Weibull fits for Theodur. 
% Released 
.20 
'00 
60 
o • 
.. 
.. 
• 0 • •• • • .. 
Time (bra) 
(a) pH 3.0 
% Released 
.20 
.00 
.. 
.. 
•• 
20 
• 
• • •• • • .. .. 
Time (lu'S) 
(b) pH 4.0 
,; Released 
.2 • 
• 00 
8. 
o. ~ - n, 
•• 
2 • 
• 
• • I. I. 2. .. 
Time (hrs) 
(e) pH 5.0 
111 
S Released 
120 
100 
eo 
eo ~ - "' 
.. 
20 
• 
• • I • l' 20 .. 
Time (hn) 
(d) pH 6.0 
% Released 
120 
100 
0 
eo 
~ eo - "' 
.. 
20 0 
• 
• • I. 1. .. .. 
Time (hI'S) 
(e) pH 6 .8 
% Released 
120 
0 
100 
0 
0 
.. 
~ .. - "' 
.. 
0 
2 • 
• 
• • 1. " 
2. 2. 
Time (hrs) 
(f ) pH 7 .5 
112 
The FW values give some indication of the total amount of drug dissolved . In all 
cases this was above 100%. The values for the p exponent are concordant with the 
slopes and shapes of the curves. All the curves, except those of Theodur at pH 3 .0-
5.0, take on a sigmoidal shape corresponding to p values greater than 1. 
(ii) Weibull Fits to Wagner-Nelson Absorption plots 
The serum concentration-time data from the Test Product and Theodur were 
transformed using the Wagner-Nelson method assuming a one compartment model 
and linear kinetics to obtain the absorption rate plots. These were subsequently 
fitted to the Weibull equation. The plots for the mean profiles (n = 10) can be seen 
in Figures 3 . 15 a-b . 
The Weibull function appeared to be robust enough to enable a good descript ion of 
the absorption rate data, albeit with larger values for the least squares summation 
of the estimates than for the in vitro dissolution rate data. The Weibull parameters 
obtained for the analysis of the data are shown in Tables A3.13 and A3.14 
(Appendix A) and a summary is given in Table 3.B . 
The mean profile data were obtained from a plot representing the mean profile 
obtained from ten subjects . This profile was then fitted to the Wei bull equation and 
the mean parameters depicted accordingly . The mean of the individual parameters 
represents the mean obtained from each individual value relating to individual 
profiles fitted to the Weibull equation. 
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Table 3 . 8 Weibull function analysis of absorption data for Test Product 1 and 
Theodur. 
Test Product 1 Theodur 
Parameter 
Mean Profile Mean of Mean Profile Mean of 
Data Individual Data Individual 
Parameter Parameter 
t" (b) 0.40 0.25 0.00 0.15 
t. (b) 1.63 2 . 19 4.48 4.48 
{J 1.35 1.75 2.32 1.32 
F- (%) 101.80 103 .00 103.07 104 .32 
The time for 63.2% of the drug to be absorbed in vivo, t" was markedly less for the 
Test Product. This is in accordance with the t, values for the in vitro dissolution. 
All the curves had a p value greater than 1 and accordingly all showed apparent 
sigmoidicity. The infinity value, F-, obtained from the analysis of absorption rate 
plots, is not a true estimate of the bioavailability since it is expressed relative to the 
AUC for that preparation . The values for both products, however, were found to be 
close to 100%. 
Figure 3.15 (al 
100 
80 
80 
.. 
20 
c~~~<T------~--~c----------~ 
~ 
o~------~------~ ________ ~ ____ ~ 
o 10 20 
Time (hrs) 
30 
Mean Wagner-Nelson plot of serum concentration-time curve 
after administration of Test Product 1 to ten volunteers. The 
solid line represents the Wei bull fit to the data. 
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Mean Wagner-Nelson plot of serum concentration-time curve 
after administration of Theodur to ten volunteers. The solid 
line represents the Weibull fit to the data . 
Riegelman and Upton (1361 compared the plots of the Weibull fit to the mean 
absorption data of a theophylline preparation, with the curve generated from the 
mean parameters obtained from 5 individual curves . The latter curve was found to 
deviate above 60% absorption and displayed a more rapid apparent absorption than 
is seen in the curve derived from the mean of individual absorption data . The mean 
absorption or dissolution time for processes which may be described by the function 
occurs when 63,2% of the process is complete. However, distribution describing 
complex CMRD' s may exhibit a mean time intermediate between 50 and 63.2 %, with 
a zero order process having a mean of 50%. The above authors evaluated 
correlations between in vivo and in vitro lag times and the mean absorption or 
dissolution times. It was found that correlations from parameters of individually 
fitted data were superior to those correlations obtained using fits to mean data. 
This i s a phenomena common to all averaged in vivo and in vitro data and therefore 
caution must be exercised in interpreting mean data, i .e . individual data should 
preferably be used. 
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Erni and Eckert (173) correlated the Weibull function of the in vivo and in vitro data 
over the whole time period. It was shown that for a particular dosage form of 
bufuralol, the t ime required to dissolve or absorb 63 .2% of the drug was the most 
accurate figure for establishing a correlation. Following linear regression of the data 
it was established that the regression line intercepted the data points at a point 
corresponding to 63.2% in vitro and in vivo (Figure 3.16). Similar curves were 
plotted using the Weibull fits to the in vivo and in vitro data from Test Product 1 and 
Theodur obtained at pH 6 .0 (Figures 3.17 a and b) . 
Inspection of the plots (Figures 3 . 17 a and b) indicate that the current data were not 
in agreement with the above findings of Erni and Eckert (1 73) as the curves from the 
correlated data did not cross the straight line at 63 % for e.ither the in vivo or in vitro 
data. The t. values do not give a good indication of the correlation of the data 
obtained in the present study. 
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Figure 3.16 Correlation of Weibull function for in vitro and in vivo data . 
Reproduced from Erni and Eckert (173), 
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3.2.3.7 Single point correlations 
Ii) Moment Analysis 
Results of the moment analysis of the data for Test Product 1 and Theodur are 
summarised in Tables A3 . 16 and A3.17 (Appendix A). A summary of the parameters 
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is given in Table 3.9 below. 
An indication of the eff iciency of the sustained release preparations is usually seen 
when values for MRT are long . In almost all cases the MRT was longer for Theodur 
than for the Test Product. The MAT is considerably shorter for the Test Product 
than for Theodur, and is in agreement with the shorter t m ., value for the Test Product 
. Since no data were available for an administered solution of theophylline, the MDT 
could not be calculated . Where dissolution is the rate limiting step, which can be 
ascertained if solution data are available, the evaluation of MDT gives some 
indication of the in vivo equivalent to the time required in vitro for 63.2% of the 
drug to dissolve . 
Table 3.9 Summary of Pharmacokinetic and Moment Analysis parameters for 
Test Product 1 and Theodur. 
Test Product 1 Tbeodur 
Parameter 
Mean Profile Mean of Mean Profile Mean of 
Data Individual Data Individual 
Parameter Parameter 
k. (b") 0.07 0.07 0 .06 0.07 
AUe. 105 .86 106.47 106.31 106.24 
(mg /l.b) 
AUMC. 1804 .75 1854 .71 2132 .93 2152.42 
(mg/l.b') 
MRT (b) 17.05 17.13 20 .06 19.49 
MAT (b) 1. 79 1.98 3.46 3 .67 
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3.2.4 Retafyllin versus Theodur 
3.2.4.1 Statement of the problem 
Dissolution studies conducted .on Retafyllin tablets following a 22 month storage 
period indicated that the dissolution profile had shifted over that period, i.e. the 
dissolution rate had decreased. A repeat bioavailabilty study [SRI 1/89 (initial) 
(139) and 22/90 (repeat) (174)] conducted on the product indicated that the product 
was still fully available in vivo. It therefore appeared that the dissolution study 
being used as a batch monitor was not able to accurately reflect the dissolution 
properties of the product. The initial dissolution studies revealed that a "jelly-like" 
layer formed around the Retafyllin tablets after initial exposure to acidic dissolution 
media. 
3.2.4.2 Objectives 
In order to establish a method of dissolution that would be predictive of the in vivo 
findings it was decided to conduct similar studies as outlined in section 3 .2.1. An 
investigation into the possible causes of the above mentioned "jelly-like" layer was 
also conducted. 
3.2.5 Methods 
3.2.5.1 Sioavailability Study 
The bioavailability study was conducted as outlined in section 2.2.6 (i). The initial 
study was conducted in 1989 and repeated 22 months later using the same batch 
of tablets. The determined serum theophylline concentrations are summarised in 
Table A3.6 (Appendix AI . 
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3.2.5.2 Dissolution Studies 
For the general methods employed, refer to section 3.2.2.2. 
Ii) Acid exposure dissolution method 
The method used has been described in section 2.2.4.5 with sample times set out 
as in section 3.2.2.2. Three replicates of each dissolution rate test for each dosage 
form were carried out. 
3.2.5.3 Data Manipulation 
Data from the bioavailability study and the dissolution studies were processed 
according to the methods described in section 2.2.3. 
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3.2.6 Results and Discussion 
3 . 2 . 6.1 Bioavailability Study 
The mean serum concentration·time curve (n = 10) for the repeat study is depicted 
in Figure 3.18. The T mu was found to be 10.0 hours with a emu of 4 .30 ± 0.32 
mgil (mean ± S.D.). 
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Figure 3.18 Serum concentration·time curve of Retafyllin following administration 
of a single 300mg tablet to ten volunteers. 
3.2.6.2 Acid Exposure Dissolution Method 
Original dissolution studies conducted on Retafyllin employed an initial exposure of 
the dosage form to a 1 hour acid medium . This was then followed by further 
dissolution testing in media of pH 6.8 . Inspection of the dosage form during these 
test showed that the tablet was surrounded by a "jelly·like" layer when transferred 
to the buffered medium. These phenomena led to several repeats of this particular 
dissolution test procedure in order to establish whether this occurrence was a single 
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event or whether it was due to the test method . A comparison of the resu lts 
obta ined on three different occasions (see Figure 3 . 19) indicated that the dissolution 
profiles were not in agreement with each other, with very large interday variations 
being observed . In order to find a possible explanation for these phenomena 
dissolut ion studies were undertaken exposing the dosage form only to the buffered 
medium at pH 6 .8. Inspection of the dosage form under these conditions showed 
the absence of any ' jelly-like" film surrounding the tablet . A plot of dissolution 
profiles obtained from three individual tests (see Figure 3 .20) indicated that the test 
procedure, excluding the initial acid exposure, resulted in highly reproducible results 
with very small interday variation. 
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Figure 3.19 Dissolution profiles of Retafyll in following dissolution in acid and 
buffered medium of pH 6 . 8 (Acid pretreatment). 
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Figure 3 .20 Dissol ution profiles of Retafyllin following dissolut ion in buffered 
medium of pH 6 . 8 only (no acid pretreatment). 
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In similar studies conducted on Theodur , it was found that the acid exposure d id not 
have any effect on the dissolution of theophylline from the tablet . 
3 .2.6.3 Standard Dissolution Studies 
Visual inspection of the dissolution medium indicated that fine material was 
suspended in the bulk of the medium after 1 hour. After about 2 hours, the tablet 
showed signs of swelling and disintegration with complete disintegration after about 
7 hours . These trends were evident throughout the pH range tested . The dissolution 
rate profiles are depicted in Figures 3.21 a-f . 
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Figure 3 .21 (a) Mean Dissolution Rate Profile of Retafyllin and Theodur. 
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Figu re 3.21 (b) Mean Dissol ut ion Rate Prof ile of Retafyll i n and Theodur . 
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Figure 3 . 21 (el Mean Dissolution Rate Profile of Retafyllin and Theodur. 
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Figure 3 . 21 (dl Mean Dissolution Rate Profile of Retafyllin and Theodur. 
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Figure 3.21 (el Mean Dissolution Rate Profile of Retafyllin and Theodur. 
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pH 7.5 
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Figure 3.21 (f) Mean Dissolution Rate Profile of Retafyliin and Theodur. 
The results of the dissolution studies are summarised in Table A3 .3 (Append ix A) . 
Inspection of the above plots show that the dissolution rate of Retafyllin and 
Theodur are similar at pH 3.0. Beyond this, the dissolution rate of theophylline from 
the Retafyllin matrix seems to be more rapid than that from Theodur. Furthermore, 
it also appears that the dissolution rate for Retafyllin increases with an increase in 
pH . It therefore appears that the dissolution of theophylline from Retafyliin is 
affected by low pH environments suggesting that the absorption profile would 
closely approximate that of Theodur, since, Theodur was also found to be pH 
dependent. 
From these plots and plots of log % remaining to be released, the orders of 
dissolution were determined. The rates of the relevant processes were determined 
by linear regression analysis . The results of these determinations are depicted in 
Table 3.10. A comparison of these results with those obtained for Theodur (Table 
3 .3) indicate that the rates for Retafyliin are, on the whole, more rapid but that the 
orders of dissolution are very similar over the pH range studied. 
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Table 3 . 10 Summary of dissolution rate order and rate constants for Retafyllin. 
pH Dissolution rate order Dissolution rate constant 
3.0 20 % instant release fraction 
with a single first order fraction K. = 0.08 h· 1 
4.0 A single first order fraction K. = 0.14 h·1 
5.0 Two first order fractions, a Kr = 0.39 h ·1 
slow fraction of 70 % and a fast K. = 0.25 h·1 
fraction of 30 % 
6.0 A single first order fraction K. = 0.45 h· ' 
6.8 Two first order fractions, a fast Kr = 1.07 h-I 
fraction of 45 % and a slow K. = 0.25 h-I 
fraction of 55 % 
7 .5 Two first order fractions, a fast Kr = 1.15 h·1 
fraction of 25 % and a slow K. = 0.46 h·1 
fraction of 75 % or zero order or 
for 4 hours followed by first Ko = 54.60 mg/hr 
order K,=1.15h· ' 
3.2.6.4 3-D Dissolution Profile 
A three dimensional topograph of the dissolution profiles obtained for Retafyllin is 
depicted in Figure 3.22. From this it is evident that the dissolution is pH dependent 
at the lower pH's. Comparing this to the profile of Theodur (see Figure 3.10) it is 
apparent that the two profiles are similar in shape at the low pH values. It is also 
evident that the dissolution rates are faster for Retafyllin than Theodur since the 
individual profiles show a steeper slope for Retafyllin. 
Figure 3 .23 (a) 
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Figure 3.23 (e) 
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Simulated profile at pH 5.0 . 
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Figure 3.23 (d) Simulated profile at pH 6.0. 
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Figure 3.23 (e) Simulated profile at pH 6.8. 
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Figure 3.23 (f) Simulated profile at pH 7.5 using two first order fractions. 
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Figure 3 .23 (g) Simulated profile at pH 7.5 using a zero order fraction followed 
by a first order fract ion . 
The pH at which the best simulation was obtained was found to be pH 4.0 as 
opposed to pH 6 .0 for the other formulations. Since it was found that the 
dissolution profile for Retafyllin' determined at pH 7 . 5 could be interpreted in two 
ways, i.e. a zero order fraction followed by a first order fraction or two first order 
fractions, two s imulations were obtained. 
The T m" value of 1 0 hours compares favourably with the in vivo value of 1 0 hours . 
The predicted Cm" was determined as 4 .05mg/1 which is i n close agreement with the 
in vivo value of 4 .30mg/1. The simulated profile at pH 6.0 exhibited a much shorter 
T m" and a correspondingly highe r Cm" value , which were not in agreement with the 
in vivo determined values . 
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3.2 .6.6 Weibull Distribution Analysis 
(i) Analysis of Dissolution Data 
The observed dissolution rate data and the predicted values calculated according to 
the Weibull equation are depicted in Figures 3.24 a-f. The Weibull function again 
proved to be a robust and versatile function as it enabled the description of all the 
dissolution profiles. In all cases the correlation coefficients were greater that 0 .99. 
The results of the Weibull function analysis are summarised in Table 3 . 11 . 
Table 3.11 Weibull function analysis of dissolution data for Retafyllin. 
I I 
pH 
II Parameter I I I I I 3 .0 4.0 5 .0 6.0 6.8 7 .5 
t, (h) 0.00 0.00 0 .00 0.00 0 .00 0 .00 
td (h) 11.53 8.27 4 .55 3 .24 5.03 3.44 
(J 0.73 0.82 1.06 1.10 1.73 1.40 
F~ (%) 104 .79 106.54 107.38 109.55 115 .26 108 .95 
The values ca lculated for the parameters are in close agreement with those 
determined for Theodur (Table 3.7) except for the values of td' These were found 
to be higher for Theodur when compared to the Retafyllin formulation. This i s in 
agreement with the fact that the dissolution rates for Retafyllin are h igher since the 
lag time is shorter. The high values of (J observed at pH 3.0 - 5.0 are in accordance 
with the shapes of the dissolution profiles, i .e . the curves are initially relatively flat 
and gradually build up to a plateau. 
Figure 3.24 (a) 
Figure 3.24 (b) 
Figure 3.24 Ie) 
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(ii) Weibull Fits to Wagner-Nelson Absorption plots 
The serum concentration-time data of Retafyllin were transformed using the Wagner-
Nelson method, assuming a one compartment model and linear kinetics. These were 
subsequently fitted to the Weibull equation. The plots for the mean profiles can be 
seen in Figure 3.25 . 
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Figure 3 .25 Mean Wagner-Nelson plot of serum concentration-time curve after 
administration of Retafyllin to ten volunteers. The solid line 
represents the Weibull fit to the data. 
The Weibull function again appeared to be robust enough to enable a good 
description of the absorption rate data, albeit with larger values for the least 
squares summation of the estimates, than for the in vitro dissolution rate data . The 
Weibull parameters obtained for the analysis of the data are shown in Table A3.15 
(Appendix A) and a summary is given in Table 3.12. 
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Table 3.12 Weibull function analysis of absorption data for Retafyllin. 
I Parameter I Mean Data I Mean of Parameter I 
to (h) 0.00 0.17 
t, (h) 4.73 4.12 
F~(%) 101.78 101.58 
fJ 0.84 0 .95 
The time for 63 .2% absorption in vivo, t., is in close agreement with that found for 
Theodur and it would therefore be expected that the two products would behave 
similarly in vivo, which is indeed the case. 
3.2 . 6 .7 Single point correlations 
(i) Moment Analysis 
Results of the moment analysis of the data for Retafyllin are summarised in Table 
A3 . 18 (Appendix AI. A summary of the parameters is given in Table 3 . 13 below. 
Table 3.13 Summary of Pharmacokinetic and Moment Analysis parameters for 
Retafyllin. 
I Parameter I Mean Data I Mean of Parameter I 
k, (h' i ) 0.06 0.06 
AUC~ (mg/l.h) 115.60 120.31 
AUMC~ (mg/l.hr') 2466.70 2819.68 
MRT (h) 21.34 22.78 
MAT (h) 3.97 3 .72 
Values for MRT and MAT of Retafyllin are in close agreement with those found for 
Theodur . The high value of MRT indicates that the formulation is effective as a 
CMRD. 
... 
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(iii Other correlations 
Attempts were made to establish correlations of t m", with t 60 % or t 90 ')l. and emu. 
Except for a possibly meaningful correlation of t m .. with t6O''' obtained in medium of 
pH 3 .0 (see Figure 3.26), these correlations were not successful and meaningless. 
These types of correlation attempts are more suited to instant release dosage forms 
and not to CMRD's. 
t--.. 
10 
a 
• 
a 
• 
• 
a 
R'= 0.872 
2 
0 
0 2 • • • 10 
Figure 3 .26 Correlation of t m •• and t60" for Theodur, Test Product 1 and Retafyllin 
using data obtained at pH 3.0. 
3 . 2.7 Conclusions 
The results obtained from both UV and HPLC analysis correlated well and it was 
therefore decided to perform all routine analysis of the dissolution samples using UV 
spectrophotometric methods . The occurrence of % theophyll ine released in excess 
of 100% of lab elle d claim may possibly be due to the tablet content having been in 
excess of 300mg . No limits are however stated in the current compendia for 
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extended release tablet formulations of theophylline. It is, however, unlikely that 
the tolerance limits would be in excess of 110% of labelled claim . 
From the dissolution rate studies conducted on Theodur it appears that the 
dissolution rate is dependent on the pH of the dissolution medium . From the results 
it is apparent that the dissolution rate increases with an increase in the pH of the 
dissolution medium. The dissolution rates were, however, found to be very similar 
in media of pH 6.8 and 7.5. The dissolution rate orders for Theodur were found to 
be first order or a combination of zero and first order processes. Test Product 1, 
however, exhibited zero order release over the whole pH range tested. The 
dissolution rate studies of Retafyllin indicated that the dissolution process occurred 
via first order rate processes. No pH dependency was exhibited by the Test Product 
but that of Retafyllin was shown to be dependent on the pH of the dissolution 
medium. 
According to the manufacturers information on Theodur, the formulation contains 
a fraction of theophylline available as an immediate release fraction. The present 
dissolution studies were able to demonstrate this at all pH's studied. 
The utility of three dimensional plotting of dissolution data clearly has merit in the 
characterisation of CMRD's over a range of dissolution pH's. The topographs 
constructed for the products discussed allowed the accurate explanation of the 
observed in vivo behaviour of the three products tested. Contrasting results for 
Theodur were found when compared to the results found by Skelly (31). This may 
however be due to the fact that Skelly employed different test conditions in his 
research. 
Classical pharmacokinetics advocates that pharmacokinetic models and parameters 
must be obtained from individual subjects's plasma concentration data and then the 
averages of these are calculated. It has, however, been correctly suggested that the 
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alternate procedure of determining this ;nformation from average plasma 
concentrations may lead to pharmacokinetic constants that differ from the 
theoretically correct ones. 
In order to employ the simulation models, Leeson (49) suggested that the 
simulations can be carried out using either individual data or average plasma data 
with equal assurance of meaningful results. This is so since the system predicts the 
plasma concentration-time curve only relative to the behaviour of a solution or an 
immediate release formulation. Hence, even if the pharmacokinetic parameters are 
obtained from the plasma concentration of an individual who received a solution, 
and using these parameters to predict the plasma concentration-time curve in that 
same individual when a CMRD is administered, the projections and interpretations 
are no more accurate than using the corresponding constants derived from average 
plasma data. 
Using pharmacokinetic parameters obtained from mean data, accurate predictions 
were, however, possible for both the Test Product and Theodur, albeit only at one 
dissolution pH, namely pH 6.0. This may be of significance in the future lot 
assessment of Theodur and the possible future development of the Test Product. 
This approach would almost certainly allow for more accurate assessment of the 
products following extended storage conditions, change of location of manufacture 
or minor formulation changes. This implies that fewer expensive in vivo studies 
need to be conducted. It should be noted that these correlations are of utility 
during pre-formulation studies conducted on CMRD's. It appears from the above 
that the simulation obtained for Retafyllin, using dissolution data obtained at pH 4.0 
provided the best estimate of the in vivo response. Dissolution studies conducted 
in media of pH 4.0 therefore appear to be suited as a lot to lot monitor for Retafyllin, 
as opposed to the initial acid exposure dissolution test. 
The Weibull function was found to be a versatile tool and was able to describe both 
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the dissolution data and the absorption data. The correlation of the in vitro and in 
vivo Weibull parameters did not allow for meaningful correlations. Hence, even 
though the Wei bull function adequately describes the dissolution rate profiles and 
the absorption profiles, it is of little utility in the prediction of the expected in vivo 
performance of a dosage form. 
3.2.8 Summary 
The utility of presenting dissolution data in the form of three dimensional topographs 
was illustrated with success. It is therefore evident that the dissolution of dosage 
forms should perhaps be undertaken over a range of pH in order to successfully 
characterise the dissolution characteristics of individual formulations. 
The simulation of plasma concentration time profiles employing pharmacokinetic 
data and dissolution parameters has enabled reasonable predictions of the in vivo 
situation. However, it must be noted that it does not appear that a single 
dissolution test at a single specified pH can be used in the assessment of all 
formulat ions. It appears from the data presented that each formulation has its own 
characteristic dissolution test requirement in order to establish a correlation 
between the in vivo and in vitro situation. 
Due to the nature of CMRD's it is perhaps not surprising that the Level C 
correlations have little value in the assessment of such products. Attempts at 
establishing these correlations did not yield any meaningful results. 
• 
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APPtNUI X A 
Table Al.l D1I.oiution Results from Theodur uling Paddle Apparatus 
Tt_ pO 
c .... ) 
).00 
'.00 >,00 '.00 .... 7.,. 
.... 0.001 t o.oot 0.00 t 0.00 0.00 t 0.00 0.00 I 0.00 0.00 t 0 . 00 0.00 t 0.00 
.... 22 . 21 • Z. )0 1).17 t 1.t1 17.U t 1.21 10." • 2." n." t l.U 13. JI t 0.0' 
.... 20. , • t 0.11 .6,40 t l.n 17 .12 t 0.14 16,3J I 0 .)1 II." t l.n zo • ., • I.)] 
) ... 26.23 t 1. 4. 24 . 10 t '.19 24.11 I I.U 10.6] t I." %3 . 10 t !I.11 n.u t 3 . '0 
.... 31." t \.2' n.u t •• n n.4I t l.n lO. U * 6 . n ".U t 12 . )(1 U." t ',)0 
, ... 37." t l.ll :U.JI t •• n 41.10 t 1.0' U." t l.)' "'" •• 'I." ".'1 t lola .... 41 • .50 I 1.11 'l.n t 1 . 06 )0. 06 I ] . 10 n.37 I 1.24 ",le t 20 . 0] 61.1' • 1. 10 7." 41 • •• • .. 19 U.U t 1.0' 3),11 t 1 . 01 n,o) t 1.lO n.lI.I1.7I n.M t 0 . 60 .... 41.0] t 2 . 76 ~.O) I 4." ".n t ].03 ".n t 1.11 71.07.11,,. 17.11 • '.00 
10. 00 n.61 t I." 
,.". t ' .1' n." t 1. to n.n t I.n n .o] t 10.to ",to t \.10 
II . DO 
,.." t 1." 61,40 t ].tJ 'D." t 1.U ".51 t I." to . ft I ••• , 101.10 t 1.40 
Z'.OO ".30 t 1.97 11.6' 1 )." ,~. U t 1.24 103." t ).]. 101." 1 1.46 
.... n ot three c1eterull.nat.lona 
Z .u.D. 
Table AJ.2 Dilsolution Re.ult. fro. rest product I usins Paddle Apparatus 
n_ pO 
( .... , 
).00 .. .., ' .00 .. .., .... 7.,. 
.... o. oot t 0 . 00' 0.00 t 0.00 D.GO :t 0.00 0 . 00 :t 0 .00 0.00 t 0 . 00 D.OO * 0.00 I." 11.1' t o.n 17 . " 1 I.n 16.32 t 1.07 IZ .II .t 0.19 11." .t D." lZ.n .t 0.1' 
.... 2D.1I • I." 27.01 I 1 .'1 26.'7 t 1.71 1'.09 t 1.06 11.11 t I." It. ll t 0.79 , ... 36.'0 t 2.99 4&.19 t 7.19 n.1l t II.U n.19 t 1.21 
".n t ".," It.U I 0 . )7 
.... 41.11 t .. " ,..,n tiD." ]J.to t J.l0 56.49 t J . O) 49.70 t ).10 4).69 10.n , ... ".49 t ,.It 69." t '.32 " •• , t ,.,. ').31 t 7.02 n.tt t '.Jt ),.,. t 1.0J 
'.00 67 .J2 t 1." 71.00 • '.U 79.DI • 11.36 14.10 • 1. J) 711.61 t ' . 70 n.n I 2.'S 7.00 76.0) I .... .,.n • 7.,. 1'.'1 :t 7.69 19.91 :t l.ll 91.11.).70 711." • 1.60 
.... 1'.7) t ,.U .. • ., t '.41 ".41 t 6.)0 91.4] t I." 100.11 t ) ... 79." t 1.36 
ID.OO 91.3' t •• 76 91.19 t 7.Z4 97.n t 3. 69 102.60 t '.11 107.11.1. 19 n.n • Z.30 
II. OO 97.11 t 3.01 ".,. t 4.76 100." t 3.0' llZ.3) t ',4' I1Z.64 • Z. " 101." :t 1.)1 
2'.00 111.60 t I . H 10'.10 t .... 10Z.30 t o.n III.n t 2.)0 IIZ. OO t I." 102.00 t I.JO 
.... n O[ tnree aeterm.lnat.lOn8 
2 :tS.D. 
Table AJ.3 Di •• olution Re.ult. from Retafyllin uling Paddle Apparatus 
n_ pO 
c-.:.) ).00 '.00 , ... '.00 .... 7.,. 
'.00 0.001 t 0.002 0.00 I 0.00 0 .00 I 0.00 0.00 t 0.00 0.00 I 0.00 0.00 I 0.00 I." n.n t 2." 1' . _' t 2." 1).03 t 1." ll. " :t I." 211.60 t I.') 20.27 t I." 
.... 23.26 t I.U 29." t 0 . '3 ".n t 1.24 ".n t 1.'2 lI.n t I.J! ".)0 t o.to 
) ... n.96 t 1. 1' n." t 0.'1 4&.71 • 1.40 '1.90 to." )).19 t 2.4& 60." t 0.92 
.... 37.10 t 1." U. n t 0 .)7 60.1] t 1.21 n.07 t 0.33 73." t 2.0) 1l • ., t 0 . 11 
, ... 43.91 • 1.0S )1 .69 t I." 70.U t 1.41 lS.ll1 t ,." ".'1 t '.10 It." t 3 . U 
'.00 41." t I.U 56.71 t 1.16 19.26 t 0.16 M.') t '.Il 96.77 t 1 . 04 91." t J . U 7." n.4] t 1. 46 '1.1' • 1. 01 IS." t 0 .72 10).71 t 1.'1 1011.20 t I.n 10).110 • I.n. 
.... 33.)0 t I.U u.n. 1.19 91.0' • 1.01 10' •• ' t I.» 10J . " I I." 10 •• ,. t 1.44 
10.00 61.62 t 1.24 74." t I . ll 100.0' • I." 10'." to." 101.)0 t I . " t07.II t '.16 
12.00 ".36 t 1.1' ".'0 t 1. 01 102.)] * 1." 10'.lZ t 0.61 107.)0 t 1.12 107.61 t 1.72 
:1:4.00 
... " t 1. 01 ".U t 1.61 10 •• 1. * I . U 10'.93 t I.U Ill." t. 1 .'0 10'.72 • 1.00 
.... n ot tnree aetenun.t.lons 
I :is.D. 
table A3.4 Theophylline Serum Concentrations following the administration of a single 300ms Theodur Tablet. 
(all 15/90). 
tl_ Collc.ellt ... tloo ot 1'heopl!11H_ ( .. 11) 
(a .... ) I't. ... t 1 . 0 . 
I • 
) • 
, 
• 7 • • 10 
0.00 .... 0.00 .... '.00 .... .... .... '.00 '.00 '.00 0.00 t 0.00 
.... 0.4' 1. 31 0.63 0.'1 0.11 O.ll 1.17 1.07 1.46 1.07 0.91 t o.n 
I." 0." 1.12 0.91 1.01 t.12 0." I." 1.27 1.17 I.U 1.10 t 0.36 
'.00 1. 01 I . " 1.)7 I.ll I . U ' .27 2.22 t.'1 1. 1Z 1.11 I." * 0." 
) ... I." I." I." I . U 1.11 '.71 1.4' '.ll I." 2. " 1.11 * I." 
.... I." 2. ]7 I.S9 I." I .l' '.16 1." l . U 2.91 l.02 3.n i I.n 
> ... ).04 2 . 41 ) ... 2.49 S.04 '.07 '.17 ' • • 1 !." ' . 46 l.U • 1. '1 
'.00 J." I . U ,." I.U S. 34 S." .. " •• 54 •. n '.l' 4.19 t 0.90 
7. 00 J.n •. n ,.n 1.21 S.ll I. J4 S." ).43 S.IO .. " '.14 t 0 .14 
•• 00 1.,0 3.01 l." 4. 0' s.n 4.17 J." l.1l 4.n 4.91 '." t 0.67 
10.00 1.l9 S.22 4.12 3.97 .... ,." '.Il ,.1, l.61 4." 1. 41 t 0.85 
1Z.00 ).21 '.21 '.24 ).6) '.34 2.96 3.U 4.11 2." 4. n 4.02 t 1.0' 
26.00 0.91 l." I.U 1.1' 1.17 1.26 )011 1.81 0." I." 1.7) t 0 .14 
".00 0 .36 I.JO 1.17 0." o.n 0.99 1.17 0 .99 0.)7 0 . 11 0." 1 0.'0 
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Table AJ . 5 Theophylline Ser~ concent~ation following the admini.tcation of a Single lOOmS Tablet of Teat product 1 
(BRI 15/90) . 
T'_ Co"untntlon of THopltylU. ... ( .. /1) 
(Su) KoI ... :l '.D. , , , 
• 
, 
• 7 I , 
" 
'.00 '.00 ' .00 ' .00 '.00 '.00 '.00 '.00 '.00 '.00 '.00 0.00 t 0 .00 ,.,. 0." O. 7~ o. )& o.n 0. ) ] O.l' 0.73 0 . '1 1.01 1.41 0." to.» 
'.00 0.7' 1.'1 0.64 1.11 0 . 111 O.H %. 73 1.H 3, 4" l.U I . n t 1 . 06 
'.00 0." 4.l' t."" J.31 l.U 1.19 6.'1 4,ll ],17 6 .20 3 .11 t 2 . 2& 
'.00 t ... 6.1' l,a] '.M 1.00 ' .n 1.49 l . U 6,'] '.OJ "n t 2.0] 
'.00 1 . 0) 6.16 6.16 1." 7 . 1' 6." 7.77 '.n l.n 1.6. l.U t 1. 11 
'.00 l . ll 6 . 21 6 . 01 2.11 1.U 6.2' 6 , 94 l . U '.n 6, " ],n t I." 
'.00 3." ',II '.61 1.01 1.0) ],'0 6." '.1' •••• 6.21 l , 42 t l.l. 7.00 1.31 l.H l.I' l.U 6.66 ],1' "., 4.91 4.61 3,n l . ll t I . U 1.00 J.,' l.10 4." ]." 6,0) 4.31 6. to ' .n 4.41 4.n '.71 • 0.&6 
10. 00 1.OJ '.n ' .1' 1." 4.n l.U l.U , ... 1.31 , ... 4 . 1l t 0 . 13 
1%.00 1.04 3.12 , ... l.1l •• 11 '.11 ... , l •• ' %.11 l.O' ,." .t 0.'. H.OO 1.0' I.H ,.,. l.n 1.12 1.0] 1.1. 1.63 0 .91 ,." 1.'1 .t 0 . " 
n.oo 0.12 0.86 0 ••• 1.1l '.90 0.'. l.n 0.81 O.U 0 . '6 0." .t 0.1' 
Table Al . 6 Theophylline Seru= concentrations followin8 the ad.ini.tration of a Sin8le 300ms Reta fyilin Tablet 
(BRI 1/891 
Co.eeat..,."t...; at n..opb:pll.1 .. ( .. Ill 
1<_ ..... 
(lIu) , I , , , • t l .D. 
'.00 '.00 '.00 '.00 ' .00 ,." '.00 0.00 t 0 . 00 ,.,. 1. U 1.16 1.14 .. " 0.'1 0." loU t 0.11 
'.00 1.11 1.'. 1.70 '.lI t." 0." 1. 61 t o . n 1.00 1.12 2." 1.U '.11 2.]' 1.14 2.41 t 0 . 14 
'.00 1.17 ,. " ' . 22 ".10 I." 2 . 2" '.07 t o.n 
'.00 2.U '.4) '.10 ".U •• 63 '.1' '.60 t O.ll 
'.00 '.lI •• 22 , .  , ".U '.6' '.6' 3. 1. t O.l' 
'.00 2.61 '.20 '.00 •• 11 4.'1 '.n 3.10 .t 0 . 30 7.00 2.l6 '.16 ,." l.IO 4.11 '.U l.n .t 0 . 30 
'.00 2.61 3.13 ].17 3.'1 4.73 ... at ].Il t 0.31 
10.00 4.Z4 1.U 4. '7 3.ll 4.U ' . U 4.30 t 0.11 
12.00 4.47 3.n ' .11 2." 4. 04 ".77 4.n t 0 . 33 H.oo 2.11 1.0' 2."1 J.f7 1.13 3.ll 1.U t o.n 
36.00 0.'1 1. 4' 1.0' 1.14 0.66 1.70 1. 16 t 0 . 16 
Table A3.7 Hodel predicted Theophylline Serum Concentration. (U.ing model . A,B and C [.ee .ection 2.1 •• . 2) ba.ed on 
di.solution parameters obtained from Theodur 
Tl_ Oh..,I."i_ pi 
(8u) 
,." .. " ' .00 '.00 .... 7." 
' .00 0.001 ,." '.00 '.00 '.00 ,." 
,." 1.31 1.1' , ... '.n I." 0." 1.00 I." 1. 7' 1.21 1. 10 2." 1. 0' 
'.00 l.ll 1.11 2.17 2.70 '.10 1." 
,." I." 2. " ].11 l.ll ' .81 1.ll 
,." 1 . U 2.1' 3. " '.11 ' .lO 1." 
.. " I." I." 3.64 .... .... l.l • 7." I." 1.11 3.77 .. " '.3l 4.01 1.00 3.0t ].11 l .1l 4. 77 ' .n .... 
10.00 3.0' '.2' J.n 4." .. " ' .37 
12.00 3 . 02 1.26 1." 4.n 3.62 4 .0' 
14.00 t.ll 2.11 2.10 , ... 0.70 1.U 
]'.00 1.20 I. " o.n 0.70 ,." 0.04 
Predl.cted Concentratl.on Drl1leophylllne (mg/l) 
Table A3.e Hodel predicted Theophylline Serum Concentration. (using Models A, B , C, [see .ection 2.1.4.2) baled on 
dissolution parameters obtained from Te.t Product 1 . 
Diualotlall. p8 
Tl_ 
(Bn) '.00 .. " '.00 '.00 6 .10 7.,. 
,." ,.00' ,." ' .00 '.00 ' .00 '.00 
, ." 0.89 1. 11 0.46 0.6.5 0.41 0." 
'.00 2.11 2.27 l . ll 1.17 1." 1.10 
,." ] .U 3. '! 1.24 1.1' 1 . l6 • t.17 
'." 
4 .14 4.14 J.12 4 .43 3.27 1 . 61 
'.00 4. " '.01 1.94 '.n 4.n J.29 
.. " 4." '.29 4 .70 '.09 4.n 1. 91 1." ' .0' ,." 4.11 4.67 '.61 ' . 91 I." '.0' '.11 4.20 4. 26 '.11 4.14 
10.00 • • H 4.17 4.0J 3.'6 4. )1 Ll l 
12.00 4. 29 4.J! J.60 2.72 ].67 l.U 
2'.00 J . 74 1.64 0.14 0.17 1.29 0.~7 
J6.00 ' .5O ,." ,.'" ,.'" O.U 0,'0 
Ircenlcteo concentrl tl.on of Theophy lll.ne (mg /1) 
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Table A1.9 Hodel pn:dicted Theophylline Serum concentration. ullng (Hodeh A,8 , C, ( ..... ction 2.1.4.2) ba.ed on 
di •• olution parameter. obtained frOB Retafyilin. 
rtt.u.,l_tL .... pi 
n_ 
!Iul I." .... I." .... 6,'0 , .,. 
.... 0.00' 0." 0." .... 0." .... I." I." 0.41 0." I.n I." I. " I." I.Oj J.1O 1.41 3.l5 '.61 l . f) 
I ... 2.H 2.01 ,.n 4.1' 4." l.11 
.... 2." 2.10 4 • ., }.l4 },%9 l.1I I." 1." 1.1t 6.'1 l." l.U •• 04 
.... l . O) 1." l.U l." l ,43 l.t' 
, ... l.IO l.7' 1.10 l.1I '.It , ... 
.... l.a l." 1.13 '.44 1.0' S,H 
11.00 I.N 4,O} ' .17 4.11 6." '.tt 
11.00 ).11 1." 4.11 4.10 6 . 0] l.tt 
24, 00 1.14 l.ll 1.10 1.41 I." I.U 
" .00 l.U 0.93 0 . 61 o.n 0." .... 
l'reCl1ctea concentcatl.onll 01: Trle 'p"yl11ne <mg/l,. 
Table A).10 Wagner-Hellon Analy.i. -I Absorbed I Theodur 
S.ItJeet 
,,- .... 
I I I • I • 
, 
• 
, 
" 
O.Ol I." ., ,4) I." 14.22 11 . 11 l .• ' !).l' n." 17.'. '6.0] '4.U 
I.' lI.n ".n t6." It.]' It," ' . 0] 1'.1" 16.11 16,92 U.O] 11." 
I.' U o)4 :n oll 13.'0 24.11 21.70 71 .'2 '0.14 13 . n )7.21 ]0.1] n." 
I.' lO.I6 11.26 ]6.23 ".n n." 117 . 11 II." 46.11 ]1.49 ... ,. 11.24 
••• n ... ".'1 U.19 n." n.M IU." -'0.94 n.IO " . 2" 46.S] n." 
I.' U.II ]'.U ".31 " .46 " • .fIt 11'.47 n.ll 7]." 17.24 '3.]4 70.96 
••• nou 4'.41 n.36 60.17 102.GO Ill.63 10.33 7].3] ".41 10 ••• 19.16 I.. n." 66.1t ".41 71." 107." 107.N n.n 17." 120.]1 77.'" 91.33 
... " . 41 &0.11 106." .... , Ill.'1 111:.91 " .ot 97." 11'.61 'J.n 100.34 
10.0 103.10 to." 101.)7 " .74 10]." 100.66 ".13 102." 110.)4 n." 101 . 91 
11.0 loa." " . ]4 101.74 " •• 0 101." ".14 100." 10]." 91." 106.04 102.n 
24.0 ".l' 101.06 91.19 101.09 '6." " . 1' ".n 97.79 96.63 97.35 ... " 
.... 101.4) 99." 101.0' ".19 IOI.U IOl.04 100." 100.67 101.ll 100.77 100.61 
. 
TableA3 . 11 WaSner-Nelson Analysis - I absorbed J Telt Product 
"bJu.t 
Tl_ .... 
• I I • I • 
, 
• • 10 
• .... .... .... . ... .... .... . ... '.00 .... .... . ... 
• • 1 1l.17 10.12 .... l . U 6.l0 I.n 1.24 12.n 14.11 17 . ]1 11.00 I.' 11.01 20.)1 10.00 1l . 43 9.14 1.01 ]1.03 3'. U 4'.01 ]1.71 24.24 
I.' 19.17 ".n Zl.U U . ., ... ,. U.46 ..... 70.41 " . 0' lO.n .59.12 
I.' 41..31 n.7I .O .~ 43.n ".72 14.79 91 . 44 91.69 107.44 1".61 ..... 
••• ".71 11'6.]3 101." -'O.u 104 . '2. IO!I." H.2' ".11 1I1t . 31 112.16 '9.1" 
I.' 11.00 104.21 106.6) n.'" lot.n 101." ".31 91.U l ot.1] 110.00 100." 
••• 11.63 10].36 106.91 6'.19 1001.02 110.49 n.61 10'.41 104.00 110.19 101.11 , .. n." 102.09 10' .14 16 ." 111.60 106.71 102.03 1 .... 10 10'.&9 IM.11 102.91 
••• " ... 104.14 103.4) 1I . 02 107.29 102." 97.n 106.07 1".13 101.94 101 • .)4 10.0 91." In.'' 10).11 ".,. 101." 101.n 100.'" 100.31 104.60 JOI . II 101." 
12.0 106 • ., 10l.14 101.71 100.14 101.76 100.94 97 . ll loo.U 100.61 " .n 100.79 
24.0 96.91 97.)4 91.42 l00.n 91 . S! 91.U 101.17 n." ".16 ".29 ,..U 
16.0 100.93 100.17 100. 92 n." 100.17 100.97 ".67 100.12 100.60 100 . " 100.36 
Table A3.12 Wagner-Nelson 8nalysi. - I ablorbed RetafylUn 
Iobj-ct 
Tl_ ..... 
I I l • I 
, 
0.0' 11.16 n.H 16.36 H.14 12.02 1.49 11.4' I.. 20.07 34.7] U.I) 43.41 n." 1).86 24.11 
I.' ]0.26 '1.41 ]7 . 1. 60.)6 n." 17.41 ".19 
l.' It.U 10 •• 6 lO.n '0.11 n.,. 34.lt "'.61 
... ".9] 1~.1' 60 . 11 '0.46 ".14 49.1' 60 . 2' 
I . ' '1.41 94.32 6].02 ".1I 7].n ".11 67.01 
... ll.n 91.24 70.43 n.ll 16.09 'I.n " .H 
... .53 .11 n." 67.61 91.4] ".n 63.17 12 ... 
••• ".23 fl.'" 14." 91." ".42 71." 76 .11 10.0 ".31 101.n 91.34 ".tt 93.96 97.11 '0.61 
11.0 101.)1 102.)1 106.44 '0. 16 97 .40 94 . U H.lI 
24.0 101.21 97.21 101.14 ... U 100.10 104 .]1 n.'1 
36.0 ".16 101." ".04 106.41 100 • .54 ".» 101. 41 
41 . 0 100.77 101.U ... " ".16 ".14 " . 41 
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Tahle Al .13 W.lbull function .naly.i. of ablorptlon data for Theodur 
hbjlct 
rar_Ur 
• 
, l • l • 
, 
• 
, 
" 
T. .... '.00 ' .00 '.00 .... 0.10 ' .00 '.00 '.00 '.00 
" .. " 
•. n 4.19 l .U 3. 16 I.U .... • • U 1. Jl 1,11 ,. tOl,7I 101 . 19 10].02 101." 104. 12 101." 101.0] 101 . 71 107.1 1 10].42-
• I . n I." 1.11 I." 1.16 l . 1l I.lj .. " , ... loU 
Tabl, 43.14 Welbull function anaIY.!1 of ablorptlon data for Telt product 1 
llabJlc.t 
rar_Ur 
• 
, , 
• 
, 
• 
, 
• 
, I. 
t. ••• O.OS .... ' .00 .... .... O •. U 0 .16 .... 0 .01 
" 
'.N l .n 1.11 , ... 1.17 1.U ioU .... 1.01 1 •. 51 ,. IOI.IM 101.11 104.11 101 .16 104 .1' 104 ,1'1 II.t1 101.10 104. '1 10l," 
• 1.1' 1. tS 
,.,. 1. 11 I.n 1.11 l . lI 1.'4 I.' I.n 
Tabl. A3.1' W.lbull function analy.i. of ab.orptloQ data for aet_frilla 
'''''Jact 
_u. 
I , , • 
, 
• 
T. .... .00 •. 00 '.00 .... . ... 
" 
'.JI ' .G< 4.14 1. 10 3. 61 l." ,. 101 ,1$ 101." 101 . )0 ".11 10' .9' 101 . 4' , 0." 0.16 0.'. 0 . 14 . ... 1.20 
Table AJ . 16 Pha rmAcokinetlc parAmeter. for Te.t product 1 
..... J ... c 
'.~"r I , , • , • , · ' • " 
.. " 
0.07 0.07 .... 0.o, 0.01 .... .... 0 . 01 0.01 0 .0' 
.... ' n .1l Ill.11 10 .... 71 110. 29 124.14 n .It "l.n 107.14 ..... t6 ".n 
'::I' U41.10 1'(11.61 11",'2 11n,,, 1011.14 11401.11 1212.7S I.U." 1O,.,,, lIU . O' 11.49 16. 1' 11.01 24." 16.10 14,]) 1',71 1l .1f 11.14 n.ll 
... ,. 
',40 '.lI 1.16 .... 1. U 1. 07 I . " I." 0.1l . ... 
Dr' DII/.l.o.r 1IlJ'" . Dr 
Table AJ.17 Pbarmacokinetic parameter. for Theodur 
klIj_c 
r ... __ ur 
• 
, , 
• 
, 
• 
, 
• 
, 
" 
.. " 0.01 0.06 0.0' 0.01 0 . 07 
.... 0.04 0 .07 0.07 .... 
oS n.o) 1)2 . 4% In,., ". ll " .11 101." 111 . 14 111 . 21 fl . U 103,12 Utl.OJ 300' , 11 UI,,60 1"',11 14".U l'll . 41 ,)to." 2U9.n 1116.01 1114.01 17.21 11. 10 :21 . 72 19.90 16.41 11." 16." 11.61 !l. U 11 . l1 
... ,. l .U s .... , .... 4." 1.n 1.U 1 . tI ' .n l. lD ' .11 
1 ms/ 1hr hr 
Tabl_ Al.l8 Ph.~cokinetic analy . is of Retafyllin 
hll Jut 
r ....... t. r 
• 
, , 
• 
, 
• 
.. ' 0.o, 0 . 04 O.Ol 0.06 0.0' 0.04 
.uc." 104,06 1)4.14 121.67 " .10 " , 06 U '.OI ""tc~ 2]0' .21 lIn.ll 211' . 04 I ,,"',n 1639.11 4101, U .. ,. 21.11 21 . 26 22.44 1','1 16." 21, 1) 
..... ,. j.22 1.11 ~ .DI 1.34 ' .16 ' .n 
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Table A3 19 Inferential statistics for Theodur and Test Product 1 . . 
Parameter 
AUClaat 
In AUC .. , 
AUCmr 
In AUC;.r 
C_ 
In emu 
Table A3.20 
determinations 
Dissolution 
pH 
3.0 
4.0 
5.0 
6.0 
6.8 
7.5 
. 
Ratio of Confidence 
means limit 
Classical Westlake 
1.05 95% 93 - 114 88 - 112 
1.06 95% 94 - 115 87 - 113 
1.07 95% 87 - 112 87 - 113 
1.07 95% 88 - 115 87 - 113 
1.04 95% 102 - 136 67 - 133 
1.05 95% 101 - 135 69 - 131 
Goodness-of-fit data (R' values) for Dissolution rate 
Product 
Theodur Test Product 1 Retafyllin 
K,: 0.9976 Ko: 0.9947 K,: 0.9994 
1<0: 0.9468 
or 
K,: 0.9880 
K,: 0.9947 
K,: 0.9996 Ko: 0.9988 K,: 0.9989 
1<0: 0.9932 
K,: 0.9946 Ko: 0.9994 K,: 0.9975 
1<0: 0.9991 K,: 0.9969 
K,: 0.9995 Ko: 0.9998 K,: 0.9976 
1<0: 0.9990 
Ko: 0.9958 Ko: 0.9968 Kr: 0.9577 
1<0: 0 . 9897 K,: 0.9845 
Ko: 0.9936 Ko: 0 . 9956 K,: 0.9993 
1<0: 0.9944 1<0: 0.9898 K,: 0.9888 
or 
Ko: 0.9958 
1<0: 0.9888 
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CHAPTER 4 
INDOMETHACIN STUDIES 
4 . 1 Introduction to Indomethacin 
Indomethacin is a non-steroidal, anti-inflammatory drug with anti-pyretic and 
analgesic properties. The compound was discovered in the Merck Sharpe and 
Dohme Research Laboratories in 1961 and is still in wide use today in a number of 
. ' . 
dosage forms . Indomethacin is designated as 1-(p-chlorobenzoyl)-5-methoxy-2-
methylindole-3-acetic acid. The structure of indomethacin is shown in Figure 4.1 . 
Figure 4 . 1 Structure of indomethacin. 
Indomethacin is defined as the Form 1 crystalline , non-solvated free acid moiety of 
the compound. It appears as a yellow to yellow-tan crystalline powder which is 
odourless and almost tasteless . The compound is a weak acid with a pKa of 4 .5 . 
It is practically insoluble in water and has varying solubility, which is pH dependent, 
in phosphate buffer . A summary of the solubility of indomethacin in phosphate 
buffer is shown in Table 4 . 1. A full analytical profile has been well documented 
1175) . 
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Table 4.1 Solubility of indomethacin in phusphate buffer. 
I pH of buffer I Solubility (mg/l OOml) I 
5.6 3.00 
6.2 11.00 
7 .0 54.00 
Indomethacin has been used effectively in the treatment of moderate to severe 
rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, bursitis and acute gouty 
arthritis. It has also been found effective in the treatment of neonates who suffer 
from patent ductus arteriosus (175, 176) . Although the compound is widely used 
and effective, tox icity often limits its use. lndomethacin is rapidly and completely 
absorbed from the gastrointestinal tract following oral absorption. The plasma 
concentrations which are necessary to produce the anti-inflammatory effects have 
not been accurately determined and there appears to be no dose-effect relationship. 
A very high proportion of patients receiving indomethacin treatment suffer from side 
effects . Complaints usually involve gastrointestinal complications such as anorexia, 
nausea, abdominal pain and in severe cases single or multiple ulcerations of the GI 
tract . The most common CNS side effect is severe frontal headache. Other CNS 
effects include dizziness, vertigo, light-headedness and mental confusion. 
Indomethacin is available in 25 and 50mg capsules, 75mg sustained release 
formulations and as 100mg suppositories. The initial dose is 25mg twice daily to 
a total daily dose of 100 - 200mg per day . The drug should be taken in divided 
doses with food or immediately following a meal (176) . In 1982 a susta ined release 
formulation of indomethacin, Indocid R, was released (177) and has the advantage 
of once or twice daily dosing . Indocid R is reported to be formulated with 25mg 
indomethacin available as an instant dose and 50mg availab le as a slow release 
fraction (177, 178, 179) . 
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A number of studies have been conducted over the past few years to establish the . 
efficacy and pharmacokinetics of indomethacin (177, 178, 179 , 180 - 1851 . Few 
studies, however, report complete sets of pharmacokinetic data (180, 1811 for the 
various formu lations of indomethacin . Values for the pharmacokinetic parameters 
vary greatly from study to study. Indomethacin is usually described by a two 
compartment pharmacokinetic model. The apparent volume of distribution usually 
falls within the range of 0.34 - 1 .57 I/kg (1821 although values as low as 0 .07 -
0 . 14 I/kg have also been reported (1801. The elimination half-life, p, is usually 
reported to be within the range of 2.9 - 8 . 5 hours (178, 181, 1821 . It has been 
suggested that indomethacin may undergo enterohepatic recycling, which would 
explain the slow terminal phase (177, 1801. This is often very unpredictable and 
sporadic and may be an indication of continued reabsorption 4 - 48 h after dosing 
(180). This leads to the fact that no researcher has been able to calculate 
consistent pharmacokinetic data of indomethacin to date . 
Indomethacin is readily absorbed following oral administration of the conventional 
dosage form. However, indomethacin capsules of differing formulations may show 
considerable differences in the serum concentration-time curve . Causes for such 
differences are not yet understood . Despite the large inter-subject variation, peak 
plasma concentrations observed are approximately dose -proportional and average 
between 0 .79 - 2.3 pg/ml, 1 .60 - 3.68 pg/ml and 3.04 - 6.80 pg/ml following 
administration of 25, 50 and 75 mg doses respectively (1781. 
To-date, no clinical studies have demonstrated a correlation between serum 
concentrations and clinical effects (1861. Tannenbaum (187) has suggested that 
although no such correlations have yet been demonstrated, it does not exclude the 
possibility, but that more carefully designed trials may be necessary . Green (188) 
has suggested that there is no convincing evidence for the use of controlled release 
formulations of indomethacin. Green's suggestions are based on the fact that there 
is no evidence that elevated serum concentrations of indomethacin will result in 
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greater relief of symptoms and that no studies have shown an improved efficacy of 
sustained re lease ov er conventional indomethacin formulations . However, a study 
conducted by Yeh et 81 (184) reported that Indocid R did indeed show sustained 
release qualities when compared to three times daily dosing of a 25mg of 
conventional indomethacin formulation. It must, however, be borne in mind that 
CMRD ' s are designed not only to provide for sustained serum concentrations, but 
also for the convenience of the patient . This was demonstrated for indomethacin 
in a study conducted by Jalava et 81 (189) in which it was shown that indomethacin 
adm inistered as a CMRD improved patient compliance when compared to immediate 
re lease and suppository formulations . 
In a study on the chronopharmacokinetics of indomethacin, Guissou et al (190) 
showed that indomethacin was influenced by circadian changes. It was found that 
the pharmacokinetics of oral Chrono-I, a prolonged release form of indomethacin , 
were markedly modified as a function of its administration time . The most striking 
variation occurred when the dose was administered at 20h after administration of 
the initial dose, when the plasma indomethacin concentration did not show a sharp 
peak . The authors suggested that the circadian changes may be partly due to 
changes in the rate of hepatic demethylation of the drug. 
The development of the Oros" system, by Theeuwes (149), has been discussed 
previously . A formulation of indomethacin, Osmosin, based on this technology was 
developed in 1983 (191,192) . The formulat ion was designed to release a dose of 
85mg of indomethacin sodium trihydrate at a predetermined zero order rate of 7 
mg /h . Problems were, howe ver , encountered w ith the dosage fo r m . Reports of 
intestina l bleeding and perforat ion follo w ing the administration of Osmosin have 
been cited (193) . This led to the withdrawal of the product in 1983. One 
suggestion for these side effects was reported as having been due to the dosage 
form adhering to the mucosa and thus releas ing indomethacin in intimate contact 
with the gu t wall. This was however disputed by Wilson and Hardy (194), who 
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conducted a study on the transit of the osmotic tablet through the GIT . The results 
indicated that the tablet moved through the GIT at an equivalent rate to other 
indomethacin dosage forms and that it was therefore unlikely that the reported 
adverse effects were due to tablet adhesion . 
Gueurten and Dubois (195) conducted dissolution studies on indomethacin to 
establish the effect of pH on the dissolution rate . Dissolution studies were 
conducted in media of pH 5.10, 5.70, 6.00, 6.30, 6.60 and 7.20. The authors 
found that the pH of the dissolution medium had a marked effect on the dissolution 
rate constant, with the rate at pH 7.20 being 200 times greater than that determined 
at pH 5.10. It was further demonstrated that the influence of slight changes in pH 
were not significant beyond pH 6.20. 
In dissolution studies conducted by Herzfeldt (196), it was established that optimal 
results were obtained using either the USP rotating basket or paddle methods for 25 
and 50 mg capsules of indomethacin. It was, however, found that dissolution rates 
for indomethacin release from a sustained release formulation were faster when the 
basket apparatus was employed when compared to the paddle method. The USP 
monograph for indomethacin extended-release capsules (72) requires the dissolution 
test to be carried out using the basket apparatus at 75 rpm in a phosphate buffer 
medium of pH 6.2 and the test must be carried out over a 24h period . 
Komuro (197) conducted dissolution studies on various extended-release 
formulations of indomethacin employ ing the paddle apparatus and a flow-through 
apparatus. These results indicated that the flow-through apparatus was more 
advantageous over the paddle method for in vitro tests on indomethacin extended-
release formulations. The reasons cited for this include the fact that the flow-
through apparatus is comparatively mild and mechanical disintegration of the 
granules do not occur. 
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Dissolution studies undertaken by Rowe and Carless (198) on various extended-
release dosage forms of indomethacin, including Indocid R, indicated that problems 
were associated with the extrapolation of the in vitro data to the in vivo situation. 
The authors found that dissolution studies undertaken according to the beaker 
method of Levy and Hayes did not adequately show the extended release properties 
of the dosage forms tested. In was also demonstrated that Indocid R exhibited a 
smoother in vivo profile than the microencapsulated formulations which showed 
very rapid and high peak serum concentrations. These findings were consistent with 
the dissolution results for the microcapsules which showed an initial burst phase, 
i.e. an initial rapid dissolution rate, followed by zero order release. The dissolution 
of Indocid R was found to be square root time dependent, i.e. the release indicated 
a diffusion controlled process from a matrix. 
In a study conducted by Soininen and Langenski61d (198) on the influence of 
polysorbate 80 on the dissolution rate of indomethacin from five different 
formulations, it was found that the dissolution rate was not affected by the 
inclusion of polysorbate 80. The dissolution tests were carried out according to the 
USP XX with and without 0.01 % polysorbate 80 . 
Ramtoola and Corrigan (200) conducted dissolution rate tests on various 
compressed discs of indomethacin and indomethacin-citric acid. The dissolution 
studies conducted were not intended to determine the intrinsic dissolution rate . It 
was established that the dissolution rate increased with an increase in the 
dissolution agitation intensity. The ratio of the rate at a stirring speed of 180 rpm 
to the dissolution rate at 60 rpm was found to be 1 :24. 
Despite the availability of various extended-release formulations of indomethacin, 
many researchers (201 - 206) have attempted to develop new types of release 
mechanisms . Bechgaard et al (204) conducted studies on two multiple unit 
formulations of indomethacin. The experimental formulations consisted of capsules 
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containing enteric coated pellets of different sensitivity to an alkaline environment. 
These authors found that the experimental formulations were equivalent to 
Indocid R. 
Aiache et 8/ (207) conducted studies on indomethacin suppositories in an attempt 
to establish in vitro - in vivo correlations. A promising correlation was established 
between in vivo and in vitro data of indomethacin suppositories . The in vitro 
dissolution rates were determined using a specially modified flow-through 
apparatus. Two types of suppositories were assessed, namely a fatty based product 
and a PEG based product . A bioavailability study was conducted on the two dosage 
forms from which it was concluded that the two products were equivalent. The in 
vitro - in vivo correlations were based on the simulation of the plasma 
concentration-time curves using the drug's pharmacokinetic parameters obtained 
from a single subject and the release parameters obtained from the dissolution rate 
test. The absorption of the drug was assumed to be zero order . It was 
demonstrated by the authors that the simulated profiles were almost identical to the 
actual in vivo profiles obtained in the bioavailability study . 
It must, however, be borne in mind that rectal dosage forms are exposed to an 
environment where the pH is fairly consistent . This is of significance for 
indomethacin since its dissolution is highly pH dependent. The establishment of 
good in vitro - in vivo correlations, based on data obta ined from dissolution studies 
carried out at a high pH, are more likely than those based on dissolution data 
obtained from studies conducted under conditions similar to those found in the 
upper GIT (pH 2 - 5), where the solubility of indomethacin is highly dependent on 
the pH. 
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4.2 Experimental 
4.2.1 Test Product 2 versus Indocid R 
4.2.1.1 Statement of the problem 
Dissolution rate studies carried out on Test Product 2 (a capsule formulation 
containing 75mg indomethacin as pellets) during research and development 
indicated that the dissolution profile for Test Product 2 closely followed that of 
Indocid R (Figure 4.2). The dissolution studies were conducted according to the 
specification as detailed in the USP monograph for Extended-Release indomethacin 
formulations. Based on the results of this dissolution study a bioavailability study 
(Study BRI 14/89) (138) was conducted on Test Product 2, using Indocid R as the 
reference product. The results of the biostudy indicated that Test Product 2 
exhibited a delayed absorption when compared to Indocid R. These findings were 
in contrast to the results of the dissolution rate studies. 
Figure 4.2 
~ Released 
120 
100 
50 
o , I. 
" 
Time (hrs) 
....... T ... t. Produot 2 
-G- IIIdoold It 
2. 
R&D Mean (n = 6) dissolution rate profiles obtained at pH 6.2 of 
Test Product 2 and Indocid R. 
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4.2 . 1 .2 Objectives 
From the above findings it is evident that the official dissolution rate test for the 
products under study, was not able to accurate ly predict the in vivo situation. In 
order to find a possible explanation for the results, it was decided to conduct a 
series of dissolution rate studies on the two products with the aim of finding 
dissolution conditions which would be more pred ictive of the in vivo situation. 
4.2.2 Methods 
4.2.2 . 1 Bioavailability Study 
The study was conducted as described in section 2.2.6(il. Results of the serum 
concentrations are depicted in Table B4 . 5 for Indocid R and in Table B4 . 6 (Appendix 
BI for Test Product 2 . 
4.2.2 .2 Dissolution Studies 
Three replicate dissolution rate determinations on each dosage form were carried 
out . 
(il Dissolution media 
Dissolution media were prepared as set out in section 2.2.4.1. Media of pH 
4 .5, 5.0 , 5.5, 6 .0, 6.2 and 7 .0 were utilised in the various dissolution 
studies . 
(iii Sampling times 
Samples were taken according to the following time schedule : 0.0 (blankl, 
0.5, 1.0, 1 .5,2.0,2 .5,3 .0,4.0,6 .0,8 .0, 10.0,12.0 and 24 .0 hours afte r 
initiation of the dissolut ion test. 
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(iii) Sample analysis 
All samples were assayed for indomethacin content according to the method 
set out in section 2.2.5. Analysis of certain studies was also carried out by 
HPLC as described in section 2.2.5.2. 
4.2.2 .3 Data manipulation 
Data obtained from the bioavailability study and dissolution studies were analysed 
according to the procedures detailed in section 2.2.3. 
4.2.3 Results and Discussion 
4.2.3.1 Bioavailability study 
The indomethacin serum concentrations are presented in Tables B4.5 and B4 . 6 
(Appendix B) for Indocid R and Test Product 2, respectively. The statistical results 
from these studies are shown in Table B4.1 3 (Appendix B). The mean serum 
concentration versus time curve is depicted in Figure 4 .3 . 
Conc.:ntration (mgll) 
• 
Tim\! (hr~) 
Figure 4.3 Mean serum concentration versus time time curve from eight subjects . 
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The results indicate that the absorption of indomethacin from Test Product 2 was 
notably slower than that from Indocid R. The mean t m" was found to be 6 . 5h ± 2 . 8 
and 3 .6h ± 1.4 (mean ± S.D. ) for Test Product 2 and the reference product, 
respectively . Only in two subjects were the t m" values for the Test Product the 
same as for the reference product . The mean Cm" value for the Test Product was 
1.5 jJg/ml ± 0.4 and 2 . 1 jJg/ml ± 0.6 for Indocid R. In five out of eight cases, Cm" 
values for the Test Product were lower than for the reference . When the AUC, ... 
(Table 4.2) for the two products are compared, it appears that they are similar with 
respect to the extent of indomethacin absorption, but they exhib it entirely different 
release rates resulting in large differences in Cm" and t m" values . Due to the large 
differences in the t m" and Cm,,' based on statistical analysis data (138) , it was 
concluded that the two products were not bioequivalent. 
Table 4.2 Mean Bioavailability Parameters . 
Test Product 2 Indocid R 
Parameter 
Mean ± S .D . Mean ± S .D . 
AUC, ... (mg.h/ l) 10 .29 ± 4.07 11.11 ± 3 .03 
AUC;. , (mg.hll) 17 .42±4.52 13 .58 ± 2 . 83 
C . .. (mgll) 1.5 ± 0.4 2 . 1 ± 0 .6 
T m .. (h) 6 .5 ± 2 .8 3 .6 ± 1.4 
4 .2.3.2 Analysis of samp les and Chromatography 
Analysis of dissolut ion samples by UV spectrophotometri c analysis was rapid, 
accurate and precise . The results of these determinations are given in Tables B4.1 -
B4 .4 of Appendix B. Since samples of 5ml were removed, this volume was 
immediately replaced w ith an equivalent volume of equilibrated fresh med ium in 
order to maintain sink conditions. 
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As for the theophylline studies, some of the results of the UV analysis indicated that 
dissolution was occurring beyond 100% of label claim. It was therefore to decided 
to analyse the dissolution samples using HPLC as set out in section 2.2 .5.2. 
Analysis of the samples was again found to be rapid, accurate and precise. Figures 
4.4 is representative of the chromatography achieved for indomethacin . 
40.30 mg!l 
(\) 
20. 14 mgll 
(\) 
(2) 
2.04 mgll 
r---I 
2 min 
InjC4;t 
(a) 
" 
2.04 mg!1 
(2) 
Inject 
" 
tb) (c) 
'. 
Figure 4.4a and b Chromatogram of indomethacin (1) and naproxen (2) (internal 
standard) in a calibrator (a) a representative dissolution sample 
(bl and a blank sample (c). 
Results of the concentration of drug determined by both methods were found to 
compare very favourably. Inspection of some of the 24h dissolution samples 
indicated more than 100% release . In order to determine whether this was due to 
contamination, a series of three dimensional chromatograms were constructed. 
These are depicted in Figures 4.5 and 4 .6. Inspection of these indicated that the 
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three dimensional chromatograms are identical for a sample of pure indomethacin 
powder and a 24h dissolution sample . The occurrence of release percentages in 
excess of the label claim was therefore not due to any contaminating species in the 
samples. Content uniformity assays conducted on both formulations studied, 
revealed that the indomethacin .content of the capsules was within the USP limit of 
90 - 110% of labelled claim. The release of indomethacin beyond 110% can 
therefore not be ascribed to excessive indomethacin content. 
AbsorboncQ (IMU] 
B2. 
'iov818flsth tnllll 
Thill [lIIln1 
Figure 4.5 Three dimensional chromatogram of indomethacin powder. 
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Figure 4.6 Three dimensional chromatogram of a 24h dissolution sample. 
4 .2.3.3 Dissolution Rate Studies 
Ii) Basket Apparatus 
Visual inspection of the dissolution process revealed that the Test Product and 
reference capsules burst after 2 - 5min of exposure to the dissolution medium. The 
baskets retained the pellets of the Test Product throughout the test. However, the 
granules of the reference formulation were only retained during the initial portion of 
the test upon which fine material sifted into the bulk of the dissolution medium, 
forming a small undisturbed mound at the base of the dissolution vessel. Upon 
completion of the dissolution test the baskets were inspected and this revealed that 
the Test Product left no material after 24h. However, the baskets which contained 
Indocid R had a white waxy material still present after 24h. 
The mean dissolution profiles for Test Product 2 and Indocid R are depicted in 
Figures 4.7 a - f. 
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Figure 4.7 Mean Dissolution Rate Profiles of Test Product 2 and Indocid R using 
the basket apparatus. 
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Inspection of the dissolution profiles of the two products indicates that the rate of 
release of indomethacin from the Test Product is similar to that of Indocid R at all 
the pH's studied except pH 6.2 and 7 .0 . The findings at pH 6.2 are in agreement 
with those reported during the R&D phase of the Test Product, i.e. the Test 
Product showing a faster release rate than the reference product. 
Inspection of the various profiles obtained using the basket apparatus, as prescribed 
in the USP monograph for indomethacin, suggests that the products could be 
expected to behave similarly or that in fact the Test Product could show a faster 
rate of absorption. These findings are in contrast to those found in the biostudy. 
It is also evident that the dissolution of indomethacin is pH dependent. This is due 
to the fact that indomethacin is only sparingly soluble in media with a pH less than 
6.0. A further fact to consider is the effect of pH on the formulation and it's 
possible retarding effect on the release of indomethacin at the various pH. 
From plots of log % remaining to be released versus time, the orders of dissolution 
rate were determined by linear regression and by the method of residuals. The 
results of these determinations are depicted in Tables 4.3 and 4.4. The goodness-
of-fit data are depicted in Table B4.14 (Appendix BI. 
Table 4.3 Results of dissolution rate order using the basket apparatus. 
Test Product 2 Indocid R 
pH 
Rate Order Rate order 
4.5 First order First order 
5.0 First order First order 
5.5 First order 15 % instant release fraction 
with a single first order fraction 
equivalent to 85 % of the dose 
6.0 First order 25 % instant release fraction 
with a 75 % first order fraction 
6.2 Two first order fractions 10 % instant release fraction 
representing 45 % and 55 % of with a first order fraction of 
the total dose 90 % 
7 .0 --- First order 
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Table 4.4 Summary of dissolution rates using the basket apparatus . 
Dissolution Product 
pH 
Test Product 2 Indocid R 
4.5 K. = 0.0052h·1 K. = 0 .0052h·1 
5 .0 K. = O.0258h-1 K. = O.0168h·1 
5.5 K. = 0 .0615h·1 K. = 0.0405h 1-
6.0 K. = 0 . 1790h-1 K. = 0.0995h-1 
6 .2 K. = 0.4260h-1 K. = 0 .2360h-1 
K, = 0 .7680h-1 
7 .0 --- K, = 1.248h·1 
No dissolution rate was determined for the Test Product at pH 7.0 since insufficient 
data points were available to perform an accurate determination. It is apparent from 
the above results that the dissolution rate of indomethacin is highly dependent on 
the pH of the dissolution medium. The rate at pH 6 . 2 is approximately 45 times 
greater than the rate determined at pH 4.5 for both products. The differences in 
rates between the two formulations can possible be ascribed to differences in the 
interaction of the matrices with the dissolution medium. 
(iii Paddle apparatus 
In an attempt to more accurately predict the in vivo phenomena, dissolution rate 
studies employing the paddle apparatus were embarked upon . The dissolution rate 
studies were conducted under identical conditions as those employed with the 
basket apparatus using a paddle rate of 50 r.p.m. Visual inspection of the 
dissolut ion test revealed that the capsule contents were dumped w ithin 2 - 3m in 
after introduction to the dissolution medium. The Indocid R capsules, however, 
remained intact for longer periods in media of lo w er pH. The mass of granules from 
the Indocid formulation showed a high degree of dispersion in the bulk of the 
medium, whereas movement of the pellets within the dissolution medium, of the 
Test Product , was less pronounced . After 24h the reference product left a flaky 
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Figure 4.8 Mean Dissolution Rate Profiles of Test Product 2 and Indocid R using 
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material in the medium. No visible material from the Test Product was left in the 
dissolut ion medium at the time of the 24h sample. 
The mean dissolution profiles obtained, using the paddle apparatus, are depicted in 
Figure 4 .8 a-f . From these plots it is again evident that the dissolution process is 
pH dependent. Inspection of the profiles also indicates that the release of 
indomethacin from the Test Product is slower than from the reference product. This 
is evident throughout the pH range tested . These findings are therefore in closer 
agreement with the in vivo findings . The results of the rate order determi!)ations are 
depicted in Tables 4.5 and 4 . 6. The goodness-of-fit data are depicted in Table 
B4 .15 (Appendix B) . 
Table 4 . 5 Results of dissolution rate order determinations . 
Test Product 2 Indocid R 
pH 
Rate Order Rate order 
4 .5 First order First order 
5 .0 First order First order 
5 .5 Two fir st order fra ctions Two first order fractions, a fast 
representing a fast fraclion of fraction of 50 % and a slower 
80 % and a 20 % slow fraction fraction of 50 % 
6 .0 First order Two first order fractions, a fast 
fraction of 26 % and a slow 
fraction of 74% 
6 .2 First order Two first order fractions , a fast 
and slow fra ction eacb equivalent 
to 50% 
7.0 First order First order 
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Table 4 .6 Summary of dissolution rates using the paddle apparatus. 
Dissolution Product 
pH 
Test Product 2 Indocid R 
4.5 K. = 0.0043h" K. = 0 .0037h" 
5.0 K. = 0.0089h" K. = 0.0063h" 
5.5 K. = 0 .0034h" K. = 0.0092h" 
K, = 0.0245h" K, = 0.0650h" 
6.0 K. = 0.1247h" K. = 0.3580h" 
K, = 0.4870h" 
6.2 . K. = 0.2090h·1 K. = 0.2420h" 
K, = 1.21h" 
7 .0 K. = 1.59h" K. = 3.04h" 
where : K, = Fast first order rate constant 
K, = Slow first order rate constant. 
A comparison of the dissolution rate orders obtained from the two procedures used, 
indicates that the orders determined in both cases are very similar. In all cases the 
dissolution rate orders were found to be first order . However, an important 
difference to note is the inability of the paddle method to detect the presence of the 
33% instant release fraction present in the Indocid R formulation. Although the 
analysis of the data obtained from the basket apparatus did not indicate a 33% 
instant release fraction it did indicate the presence of an immediate release fraction 
in the order of 10 - 25%, at pH 5.5, 6 .0 and 6 .2. Inspection of the rates of 
dissolution indicates that in almost all cases the rates determined by the basket 
apparatus were faster than those determined by the padd le method. These 
differences may, however, be due to the choice of paddle rate and not due to the 
change in procedure. 
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4 . 2 .3.4 3-D Dissolution profiles 
As previously mentioned, CMRD's are exposed to a range of pH as it traverses the 
GI tract. Dissolution studies conducted in dissolution media of varying pH would 
therefore be more predictive or indicative of the overall in vivo conditions. Three 
dimensional dissolution profiles of Test Product 2 and Indocid R obtained using the 
basket apparatus are depicted in Figures 4.9 and 4.10. 
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Figure 4 .9 3-D Dissolution Rate Profile of Test Product 2 using the basket apparatus. 
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Figure 4.10 3-D Dissolution Rate Profile of Indocid R using the basket apparatus . 
Inspection of the profiles indicates that the topographs for the two products are 
very similar over the entire pH range tested . The region of particular interest is the 
area of the lower pH's, namely pH 4 .5,5.0 and 5.5. The profiles are very similar in 
this region which would indicate that the products can be expected to behave 
similarly in the upper portions of the GIT . 
Similar topographs were constructed using the data obtained from the dissolution 
studies employing the paddle apparatus . These are depicted in Figures 4.11 and 
4 . 12 for Test Product 2 and Indocid R respectively . From an inspection of the 
topographs it appears that they differ in shape . 
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Figure 4.11 3-D Dissolution Rate Profile of Test Product 2 using the paddle 
apparatus . 
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Figure 4 . 12 3-D Dissolut ion Rate Profile of Indocid R using the paddle apparatus. 
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The slope of the Test Product appears to be shallower than that of the reference 
product. If the region of pH 4.5 to 5 . 5 is considered, it is clear that the release of 
indomethacin from Indocid R is more rapid than from the Test Product . These 
findings are concordant with the in vivo results which indicated that indomethacin 
was more rapidly absorbed from the reference product than from the test 
formulation. 
4.2.3.5 Simulated Serum Profiles (Type A Correlation) 
Simulations for Test Product 2 and Indocid R were obtained using the dissolution 
rate data as set out in Tables 4.3 - 4.6 . Due to the lack of comprehensively reported 
pharmacokinetic parameters for indomethacin in any single research paper, the 
relevant parameters were obtained from studies conducted by Chaudhari et al (181), 
Alvan et al (182) and Yeh et al (184) . These are summarised in Table 4.7. 
Table 4.7 Pharmacokinetic parameters for indomethacin. 
I Parameter I Value I 
'" (181) O.737b·' 
B (181) O.170b·' 
k. (181) 1.359b·' 
V, (182) O.831/kg 
k21 (184) 2.00h·' 
(i) Test Product 2 
Predicted serum concentration data are given in Tables B4.8 (basket apparatus data) 
and B4. 1 0 (paddle apparatus data) (Appendix B). The predicted profiles, simulated 
using dissolution data obtained with the basket apparatus, are depicted in Figures 
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4.13 a-e. The plot of Test Product 2 represents the in vivo profile obtained 
following the administration of a single 75mg capsule of the formulation. The 
equations, as set out in model D of section 2.1.4.2, were used to perform the 
simulations. 
Inspection of the simulated profiles indicates that the simulations obtained from 
dissolution data obtained at the low pH's, i.e. pH 4 . 5, 5.0 and 5.5, do not provide 
accurate predictions of the in vivo situation. The predicted serum profiles from the 
dissolution data obtained at the other pH's appear to be slightly better, however, 
they also appear not to be accurate reflections of the actual profiles. The profile 
obtained at pH 6.0 does show some similarities where the predicted profile shows 
a lag time similar to that found in the in vivo situation, although the time to reach 
the maximum concentration is longer and the predicted plasma concentrations are 
somewhat elevated for a longer period of time. 
Similar predictions were made using the dissolution data obtained following the 
dissolution studies conducted by the paddle method. These predicted profiles are 
depicted in Figures 4.14 a-f. Inspection of these again indicated that the 
predictions obtained are not truly reflective of the in vivo situation. The possible 
exception is the profile obtained at pH 6.2. The two curves again show similar lag 
times and t m " val~es. The predicted maximum concentration is, however, again 
higher than the determined em,,' 
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Figure 4.13 Simulated serum concentration profiles for Test Product 2 utilising 
dissolution data obtained from the basket apparatus. 
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Figure 4.14 Simulated serum concentration profiles for Test Product 2 utilisinQ 
dissolution data obtained from the pad dill apparatus. 
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(ii) Indocid R 
Simulations were also performed to determine the expected serum concentration-
time curve following the administration of a single 75mg capsule of Indocid R. 
Simulations were performed using data obtained from dissolution studies conducted 
utilising the basket apparatus (Figures 4.15 a - f) and the paddle apparatus (Figures 
4.16 a - f) . Results of the simulations are reported in Tables 84.7 and 84.9 
(Appendix 8). 
The simulations employing dissolution data from the basket apparatus are again not 
truly reflective of the in vivo situation. The profiles obtained at pH 6.2 and 7.0 are 
perhaps the most predictive, however, the predicted t m " values are longer although 
the Cm " values of the actual profile and the simulation are comparable. 
Inspection of the profiles obtained using data derived from the dissolution studies 
conducted utilising the paddle apparatus, indicated that only at pH 6.2 and 7.0 the 
predictions are fairly reflective of the in vivo situation. Considering these profiles 
it is evident that the predicted and actual absorption rates are very similar since the 
absorption phase of the profiles are superimposable. The values for t m " of 4.5h and 
5h for the actual and predicted profiles respectively, are in close agreement. The 
values for Cm " of 1 .5mg/l are highly comparable. However, the elimination phase 
of the predicted profiles are slower, resulting in predicted elevated serum 
concentrations. In all cases, the simulated profiles fail to provide a accurate 
indication of the actual elimination rate. This may cause problems in the prediction 
of profiles following multiple dose therapy, giving rise to steady state 
concentrations above those than which would be expected in vivo. 
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Figure 4 . 15 Simulated serum concentration profiles for Indocid R utilising 
dissolution data obtained from the basket apparatus . 
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Figure 4.16 Simulated serum concentration profiles for Indocid R utilisinll 
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4.2 .3.6 Weibull Distribution Analysis 
(i) Analysis of dissolution data 
Dissolution rate data for both products, obtained from the basket and paddle 
methods, were plotted and subsequently fitted to the Weibull equation . The 
observed dissolution rate data and the predicted values calculated according to the 
Weibull equation are depicted in Figures 4.17 and 4.18 for the Test Product and 
Figures 4.19 and 4 .2(}for the reference product. The Wei bull function again proved 
to be robust and versatile as it enabled the reasonable description of all the 
dissolution prof i les . However, the values for the sum of least squares were higher 
than those found for the theophylline data sets. 
The results indicate that the mean dissolution time, t" was faster for Indocid R at 
all the pH's studied when compared to the values obtained for the Test Product. It 
a lso appears that the function was unable to fully describe the dissolution profiles 
for Indocid R obtained using the paddle apparatus even thought the fits to the data 
appear to be very good. However, when the t, values are considered at the lower 
pH's it is evident that these are significantly shorter than those found for the Test 
Product and Indocid R using the basket apparatus. Bearing in mind that the t, value 
is representative of the time to reach 63.2% release it is unlikely that Indocid R will 
reach this point in 2 hours at the lower pH's. 
The detailed parameter values from the Weibull function analysis of the two 
products are depicted in Tables 4.8 - 4 . 11. In Figures 4 . 17 - 4 . 20 the symbols 
represent the experimental data whilst the solid line is the best fit according to the 
Weibull equation . 
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Figure 4.17 Dissolution profiles and Weibull fits for Test Product 2 obtained from 
dissolution tests employing the basket apparatus. 
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Figure 4.18 Dissolution profiles and Weibull fits for Test Product 2 obtained from 
dissolution tests employing the paddle apparatus. 
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Figure 4.19 Dissolution profiles and Weibull fits for Indoeid R obtained from 
dissolution tests employing the basket apparatus . 
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Figure 4 .20 Dissolution profiles and Weibull fits for Indoeid R obtained from 
dissolutkln tests employing the paddle apparatus . 
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Table 4.8 
Parameter 
to (h) 
td (h) 
B 
F~ (%) 
Table 4.9 
Parameter 
to (h) 
td (h) 
13 
F~ (%) 
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Wei bull function analysis of dissolution data for Test Product 2 
(basket apparatus). 
Dissolution pH 
4.5 5.0 5.5 6.0 6.2 7 .0 
0.00 0.00 0.02 0.00 0.00 0.42 
20.20 20.00 20.00 8.86 3.00 0.51 
0.71 0 .89 0.89 0 .98 1.11 0 .5 
11.93 55.07 111.5 127.23 116.23 126,76 
Weibull function analysis of dissolution data for Test Product 2 
(paddle apparatus). 
Dissolution pH 
4.5 5.0 5 .5 6.0 6.2 7.0 
0.00 0.00 0 .31 0.00 0.00 0.11 
24 .37 24.49 19.97 7.64 4.74 1.40 
0.77 0.82 0.89 1.17 1.27 1.22 
15.59 31.46 76.44 92.61 95.82 108.60 
Table 4.10 Weibull function analysis of dissolution data for Indocid R (basket 
apparatus) . 
Dissolution pH 
Parameter 
4.5 5.0 5.5 6.0 6.2 7.0 
to (h) 0.20 0.26 0.26 0.30 0.33 0.40 
td (h) 16.00 23.59 26.07 4.74 10.00 0.50 
13 0.45 0.49 0.53 0 .74 0 .65 0.82 
F~ (%) 12.36 34.84 86.44 79 .72 162.14 99.48 
Table 4 . 11 
Parameter 
to (h) 
t, (h) 
Jl 
F~ (%) 
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Wei bull function analysis of dissolution data for Indocid R (paddle 
apparatus) . 
Dissolution pH 
4 .5 5.0 5.5 6 .0 6 .2 7.0 
0 .20 0 .21 0 .21 0.37 0.30 0 .00 
2.05 2 . 10 2 .80 2.52 1.86 0 .78 
0.47 0.65 0.68 0 .65 0 .72 1.30 
14.72 25.07 60.42 102.41 99.69 112.24 
(ii) Weibull Fits to Wagner-Nelson Absorption plots 
Wagner (128) has reported that the Wagner-Nelson Absorption method can be 
successfully applied to the two-compartment open model. Wagner has also 
demonstrated that the Wagner-Nelson method can be applied not only to estimate 
k, but also k2" k'2 and k. and that this method can be more accurate than the 
classical feathering or back-projection method . 
The mean concentration-time data from the Test Product and Indocid R were 
transfo rmed using the Wagner-Nelson method to obtain the absorption plots . The 
method could, however, not be successfully applied to the individual subject data 
due to the lack of sufficient data points in the terminal el iminat ion phase . The lack 
of suffic ient data points in this region led to the inabil ity to calculate the term inal 
rate constant due to the non-linearity of the log data . The absorption plots of the 
mean profiles were subsequently fitted to the Weibull equation . The p lots for the 
mean profiles are depicted in Figures 4 . 21 a and b . 
The Wei bull function appeared to be robust enough to enable a description of the 
absorption rate data, even though the values for the least squares summation were 
very large . The Weibul.1 parameters obtained for the analysis of the data are 
summarised in Table 4 . 12. 
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Table 4 . 12 Weibull function analysis of absorption data for Test Product 2 and 
Indocid R. 
Mean data 
Parameter 
Test Product 2 Indocid R 
t, (h) 1.50 0.50 
td (h) 3.51 1.43 
8 2.40 1.86 
F- (%) 104 .51 112.25 
The time for 63.2 % of the drug to be absorbed in vivo, t d , was markedly longer for 
the Test Product than for the reference product . The curves showed sigmoidicity 
which is in accordance with the high values for B. It must, however, be pointed out 
that the data shown are based on the mean serum concentration profile and not on 
individual data sets . 
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Figure 4 . 21 (a) Mean Wagner-Nelson plot of serum concentration - time curve 
after administrat ion of Test Product 2. The solid line represents 
the Weibull fit to the data. 
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Figure 4.21 (b) Mean Wagner-Nelson plot of serum concentration-time curve 
after administration of Indocid R. The solid line represents the 
Wei bull fit to the data. 
4 .2.3.7 Moment analysis 
The lack of sufficient points in the elimination phase of the individual subject 
profiles did not allow for the calculation of the parameters for these data sets . The 
parameters could, however, be estimated for the mean subject profiles . Results of 
the moment analysis of the mean data for Test Product 2 and Indocid Rare 
summarised in Table 4.13 . 
The long values for MRT are indicative that the formulations are CMRD's as long 
values for this parameter are usually an indicator of the efficiency of the dosage 
form as a sustained release product . It is evident that the MAT is considerably 
longer for the Test Product than for Indocid R, and is in agreement with the longer 
t m .. for the Test Product . The MRT is also longer for the Test Product when 
compared to that of Indocid R. 
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Table 4.13 Pharmacokinetic and Moment analysis parameters for Test Product 2 
and Indocid R. 
Mean Data 
Parameter 
Test Product 2 Indocid R 
K. WI) 0 .10 0.12 
AUC~ 11.53 11.50 
(mgll .b) 
AUMC~ 153.88 103 .08 
(mg/l.b') 
MRT (b) 13.34 8.96 
MAT (h) 3.40 0.69 
4.2.4 Test Product 3 
4.2.4.1 Objectives 
The failure of Test Product 2 to provide in vivo results similar to those of Indocid R 
prompted the modification of the product, with the purpose of designing it to mimic 
Indocid R more closely. As mentioned previously, Indocid R consists of two 
components, namely a 25mg instant release portion in combination with a 50mg 
sustained release portion. Test Product 2 consists solely of a sustained release 
portion. It was therefore decided to develop a dosage form which contained a 25mg 
instant release fraction and a 50mg sustained release fraction based on Indocid 
25mg capsules and Test Product 2. 
4.2.4.2 Dosage form development 
Dosage form content assays conducted on Test Product 2 indicated that the 
capsules contained approximately 287mg of pellets per 75mg of indomethacin. To 
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obtain a capsule which contained the correct proportions of indomethacin, the 
contents of a single Indocid 25mg capsule was combined with 1 93mg (representing 
50mg indomethacin) of the pellets of Test Product 2 . The material was filled into 
size 00 capsules (Elanco, USA) . A .content uniform ity assay conducted on three 
capsules indicated that the capsules contained 80 .90 ± 1.41mg indomethacin. 
4.2.4.3 Dissolution Rate Studies 
Dissolution rate studies were conducted as set out in section 4 . 2 .2.2: Drug 
concentrations were determined spectrophotometrically . The mean dissolution 
profile obtained at pH 6 . 2 is depicted in Figure 4 . 22 . The profile represents the 
mean of three replicate determinations . 
Inspection of the dissolution profile indicates that the profile closely approximates 
that of Indocid R. The dissolution rate was determined to be 0 . 170h ·' .The results 
suggest that the slower dissolution rate of Test Product 2 may have been due to the 
lack of the 25mg instant release portion . The dissol ution profile obtained at pH 6 . 2 
also suggests that Test Product 3 may be expected to behave sim i larly to Indocid 
R in vivo. 
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Figure 4 .22 Mean dissolution profile of Test Product 3 us ing the padd le method in 
phosphate buffer of pH 6 . 2 . 
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4.2.4.4 Simulated Serum Profile 
In order to establish the expected in vivo serum concentration-time profile for Test 
Product 3, simulations were conducted according to the methods set out in section 
4.2.3.5. Simulations were conducted over the range of pH's tested and the results 
are depicted in Table 84.11 (Appendix B). The predicted profile obtained at pH 6.2 
was selected as the profile on which to predict the outcome of a bioavailability 
study, and is depicted in Figure 4.23. 
Concentration (mgll) 
La 
• 
.. 
Time (bn) 
Figure 4.23 Predicted serum profile for Test Product 3 obtained at pH 6 . 2. 
Inspection of the profile suggests that the time course for the Test Product would 
approximate that of Indocid R. The predicted t mu of 4h is similar to that of the 
reference product although the expected Cmu value is lower. 
4.2.5 Conclusions 
The results from the UV and HPLC analysis correlated well and it was therefore 
decided to perform all routine analysis of the dissolution samples using UV 
spectrophotometric methods. The release of indomethacin beyond 100% of labelled 
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claim can possibly be ascribed to excess indomethacin content even though a 
capsule content uniformity test indicated that the capsules contained only a 
marginal excess. However no reason was found to explain the release of 
indomethacin beyond 110% which is the USP upper limit for capsule content. 
From the dissolution studies undertaken employing the basket apparatus it is evident 
that the results do not reflect the in vivo findings. The results indicated that the 
Test Product should have behaved similarly to the reference product, with the Test 
Product possibly having a faster absorption. The basket method was, however, able 
to verify the existence of the immediate release fraction of Indocid R even though 
only a maximum of 25% was accounted for. This is marginally less than the 33% 
which is reported in the literature. 
Dissolution rate studies employing the paddle apparatus allow for a more accurate 
prediction of the in vivo behaviour of Test Product 2 and Indocid R. The paddle 
method successfully differentiated between the faster Indocid R and the slower Test 
Product. It therefore appears that the paddle method should perhaps replace the 
prescribed basket apparatus as the method of choice for the dissolution rate testing 
of extended-release indomethacin capsule formulations. However, it remains to be 
established whether the paddle method would be able to differentiate between other 
formulations of indomethacin before any conclusive decision can be made. The 
paddle method in contrast to the basket method, was, however, not able to confirm 
the presence of the immediate release fraction of Indocid R. 
The method of representing dissolution rate data in the form of three dimensional 
topographs was able to successfully highlight differences between Test Product 2 
and Indocid R. The topographs constructed from dissolution data obtained with the 
paddle method indicated that Test Product 2 shows a decreased release rate at the 
lower pH's studied when compared to Indocid R. Topographs constructed with data 
obtained from the basket method indicated that the two products had similar release 
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profiles. The following conclusions can therefore be made: (1) the official USP 
dissolution test for extended-re lease indomethacin formulations, and specifically for 
the two products tested, is not sens itive enough to predict product differences; (2) 
the basket method in conjunction with pH profiling was also unable to predict the 
in vivo findings, and (3) the use of the paddle method with pH profiling could 
indicate possible in vivo bioavailability problems . 
Using pharmacokinetic parameters obtained from mean data, predictions were 
possible ·for both Test Product 2 and Indocid R. Simulations based on dissolution 
data obtained with the paddle apparatus yielded more accurate predictions for both 
products. These findings support the suggestion that the paddle apparatus should 
be employed to evaluate the dissolution characteristics of extended-release capsule 
formulations of indomethacin. Although the simulated profiles are not as predictive 
as those determined for theophylline, they do provide an indication of the in vivo 
response expected from the two dosage forms tested . It, however, must be 
established whether the methods demonstrated for these two formulations are also 
able to predict the expected in vivo response for other extended-release 
formulations of indomethacin. It is also apparent that the predicted profiles could 
have forewarned the outcome of the in vivo bioavailability study that was 
undertaken on the formulations . 
It is suggested that on the basis of the dissolution profile obtained at pH 6 . 2 and the 
simulated profile obtained from this, that the test formulation, Test Product 3, could 
be expected to provide an in vivo response similar to that of Indocid R. These 
findings would however need to be substantiated with a pilot scale bioavailability 
study in order to establish the accuracy of the predictive serum profiles . 
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4.2 .6 Summary 
The failure of the official compendial method for the dissolution testing of extended-
release indomethacin capsules was demonstrated for two formulations . The 
conversion to the alternative USP dissolution method, namely the paddle method, 
allowed for the accurate prediction of the in vivo behaviour of the two dosage forms 
tested. It is suggested that the basket apparatus be replaced with the paddle 
apparatus for the routine dissolution testing of indomethacin CMRD's although the 
utility of the method has 'only been demonstrated for two formulations . In order to 
substantiate these suggestions, additional dosage forms would have to be assessed 
using this method. 
The utility of dissolution topographs was again demonstrated with success. The 
topographs allowed for the identification of a product which had been shown to 
exhibit a delayed in vivo absorption profile . It appears that the routine use of 
profiling CMRD's over a range of pH may forewarn of any possible bioavailability 
problems. 
The use of predictive or simulated serum concentration-time profiles was 
successfully demonstrated for Test Product 2 and Indocid R. The simulations were 
able to give an approximation of the expected outcome of a bioavailability study. 
Furthermore, simulations based on the dissolution data of an "in -house" formulation 
indicated that this product would behave similarly to Indocid R. 
The use of predictive methods provide for an alternative to expensive pilot 
bioavailability studies. It must, however, be borne in mind that these methods will 
unlikely be able to completely replace in vivo methods but they are of use as an 
adjunct and aid in the development of new CMRD's 
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.Table a •. 1 Di •• olution rate data for Indocld i u.in, baaket apparatu • 
.. 
Tt..- (Iu) 
.... '.00 , ... '.00 ,.~o 1.00 
0.00 0.00 t 0.001 0.00 t 0.00 0.00 t 0.00 0.00 " 0.00 0.00 t 0.00 0.00 t 0.00 
0." 1.".O.ll l . U t 0.41 '.1' .. I.U 1.14 to." 10.3' t 1.)0 11.00 t 1.)4 
I." 1." t 0.4' '.11 * I." 11 . 07 t 1.44 17.14 t 1.11 2..1.11 t LfCI 69.16 t 1.11 
I." 3 . 44 t 0 .10 1.41 t 1. 14 u.n t I.U 14. U t 1.40 16.11 • 3.40 n." to 0.14 
, ... l.U .. 0." '.20 1 1.'1 11.01 • 0." It, lO .. 1.66 U." t l.WI U.U .. O.N 
,." 4.lt.l.13 t.77 .. 1.·U 10." .. 1.0. 14 . 61 • I.n .)0.41 • 4.10 n.n * 1.0] , ... 
' • . )1 • I.U 10.34 • 1 • .0 11." • '.H 31.'7 • 1.0] ",01 .. ' •• 0 n.,. • I.U 
.... 4.91 • loU 11.::U t 1.11 16.U t o.n U.U • I.n n.lO t 3 , 10 M." • 1.14 
.... ',41 t 1." n .• ' t 1 . 46 ]J.n t 1.1' l, .U l I.,. JI •. U I 10.0 ".n. I.ll 
.... .. " . I." U.61 • '.16 ".S) * 0." 60.10 t 1.04 t4." t 14.' H." .t 1.11 
1 ~&D (t S.D) of three d.t'~n&tion. 
t.bl. 14.2 Dia.olution rat. data for Tilt product 2 uliug baeklt apparatul 
.. 
n.. (.I) 
.... '.00 , ... '.00 ..,. 
'.00 
.... 0.00 * 0.001 0.00 * O.GO 0. 00 * 0.00 0.00 * 0.00 0.00 * 0.00 0.00 * 0.00 0." l.n * O.Of 1.0' * 0.10 4o.ot * o.a '.0' * '.n u . n * 0.~1 '0.17 * I.K I." 1.n * 0.10 ,.,. * 0.12 J . 10 * 1.11 14.J' * l.n :at.1l * 1.06 ".06 * '.1' I." I." II; 0 . " • • U II; 0. 11 .... II; 1.11 10.'-4 * I .M ".n II; 2.U }04." II; '.n 
'.00 1.06 II; 0 • .0 ' . n II; 0." n." II; '.71 16.10 * •. " 34.» II; 1:." Ul.JO II; '.00 L .. 1." II; 0.40 J ... II; 0." lI.n II; 4.0' n.o II; , ... ".16 * 1.IJ lU." * ' . .so ~ .. 1.71 * 0.60 '.11 * 0." 11.'1 II; 4.f! 17 .40 II; ' . 61 76." II; 1.61 114." II; '.00 
'.00 1.11 * 0.71 11." II; O.ll 14.11 II; '.11 47 . 01 II; '.11 teI.O' * I.U IlJ.l0 * l.10 
.... 4." * 1.0] II.~ II; 1.10 ll.U II; '.11 61.90 II; 11.1' 10J.4] II; 1.60 116.11 • 4o.teI I." 4.73 II; l.n 1'.14 • 0." ".4) * 10.16 7l." * 16.0. 101.11 • U.l 116.16 • '.00 
1 Hean (~ S.D.) of three determination. 
Table 84.3 Dil.olution rate data for Indocid I u.ioa paddle apparatu • 
.. 
'Hal ("I) 
.... '.00 '.>0 ' . 00 •• ZO 1.00 
I." 0.00 * 0.00' 0.00 • 0.00 0.00 • 0.00 0.00 II; 0. 00 0.00 • 0.00 0. 00 I: 0.00 .. ,. 4.91 II; o.n '.01 • 1.17 l1.n II; 1.4040 14.40 .t 2.06 1'.10 I: 1. 61 ".61 II; '.U I." '.f! I: 1.14 }0.50 II; 0. " 10." .t 0. " 11.60 I: 1." ,. ... .t 1." ".11 * '.61 
1.>0 '.00 I: O.ll 12.N II; 0.4] 1'.70 II; 2.1' ".11 II; 2. :at ".11 II; 2.ll 10' • .so • l.U 
'.00 •• 01 I: 0.41 140.71 • 0.62 :U.OO II; 1.U ".Of.2 .• 1 61.14 * 2.4' lot.M • '.6) 
'.>0 '.11 II; 0." 16.20 II; 1." 13.60 • l.U ai." ••. n ".21 II; 1 • .u l1~.lI II; 4.01 
.... 10.14 • 0." 11.4040 II; I.SO ]f.lI • 1.12 67.01 • 2." n.ll I: 1." 10'.11 • ' . lI 
.... 10.'1 • 0.41 U.lO II; 1.1' 41." II; .... 73.14 I: 1.11 10.1' II; l.ll 111.10 * 2." 
~oo 11." * 0." 11.10 II; I.M 41.1t II; 4." '2.73 * l . U II." II; 4.11 112. 31 • 2.M 
.... 11.46 .. 0.]1 21 . 11 I: 2.11 ".00 II; 1. 11 11.14 • l.ll n.n .. '.l4 112.11 • l.ll 
11.00 l1.tl .. 0." 1l.40 • 2. 11 ».ll • 1." n.ll II; 2.teI " . ., • '.n 111.50 • .s.ot 
11.00 n.n • o.n 1l.lD • 1.11 ».10 * ' . U ".10. 1.17 ".10" 4.16 111.00 .. 2." 
1'.00 n.l0 • 0." 14.10 ... 1 ." )1.61 ••• ,. 100.10 * 1.61 l00.lD * 4.:at 111.00 II; 1.11 
U.OO 14.10 II; 0 . " 14." * 1.0J 10.00 II; '.J] 100.11 II; 1.0' l00 • .so • ' . 71 101.11 • 1." 
1 Hean «i: S.D. ) of thre. determinatione 
Table !4.4 Die.olution rate data for Teet Product 2 U.inl paddle apparatu • 
.. 
n. (I",) 
.... '.00 ,.,. '.00 '.10 1.00 
.... 0.00 • 0. 001 0.00 • 0.00 0.00 • 0. 00 0.00 * 0.00 0. 00 • 0.00 0.00 • 0.00 
.. " I . " • 0.11 ] •• 0 II; 0. 61 ' .ot II; 0. " '.11 * 1.41 '.n 1 0. 40 10.11 1 O.N 
1.00 l.n • 0. " 1.'so • 0.11 4. 14 II; 0.1t l.teI * 1.11 11 . 11 • 1." 41.11 • 4.14 I." I." i o.lt '.10 * o.It ,.jQ II; 0. " 11.10 • 2.11 10." • l.n 61.11 • '.1I 
'.00 ] . 10 * 0.4' 1.70 * 0.36 , ... 1 O.to 17.10 * 1. " ]7.17 * 0." ".41 • 7.01 
,." ].n II; 0.11 4. 20 1 0. 10 I.U. 1.06 11 .... ).41 ".11 • '.17 ".10 • J.n 
'.00 1.n 1 o.n ~.14 • 0.10 10.11 * 1.41 ]1.'1 • ~.O, 61 . 11 1 7.11 n.ll • 7." 
'.00 ].It II; O.ll '.Il i 0.30 n." * l . n l4.n 1 '.31 '4." * '.H 10'.31 II; l.tI 
1. 00 1.'0 1 0.340 1.0] 1 0." It.n * ].Il 49.39 * '.n 11.31 t 9.71 tOJ.n 1 '.n 
'.00 '.U t 0.31 10.70 • 0.36 17." 1 ,.U 61." • 1.16 II.U 1 10.11 10'.00 • '.11 
ID.oo ,.j, 1 0.62 12.10 1 0.'0 n.lO • '.44 74 . 11 t '.01 '7.ll 1 11.0] 10'.XI • I . ll 
11. 00 7.06 II; O.H l1.n i 0.17 34.'0 1 4.,7 71.41 1 '.'0 ,1.7] 1 10 . n 10f.lO • I.ll 
".00 1.71 * O.ll 11.00 • 1.21 ".lO 1 l . U ".n * ,." fl .1l 1 10.21 10'.lO t I. ll 
n.oo , ... t O.H 19.11 * 1.11 lO.70 • l.n ".10.10.41 ".71 1 9. 11 101.90 • ' .17 
I Hean (~ S.D .) of three determinations 
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T.bl.,!~., Serum Concentration. of Indomethacin (mall) followin& the administration of on. 7'-a IDdocid I cap.ule 
'''''Jeu 
1'1.00 ..... 
(Be.) I I , • • 
, , 
• • '. 0. 
0 . " 0 . " 0 . " 0." 0." 0 . " 0." 0 ." 0 . " 0 . 00 t 0.00 
0 . " 0 . " 0." 0 . " 0.00 0 . " 0. " 0. " 0." 0 .00 t 0. 00 
I . " 0.47 0." 0.00 o.a 0 . " 0.00 .. " 0 . " D.n it 0. 22 
I . " 2.01 0.00 0 . 00 O. lt 0." 0.00 1.01 o.n 0.61 .t 0." 
I . " 1.41 0 . 00 0." 0.10 1. U 0.00 1 . Of 1. 07 D." • 0." 
I . " 1." 0." 0." 0,74 1 . )) 0.00 1.7. 0 . " 1. 0' * 0 . 10 
.... 1.16 1.11 0." O. J7 l.n 0 . 00 1.11 1.)1 I . U. D.H 
,. " 1.11 .... 1.29 1.11 1. 11 D • ., I." 1." l.U • 0," .... 0 . 1' 1. 17 1 . 14 I.n 1." 0." 0." 1.16 I . ll * 0 . 10 
'.00 D.ll 1.17 l . lt 1.11 1. 11 1.10 0 . 11 0." 1.13 t O • .se 
'.00 0." 0.14 1.10 I .• ' .... 1.37 o.n 0." 0.91 • 0.16 
.... 0." 0 . 11 0 . " 0.6.5 o.n 1.04 0." 0 . " 0. " t 0.1' 
10 . 00 0." 0." 0 .61 0." D, U O. " 0 . )1 O. ll 0. 61 " 0. 14 
11 . 00 0.14 0." 0 . ') O. ll 0." 0." 0.00 o.n 0 . 11 • 0.14 
141.00 0.00 0." o.n 0.11 0." 2 . " 0." 0." 0.01 * 0.11 
tabl' ),,6 Serum Concentrationl of Indomathacia ( .. /1) followina the adminbtration of ODe 7,-& capsule of T .. t 
product 2 
""'Jut .... 
.... • I.D 
, .... ) 1 I , , , , , • 
0.00 0.00 0.00 0 . 00 0 . 00 0 . 00 0.00 0." 0 . 00 0.00 .. 0.00 
0." 0 . 00 0 . " 0.00 0.00 0." 0.00 0." 0." 0 . 00 * 0 . 00 
1.00 0." 0." 0 . 00 0 . 00 0." 0." .... 0.00 0 . 00 *' 0.00 
1." 0 . " 0.4' 0.00 0 . 00 0 . 00 '.00 0." 0 . 00 0 . 06 *' 0 . 17 
2.00 0." 0.'1 0." 0.00 0 . " 0.00 0." 0 . " 0.11 *' o.n 
2." 0 . 00 .. " 0." 0 . 11 .... 0." 0 . " 0 . 00 0.14 *' o.n 
'.00 0 . '4 l.ot D. ,. 0.11 0 . 00 0.00 0 . .. 0.1~ o.n *' 0.31 
'.5O 1.01 l.n 0." o.n 0 . l4 0.24 0." O. U o.U *' O.M 
'.00 0 . 71 1." 0." 0 . " 0 . '1 0." 0 . " D . .. 0 . 70 *' 0." 
'.00 0 . " 1.14 .... D." 0." 0 . '4 0.61 1." 0." *' 0.)1 
'.00 0.61 0.1l 0.90 I." 0 . 67 1.70 0." 0.1l 0." *' 0 .:14 
'.00 0 . " O.lt 1.90 1.1' O. U o.n 0 . 4l 0 • .31 0.10 *' D." 
10.00 0.15 O.ll o.n 0.10 1. " 0." 0." 
• 
o.n 0.61 *' 0.11 
11.00 0 .. '" 0.l4 0.4l 0." 1.11 0.14 0.00 0." 0.41 *' 0.]7 14 . 00 .... 0.00 0. l4 O.lt 0." .... 0." 0." o .U *' 0.11 
Table 14.7 Kadel predicted Indomethacin Suwa Conentration. (V.in, model D [ue lIetion 2 . 2.4.2)) ba.ed on dillolution 
par&meter' obtained froe Indocid 1 ~pl01inR the B •• ke t apparatu •. 
Dl.Ml .. t:lo& ,. 
.... (Iu) 
, .. 
'.0 ••• '.0 '.1 , .. 
0. 00 0 .... 0 . 00 0 . 00 .... 0 . 00 0.00 
1.00 0 . 01 O.OS 0.)2 G.77 0 . 00 0 .11 
1. 00 0.02 O.OS G. )' 0.14 o . n 1.2' 
'.00 0 . 01 0.0' 0." 0. ' 1 o.n 1.11 
1.00 0.0) O.ll 0.'0 0." l . ll 1.U 
1. 00 0 . 04 0.1:t o.n 0 . 94 1. 11 1.11 
' . 00 0.0' 0.16 0 . '4 O. U l.n I." 
' . 00 0.0' 0.20 0 . S4 o. n I.lt .... 
10.00 0.07 0.22 O. S) 0." I.U o.n 
11 . 00 0." 0.14 0 . " 0 . 1' o.t) 0 . 67 
24.00 0.0' 0.14 0 . 14 O.ll 0.1' 0.0' 
1 Predicted .erum concentration of indomethacin (mg/l) 
Table !4.8 Hodel predicted Indomethacin Serum Concentrationa (UdnR model D ( .... ection 2.2.4.2)) baud on diuolution 
parameter. obtained from Teat Product 2 ~plo7inl the Ba,ket .pparatu •• 
ot.uoluioll pi 
TI.aa ' .... 1 
.. , 
' . 0 ' . 1 '.0 '.1 
0. 00 0 . 001 0.00 0 .00 0.00 '.00 
1.00 0.01 0.0' 0." 0 . 00 0 . " I." 0.01 0 . 0' 0 . 1t 0.00 0.1l 
'.00 0.02 0 .11 0 . 11 0 . 1' l . ll 
1. 00 0.0] o. " 0.]6 0 . 14 1.61 
'.00 0 . 04 0.20 0.43 0." 1. 10 
1.00 0 .0' O. ll 0 • .31 1.11 1." 
1'.00 0 .06 o.lt 0.61 1.11 .... 
10.00 0.07 O. )) 0." 1.11 1.0' 
11.00 0. 0' O. )4 0." 0.91 0 .11 
H.OO 0 . 0' O. ll 0.41 0.21 0 . 11 
I Predicted ' Brim concentration of indomethacin (mall) 
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tabl.!4.9 Model predicted Indomethacin Serum. Concent.ration. (Udoa model D { ..... etion 2 . 2 . 4 , 2» baled on diuolution 
par .... t. bt i d from Indocid 1 ttmploying the Paddle appara tu s on 0 • no 
Dt.,aol .. tJ.oe. pi 
fl. (In) , 
••• ••• ••• ••• ••• 7.' 
0.00 ..... ' .00 '.00 0.00 0.00 0. 00 
1.00 0.01 0.01 o. ll ' . 00 0. 1' .... 
'.00 0 . 01 0.01 0.19 .... 0." I . U 
'.00 0 . 01 0.0] .. " 1. 0' 1.11 ' . 00 
'.00 0. 01 0.04 1. 01 1.40 I .n 1." 
' . 00 0.0) O . O~ 0.91 I .ll 1." 1.11 
' .00 0.04 0.0' .... 1,)7 1. '1 1. '1 
'.00 0 .0' 0 . 01 0. " ioU 1.>0 I . U 
10.00 0 .0' 0.0' 0.'1 1.1' I." 0." 
11.00 .... 0 .10 o.n .... 0." 0." 
14.00 0.01 0.11 0.12 O.ll 0.14 .... 
I Predicted . arum concentration of indomethacin (mall) 
Ta bl. !4.10 Hodel predictad Indomethacin Seruza Concentration. (Ulina model D [ I . ... ctleD 2 . 2.4.2}) b ... d on dillolution 
par ... t er. obtained from relt Product 2 .mployinS the Paddle apparatu. 
Di,Ml. .. d_ pi 
,,- ''''1 
.. , , .  .., ••• ••• I •• 
'.00 ..... ' . 00 '.00 ' . 00 ' . 00 '.00 
1. 00 0.01 0. 0) 0 . 01 ' .00 .... D.lt 
.... 0.01 0 .0] 0.0' o.n ' .00 1.41 
' . 00 0.01 .... .... .. " .... 1." 
'.00 0.0] .... o.n .. ., O.t4 I.N 
'.00 0.04 0 . 01 0.16 .... l . ll 1." 
.... 0.04 o.ot O. lt .... 1. 2) 1.67 
' . 00 0.0] 0 .11 D.n 1.00 1.2.' I .... 
10.DO 0.0' O. U. .. ,. 0." I .U .... 
12 . 00 0.01 O.ll 0.27 o.n .. " ..... 
14 . 00 0.07 0. 14 0.26 U. O.ll 0. " 
1 Predicted .erum concentra tion of indomethacin (mall) 
rabl . B • . 11 Kodel predicted Indomethacin Serum Concentrations rUsing model D (I .... ction i . 2.4.2]) ba .. d on db . elution 
par ... ter. obtained from Telt Product 1 amploying the Paddle apparatus 
l)t . . ol. .. u.oa pi 
,,- (Bn) 
.. , , .. , .. , .. ••• 7.' 
'.00 0.001 .... .... ' .00 ' .00 .... 
1.00 0." 0.44 O. U ' •. 51 .... D.H 
' . 00 0.'" 0.64 ..... 0. 71 .... loU 
3.00 .... 0." 0. 71 O. lt '.N 1.7t 
• • 00 .. ., 0." 0." .... .. .. 1.., 
'.00 .... .... 0.64 0 . 71 1.07 1. U 
' . 00 0.':1 o.n O.Sf O. U I." I." 
' .00 0." 0.41 0." .. " .. " I." 10. 00 G. lf 0 . 31 •• S< '.K 0." 0." 11.00 0 . %1 O. ll ' . >0 0 . 31 0.1' 0." 14,00 '.Ol 0 . 07 O. U .. " O.Z' O. Ot 
1 Predicted ' arum concentra tion of indomethacin (ms/l) 
Tabl. 84 12 Di •• olution rate data for Te l t Product 3 obtained u. ing the paddle a pparatus 
pi 
,,- (Sn) 
'.>0 ' .00 .. " .... 6.20 7." 
.... 0.00 t 0. 001 0.00 t 0. 00 0.00 :t 0.00 0 . 00 t 0.00 0.00 t 0.00 0.00 t 0.00 
0.17 0 . 00 t 0.00 10.60 t J.04 10.31 t 1. 47 n.10 t 1.07 16.17 t 1.07 l.5." .t. 1.00 
O.ll 0.00 t 0.00 11.'0 t 0.77 17 . ,:14 t 1 . 71 11.11 t O. U U . l:S t 1.n a4.'1 .t 0.11 
'.>0 0.00 t 0.00 n . n t 0.7' n.U t l . ll n.34 t o . n 1O. n t 1.11 n.17 .t 0.23 
1.00 l.n t 0.91 14 . 60 to." U.04 t l.ll 11. 10 t 1. 11 41." t a." '7." t 1.41 
'.00 ' . t7 t 0.10 14." t 1.0l ll.ll.t 1. 14 ])'}l t 1. 71 " , 00 t 1. to 7].21 .t '.n 
'.00 ,,» to." 16.03 t 1.11 34.ll t '.It l6. U t 1 . '7 71.11 t '.11 ".00 t t •• , 
' . 00 '.fl t O.ll 16.79 .t I.U " . 71 .t. 1 . 21 ]f." t 1.19 11.14 .t l . U U.16 t t.lI 
'.00 ?7ttO.'1 11 . 41 .t 1 . 36 17." .t. l.l1 ... ,. .t ' . 10 " .Ot .t l . " 101." .t 1.11 
'.00 1.11 t 0.64 18.30 to." n.11 .t. 1.01 41.)1 t a . u 100." t 1.U 104.46 t 7.11 
11.00 '. lI t 0.91 19.11 t loll ".}(1 t 1.10 ".91 t l.U 10' . 0' t 1.41 10' , 10 .t 1." 
14.00 '.61 to." 10.0' t 1 . )6 46 . 62 .t l.ll 11 . " t 7.10 111." t o . n 11' .... .t 1.1' 
1 Hun (± S . D. ) of three determinations 
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Table B4 13 Inferential statistics for Indocid R and Test Product 2 . 
Ratio of Confidence 
Parameter means limit 
Classical Westlake 
AUCl2 0.78 95% 63 - 94 66 - 135 
AUe,.. 0.93 95% 78 - 108 81 - 120 
C~ 0.69 95% 42 - 96 47 - 153 
Table B4.14 Goodness-ai-fit data (R2 values) for Dissolution rate 
determinations obtained form the basket aooaratus. 
Product 
Dissolution 
nH Indocid R Test Product 2 
4.5 1(,: 0.7574 1(,: 0.9130 
5.0 1(,: 0.9399 1(,: 0 . 9906 
5.5 1(,: 0 . 9729 1(,: 0.9987 
6.0 1(,: 0.9878 1(,: 0.9967 
6.2 1(,: 0 . 9968 1(,: 0.9980 
Kr: 0.9945 
7.0 1(,: 0.9977 ---
Table B4.14 Goodness-of-fit data (R' values) for Dissolution rate 
determinations obtained form the paddle apparatus . 
Product 
Dissolution 
DH Indocid R Test Product 2 
4.5 Ks: 0.7211 1(,: 0.9388 
5.0 Ka: 0.8630 1(, : 0.9601 
5.5 K. : 0 . 9032 1(,: 0.9734 
Kr: 0.9123 Kf : 0.9861 
6.0 K. : 0.9645 1(, : 0.9916 
K,: 0.9762 
6.2 1<,: 0.9786 Ks: 0.9970 
K,: 0.8960 
7.0 1<,: 0.9096 1<,: 0.9827 
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